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Abstract 
 
Worldwide, gelatin has been used in the rotary die process as a shell-forming material of 
soft capsules due to its unique physicochemical properties. The development of soft 
gelatin capsules (SGCs) is, however, challenging because of their highly dynamic nature. 
Migrations of components between the shell and the fill, as well as between the shell and 
the external environment, are very common. These migrations might occur during 
manufacture, drying and on storage. A major challenge is the large amount of water (up to 
35% w/w) that the capsule shell contains immediately after encapsulation. During drying 
the water migrates from the shell into the environment and the fill until equilibrium 
moisture content is reached. The water migration pattern greatly depends on the nature of 
the fill formulation. For lipophilic oily formulations there is no water uptake from the 
shell. However, a considerably hydrophilic fill might take up a high amount of water (up 
to 20% w/w). Some water migrates back into the shell with further drying, resulting in 
capsules containing up to ~ 8% w/w of water in the fill. This water creates a risk of drug 
precipitation in the fill mass, since the drug solubility in the formulation can be greatly 
reduced.  
To overcome the disadvantages of gelatin, a great effort has been directed into finding 
new materials as a substitute for gelatin in soft capsules. The present thesis comprises two 
studies that focus on a novel thermoplastic shell material for soft capsules. A particular 
aim was to gain a better mechanistic understanding of drug-excipient-shell interactions 
using SGCs and different starch-based thermoplastic capsules. Since thermoplastic 
capsules allow a filling at rather high temperatures, formulations that are even solid at 
room temperature can be encapsulated. Therefore, a third study used such solid lipid-
based formulations with the aim to investigate drug-excipient-shell interactions on 
different biopharmaceutical levels in vitro. 
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Recently, a novel starch-based polyvinyl alcohol thermoplastic capsule (S-PVA-C) has 
been introduced by researchers at Swiss Caps AG, member of the Aenova group 
(Kirchberg, Switzerland). In the first study, we provided a thorough physical 
characterization of the new shell material. Additionally, we aimed to determine whether 
this capsule material is associated with less water exchange between the fill and the 
capsule shell compared to gelatin, thus preventing precipitation of a poorly water-soluble 
drug in the fill mass. Both SGCs and S-PVA-Cs were filled with a hydrophilic lipid-based 
system of fenofibrate and different water migration patterns were observed. SGCs 
exhibited considerable water migration from the soft gelatin shell to the fill during drying 
resulting in drug crystallization. In contrast, S-PVA-Cs displayed no substantial water 
exchange or drug crystallization upon storage. Therefore, S-PVA-Cs provided a more 
robust drug product following encapsulation of a rather hydrophilic lipid-based 
formulation compared to SGCs. Furthermore, the thermoplastic capsule material 
exhibited larger surface roughness and higher resistance to mechanical deformation 
compared to gelatin. These physical properties may be beneficial for capsule coating and 
for reducing the duration of the manufacturing process.  
The second study is focused on the biorelevant drug release from the novel S-PVA-Cs, 
SGCs, and VegaGels®. We studied the effect of the shell material by considering 
microstructural formulation changes during hydration. It was found that S-PVA-Cs 
opened only partially in biorelevant media compared to completely opened SGCs and 
VegaGels®. This different opening mechanism caused sustained drug release from S-
PVA-Cs for formulation that demonstrated high viscosity upon hydration. Such a 
rheological effect on drug release was barely noted for SGCs or VegaGels®. Additionally, 
small angle x-ray scattering (SAXS) showed differences in the hydrated microstructure 
(using a Teubner-Strey model for microemulsions). Our results suggested that even 
though S-PVA-Cs are highly attractive for encapsulation of rather hydrophilic 
formulations, some care is needed regarding an immediate release form. 
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In the third study we developed a solid lipid-based system that requires elevated filling 
temperatures for encapsulation. We aimed at better mechanistic understanding of the 
effects of drug-excipient interactions at different biopharmaceutical levels (i.e. anhydrous 
formulation, upon dispersion in simple buffer media and, in particular, regarding 
precipitation kinetics). Loratadine and carvedilol were chosen as model basic drugs. 
Drug-OA molecular complexes were formed upon addition of oleic acid (OA) in the 
formulation, which led to a marked increase in drug solubility. Precipitation kinetics of 
drug formulations was monitored in phosphate buffer (pH = 6.5) in real-time using 
focused beam reflectance measurements. The results clearly demonstrated that OA 
influenced the extent of drug precipitation as well as its kinetics. More importantly, solid-
state analysis showed an amorphous precipitate demonstrating that OA acted also as a 
precipitation modifier. The role of OA as a precipitation inhibitor, and more importantly 
as a precipitation modifier, can be used in a novel formulation approach. In situ forming 
amorphous system obtained from OA-containing formulation may be valuable from a 
biopharmaceutical perspective for the delivery of poorly soluble basic drugs.  
In summary, the present thesis introduced novel starch-based thermoplastic capsules (S-
PVA-Cs) and demonstrated their advantage over SGCs with respect to hydrophilic lipid-
based formulations. Release studies in biorelevant media revealed differences in how 
formulations hydrated and interacted with the shell material. Drug-excipient-shell 
interactions were observed in various capsule types (SGCs, S-PVA-Cs, and VegaGels®) at 
different levels of biopharmaceutical in vitro testing. A better mechanistic understanding 
was attained that may guide future development of soft capsule products. 
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 Chapter 1 
 
Introduction 
 
1.1. Background 
Soft gelatin capsules (SGCs) are established pharmaceutical dosage forms that have been 
in use for over 160 years (1). Besides masking odours and unpleasant tastes, SGCs offer 
many other advantages over other oral dosage forms, including an improved 
swallowability, optional drug protection against hydrolysis or oxidation, and an ability to 
readily dissolve in gastric fluids (2). SGCs are suitable for administration of poorly water-
soluble drugs in dissolved form, which is one of several strategies by which lipid-based 
formulations can enhance oral bioavailability. Several other benefits of SGCs derive from 
the fact that the encapsulation process requires that the drug is in solution or at least 
suspended in a liquid fill (3, 4). Drug in solution or suspension, typically leads to a much 
higher degree of reproducibility compared to tablets and hard gelatin capsules filled with 
powder or granules, since a positive displacement pump is employed for the filling 
process. Moreover, a higher content uniformity of low-dose drugs is usually achieved 
compared to powder blends of other conventional oral dosage forms.  
However, gelatin has also several drawbacks. For example, the animal source of gelatin 
can be an issue for patients living under religious (Jews, Muslims, Buddhists, and Hindus) 
Introduction and objectives 2 
or dietary restrictions (vegetarians and vegans) (5). Also, unmodified gelatin is 
susceptible to cross-linking, which can be an issue for in vitro drug release. Migration of 
drug and other formulation components (e.g. hydrophilic co-solvents) into the capsule 
shell presents another potential drawback of SGCs (6-12). Additionally, water exchange 
between the shell and the formulation can also be critical. Typically, the gelatin shell 
contains a large amount of water (up to 35% w/w) immediately after encapsulation. 
Depending on the nature of a fill mass, this water may migrate from the capsule shell into 
the fill and decrease drug solubility leading to precipitation in the fill mass (2, 13).  
To overcome the disadvantages of gelatin, there has been a great interest in the last 
decade in finding substitutes for soft capsules. However, only a few non-gelatin soft 
capsule prototypes and methods of encapsulation have been patented so far. All materials 
were based on plant-derived hydrocolloids (e.g. carrageenan, modified starch), except for 
one that mainly comprised a synthetic polymer (polyvinyl alcohol) (14-16). For the 
manufacture of such nongelatin capsules, processes like casting or extrusion are coupled 
with the standard rotary die process (17, 18). However, it appears that options for 
manufacturing capsules from carrageenan or starch-based materials are limited due to the 
technical difficulties. Carrageenan, like other hydrocolloids, requires a large fraction of 
water for full hydration, which in turn reduces the strength of the film. Therefore, a 
method for extracting a portion of water from the film-forming composition was 
recommended (19). To avoid these water-related issues, already in 2002 polyvinyl alcohol 
(PVA) has been proposed for the encapsulation process (16). Although PVA is less 
hygroscopic than hydrocolloids or gelatin, it lacks the gelling properties. Therefore, it was 
suggested to use preformed rolls of almost water-free films that can be fed into the rotary 
die encapsulation. 
The research of novel shell materials has brought to light the difficulties of replacing 
gelatin. In particular, the production step remains a technical challenge for alternative 
materials. Furthermore, it remains uncertain whether such alternative soft capsules have 
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any pharmaceutical advantages other than their non-animal origin. This stresses the need 
for more pharmaceutical research in the area of identifying new shell materials.  
Research activities conducted in Swiss Caps AG (Kirchberg, Switzerland) resulted 
recently in a novel starch-based thermoplastic material that was obtained from a two-step 
extrusion process. The new shell material combines the thermoplastic properties of starch 
with the characteristics of PVA. In our first study, we aimed at exploring whether this 
material would be specifically suited for encapsulation of hydrophilic lipid-based 
formulations (LBFs). 
In vitro drug release tests to evaluate drug and formulation behaviour under simulated 
physiological conditions are essential for efficient drug development. To better simulate 
the environment of gastro-intestinal (GI) tract, many biorelevant dissolution media have 
been developed and tested over the last decade (20, 21). Such biorelevant media, 
containing bile salts and phospholipids, are especially interesting for LBFs, since these 
natural surfactants can affect drug solubilization as well as reduce interfacial oil/water 
tension, which would affect formulation dispersion. Until recently, biorelevant drug 
release from soft capsules was not often investigated. As the shell material might have an 
impact on the drug release profile, there is a need for research in this direction. Moreover, 
the interaction of the shell material and the hydrated formulation should be studied, in 
order to gain better mechanistic understanding of the fate of the encapsulated formulation 
upon oral administration. 
Apart from studying formulation-shell interactions, also drug-excipient interactions (at 
the level of the anhydrous formulation and upon dispersion) are important from a 
biopharmaceutical perspective. Better understanding of drug-excipient interactions and 
their impact on formulation properties and the fate of formulation in GI lumen is crucial 
for a more rational selection of systems in pharmaceutical formulation development. 
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1.2. Objectives 
The present thesis is subdivided into four chapters that focus on innovations in soft 
capsule technology and a better mechanistic understanding of drug-excipient-shell 
interactions using SGCs and various starch-based thermoplastic capsules. 
In the theoretical section (Chapter 2) an overview of alternative shell materials, their 
manufacturing methods, and comparison to SGCs is provided. In addition, drug 
precipitation and supersaturation following dispersion and digestion of LBF are 
described. 
In Chapter 3 the aim was to physically characterize the novel starch-based PVA 
thermoplastic shell material (S-PVA) and to explore its pharmaceutical characteristics for 
soft capsule technology. Especially, the potential of the novel starch-based PVA 
thermoplastic capsules (S-PVA-Cs) for encapsulation of hydrophilic LBFs was evaluated. 
Moreover, we aimed to determine whether S-PVA-Cs exhibit less water exchange 
between the fill and the capsule shell compared to SGCs, thus preventing precipitation of 
a poorly water-soluble drug in the fill mass. 
Chapter 4 is focused on the biorelevant drug release from the novel S-PVA-Cs, SGCs, and 
VegaGels®. Particular attention was directed to microstructural formulation changes 
during hydration. These formulation hydration changes were to be studied by means of 
small angle x-ray scattering (SAXS) and microchip-based rheology. Furthermore, we 
investigated the correlation of the opening mechanism of capsules with the formulation 
hydration and its impact on the drug release profiles. 
In Chapter 5 the solid-lipid based system that contains oleic acid and requires elevated 
filling temperatures for encapsulation was developed. The aim was to elucidate 
interactions of oleic acid with basic drugs in solid lipids on different levels of 
biopharmaceutical in vitro testing. A particular interest was in the influence of drug-oleic 
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acid interactions on drug precipitation kinetics and on the solid-state properties of the 
precipitates following dispersion.  
  
Chapter 2 
 
Theoretical section 
 
2.1. Soft gelatin capsules 
Soft gelatin capsules (SGCs) are single-unit solid dosage forms consisting of a soft 
gelatin shell and usually a liquid or a semi-solid filling. They are one-piece hermetically 
sealed capsules, which can be administered via various routes, although the oral route is 
the most common one. In the following paragraphs composition of the shell material, as 
well as advantages and challenges of SGCs will be discussed. 
2.1.1. Composition of soft gelatin capsule shell 
A soft gelatin capsule shell usually consists of gelatin, plasticizer(s), and water. It may 
also contain other minor additives such as preservatives, colouring and opacifying agents, 
flavourings and sweeteners, gastro-resistant substances, or even active compounds.  
Gelatin is basically protein derived from the native protein collagen which is present in 
animal skin, bone, and hide. It has unique physicochemical properties (e.g. solubility, 
solution viscosity, thermally reversible gelation properties) making it particularly suitable 
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for the pharmaceutical capsule industry. Produced gelatin films are strong, clear, flexible, 
and easily soluble in gastric juices. The major sources of collagen for the production of 
gelatin are porcine skin, cattle hides, and bones (22). The manufacturing procedure 
comprises cleaning of raw material, pretreatment, extraction of gelatin, filtration, 
concentration/evaporation, sterilization, and drying. The raw material can be pretreated 
with either dilute acid (acid pretreatment) or alkali, depending on the origin of the 
collagen. A short acid pretreatment is typically used for the less covalently cross-linked 
collagens found in young animals, while a more intense alkali pretreatment is normally 
applied for more covalently cross-linked collagens from older animals. Gelatin derived 
from acid-treated and alkali-treated precursors are known as type A and type B, 
respectively (23). As mentioned earlier, gelatin has a unique ability to form a thermally 
reversible gel. Gel strength depends upon the gelatin concentration, pH, temperature, and 
maturing time. The Bloom value is the most important industrial criterion for grading a 
batch of commercial gelatin. It defines the gel strength as the force required for a 12.7 
mm diameter flat-bottomed cylindrical plunger to depress the surface of a 6.67% w/w 
gelatin gel (matured at 10° C for 16-18h) to a depth of 4 mm (22). Pharmacopoeial 
specifications for gelatin (24) generally present minimum requirements (pH, conductivity, 
gel strength), while capsule manufacturers require more detailed specifications including 
some performance-related parameters. Apart from gelatin type and gel strength, industrial 
specifications usually include viscosity at 60° C and 6.67% w/w concentration in water, 
viscosity breakdown (the impact of temperature and time on the degradation of gelatin), 
melting point, setting point, setting time, particle size, and molecular weight distribution. 
An ideal soft capsule gelatin should have a gel strength of 150-200 Bloom, a viscosity of 
2.8-4.5 mPas, a well-controlled degree of viscosity breakdown, a well-defined particle 
size, and a broad molecular weight distribution (25). Table 2.1 lists the main gelatin types 
and grades used for soft capsule production. Recently, gelatins derived from poultry and 
fish have been introduced as alternatives to gelatin of bovine and porcine origin. While 
poultry gelatin has comparable physicochemical properties to those of pigskin gelatin, 
and therefore could be used as a substitute for conventional gelatin, fish gelatin lacks the 
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gelling and setting attributes needed for soft capsule production. The overall 
technological issues, limited availability, and high costs are the main reasons that these 
alternative gelatin sources have not yet become commercially available. 
 
Table 2.1: Physicochemical properties of pharmaceutical-grade soft capsule gelatins (LB-
limed bone, LH-limed hide, AB-acid bone, PS-pigskin). Adapted from 
reference (25). 
Gelatin Origin of raw 
material 
Type Bloom (g) 
(10° C; 6.67% w/w) 
Viscosity (mPas) 
(60° C; 6.67% w/w) 
160 LB Bovine/porcine bone B 155-185 3.4-4.2 
160 LH Bovine hide B 150-170 3.5-4.2 
160 LB/LB Blend of 
bovine/porcine bone 
and bovine hide 
B 150-170 3.5-4.2 
200 AB Bovine bone A 180-210 2.7-3.2 
200 PS Pigskin A 190-210 2.5-3.1 
160 
PS/LB/LH 
Blend of pigskin, 
bovine/porcine bone 
and bovine hide 
A/B 145-175 2.7-3.3 
 
As mentioned beforehand, the soft gelatin shell typically contains gelatin, plasticizer(s), 
and water. The weight ratio of water to dry gelatin (W/G) can vary from 0.7 to 1.3, 
depending on the viscosity of the gelatin. After encapsulation and drying, most of the 
water is removed, leading to final capsules with a moisture content of 4-10%. The weight 
ratio of dry plasticizer and dry gelatin (P/G) determines the shell strength and usually 
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varies between 0.3 and 1. Plasticizers have a highly important role in shell formulation. 
Thus, plasticizers ensure that the capsules retain their elasticity during the drying process 
and subsequent storage, i.e. that brittleness is avoided. Commonly used plasticizers for 
soft gelatin capsules are polyalcohols (e.g. glycerol, some grades of non-crystallising 
aqueous sorbitol, and sorbitan/sorbitol solutions). The selection and concentration of the 
plasticizer together with the residual moisture and the thickness of the shell (250-500 µm) 
determine the hardness and mechanical stability of the capsule. Glycerol is the most 
frequently used plasticizer, due to its high plasticizer efficacy, sufficient compatibility and 
its lacking interference with the formation of a stable three-dimensional gelatin network 
(25).  
2.1.2. Advantages of soft gelatin capsules 
The first invention of gelatin capsules dates from the early 19th century, as a result of the 
need to mask the obnoxious taste of many drugs popular at that time (1). Besides masking 
odours and unpleasant tastes, SGCs offer many other advantages over other oral dosage 
forms, including an improved swallowability, optional drug protection against hydrolysis 
or oxidation, and an ability to readily dissolve in gastric fluids (2). Recently, significant 
advances have been made in the development of liquid and semi-solid formulations for 
SGCs. Studies have focused on increasing drug bioavailability and decreasing plasma 
variability by improving solubility and promoting drug absorption (26-29). The SGC 
encapsulation process has the pharmaceutical advantage, that the drug is solubilized or at 
least suspended in a liquid fill. A positive displacement pump is employed for the filling 
process and therefore a much higher degree of reproducibility is obtained compared to 
tablets and hard gelatin capsules filled with powder or granules. Moreover, a higher 
content uniformity of low-dose drugs is usually achieved compared to powder blends of 
other conventional oral dosage forms (3).  
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2.1.3. Challenges and limitations of soft gelatin capsules 
Worldwide, many consumers of pharmaceutical products readily accept SGCs due to their 
favourable characteristics for an oral dosage form. However, SGCs have also some 
drawbacks. One of them is the animal source of gelatin that can be an issue for patients 
living under religious (Jews, Muslims, Buddhists, and Hindus) or dietary restrictions 
(vegetarians and vegans). In addition, the appearance of transmitting animal diseases, 
especially bovine spongiform encephalopathy (BSE; commonly known as mad cow 
disease) raised many concerns among both manufacturers and consumers. The BSE crisis 
hit the gelatin industry worldwide, although the scientific community reported early on 
that the gelatin manufacturing process delivered a safe product, even if infected animal 
materials were used (5).  
Nowadays, gelatin manufacturers have established certified Quality Management 
Systems according to the worldwide standard ISO 9001 in order to ensure that their 
products comply with all required physical, chemical, microbiological, and technical 
production and quality standards (30). Additionally, manufacturers of pharmaceutical 
gelatin have to follow strict guidelines published by many national and international 
regulation authorities (e.g. Food and Drug Administration, FDA, “Guidance for 
Industry”, and European CPMP’s regulation ‘‘Note for Guidance’’ EMEA/410/01 Rev.3) 
(31, 32).  
One of the key challenges in the development of SGCs is preventing or minimizing the 
chemical and physical interactions between the capsule shell and the formulation fill 
(compatibility issues). One well-known chemical interaction is the cross-linking of 
gelatin in presence of aldehydes. Cross-linking is chemical covalent bonding between 
different polypeptide chains, which may results in partially insoluble gelatin protein. This 
phenomenon can affect in vitro drug release by forming swollen, rubbery water-insoluble 
membranes that are known as pellicles and that may act as a barrier to drug release. 
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However, in vivo disintegration of cross-linked capsules is rapid, which led scientists to 
develop a two-tier in vitro dissolution test using enzymes (e.g. pepsin) (33). Some 
approaches to minimizing the cross-linking of gelatin include use of excipients with a low 
aldehyde content, incorporation of succinic acid into the gelatin shell, and/or the addition 
of antioxidants to the formulation. Antioxidants are often necessary, because auto-
oxidative degradation of some excipients (e.g. polyethylene glycol) may generate 
aldehydes (34). Another chemical interaction that might occur is esterification or 
transesterification of drugs with polyols. To prevent this unwanted interaction, Gullapalli 
et al. (35) suggested a glycerol-free shell formulation and the addition of polyvinyl 
pyrrolidone to the fill. 
A soft gelatin capsule is a very dynamic system, as presented in Figure 2.1. Migrations of 
constituents between the shell and the fill, as well as the shell and the external 
environment, are very common. These migrations might occur during manufacture, 
drying and on storage, and they present substantial challenges for development of stable 
SGCs. 
 
Figure 2.1: Schematic representation of fill/shell dynamics during drying process and 
storage. Arrows indicate possible migrations and MW holds for molecular 
weight. 
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Immediately after encapsulation, the capsule shell contains high water content (≥30% 
w/w). During a two-step drying process (primary and secondary drying) water migrates 
from the shell into the environment and the fill until equilibrium moisture content is 
reached (usually 10-15% w/w). As reported by Gullapalli et al. (2), the water migration 
pattern greatly depends on the nature of the fill formulation. While for lipophilic oily 
formulations there is no water uptake from the shell, a rather hydrophilic fill might pick 
up a higher amount of water (up to 20% w/w) during primary drying. During secondary 
drying, some water migrates back into the shell, resulting in capsules containing up to 8% 
w/w of water in the fill. This water creates a risk of drug precipitation in the fill mass, as 
shown by Serajuddin et al. (13). They demonstrated that even a small increase in water 
content in polyethylene glycol 400 (PEG 400) can greatly reduce the drug solubility. 
After the drying process, the packaging and storage of produced SGCs might also be 
problematic due to the moisture and temperature sensitivity of the gelatin material and, 
therefore, special care should be taken in very hot and humid regions. 
The gelatin capsule shell is compatible with a broad range of liquid and semi-solid 
lipophilic excipients, solubilizing agents, surfactants, and absorption enhancers. However, 
the encapsulation of hydrophilic components is very critical, as they usually migrate 
easily into the shell. Namely, hydrophilic excipients such as low-molecular weight PEG, 
ethanol, and propylene glycol can readily diffuse into the capsule shell and act as 
plasticizers. Recently, Cao et al. (10) studied the effects of different kinds of plasticizers 
on the mechanical properties of gelatin films. They concluded that PEG of lower 
molecular weights (MW) exhibited better plasticizing effects when compared to PEG of 
higher MW. Also, mannitol and sorbitol proved to be good plasticizers. In addition, it was 
shown that malic acid (short-chain fatty acid) diffused into gelatin film and improved the 
flexibility of tested film. Plasticizers in the shell also tend to migrate into a hydrophilic 
fill. Therefore, to avoid compatibility issues, the amount of hydrophilic excipients should 
be kept to a minimum level. Besides reducing their amount, other approaches for the 
successful encapsulation of hydrophilic fill mass have also been suggested. For example, 
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Brox et al. (36) proposed to partially replace glycerol with sorbitol in the capsule shell, 
and to add glycerol and sorbitol into the fill material. 
Volatile excipients (e.g. ethyl alcohol, commonly used as a co-solvent for poorly water-
soluble components) can easily diffuse through gelatin shells and potentially cause the 
precipitation of a dissolved drug (11, 12). In such cases, solvent-tight packaging material 
(aluminium blister) is commonly used to prevent volatilization. 
Migration of drug into the capsule shell presents another potential drawback of SGCs. 
The extent of drug migration greatly depends on its aqueous solubility and partition 
coefficient between water and non-polar solvent, as demonstrated by Armstrong et al. (6, 
7). They also showed that there was no correlation between the extent of drug migration 
and the drug solubility in the fill formulation (isopropyl myristate). Later, Gebre-Mariam 
et al. (8, 9) studied the effect of gelatin grade and concentration on drug migration 
through gelatin films. It was found that the diffusion of the analysed compound (4-
hydroxybenzoic acid) was independent of the type of gelatin used. They concluded that 
the microviscosity of the prepared gelatin films, rather than the bulk viscosity, was the 
critical factor governing drug diffusion. 
In summary, even though SGC provide an attractive dosage form, there are certainly 
some challenges and limitations of gelatin as a shell-forming material. Therefore, there 
was a great interest in the last decade to either modify existing gelatin shell compositions 
or to elucidate novel shell materials. In 2001, Gennadios (37) proposed to partially 
replace gelatin with gum acacia (up to 20% w/w). This novel capsule shell composition 
offered obvious economic benefits, as gum acacia is much cheaper than gelatin. In 
addition, shorter drying, opening and disintegration times were presented as some 
functional improvements of the developed shell composition. Also recently, the patent by 
Zoppetti et al. (38) was granted for novel soft gelatin capsules containing a cyclodextrin 
in the capsule shell. This delivery system was developed particularly for the encapsulation 
of poorly water-soluble drugs (PWSD). Upon disintegration of such a capsule, an active 
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compound would form a complex with a cyclodextrin, which would improve the drug 
solubility. In the next paragraph is provided an overview for potential gelatin substitutes 
in soft capsule technology. 
2.2. Alternative materials for soft capsules 
The search for the ideal replacement of gelatin in soft capsule technology has resulted so 
far in only a few potential alternative materials. This could be due to the fact that as well 
as overcoming the above-mentioned drawbacks of gelatin, capsule shell polymers would 
need regulatory approval and adequate methods of production (either coupled with the 
standard rotary die soft capsule process, or by using different machinery). 
To date, most patented soft capsule prototypes have been based on plant-derived 
hydrocolloids (14, 15), with one exception that contained a synthetic polymer (16). With 
respect to plant-derived hydrocolloids, two types of carrageenan (iota and kappa), and 
modified starch of different origin (pea, corn, potato, tapioca) were used in different 
combinations. For example, the mixture of iota carrageenan with modified starch 
(hydroxypropyl potato starch) was described in the patent US 6,340,473 (15). 
Conventional plasticizers (e.g. glycerol and sorbitol) and water were added, and the 
mixture was casted to form mechanically strong, elastic films. A similar film-forming 
composition comprising iota and kappa carrageenan with modified corn starch was 
patented by Fonkwe et al. (39). Recently, Popescu et al. (40) studied various blends of 
carrageenan with modified starch from different sources (pea, corn, potato). They 
concluded that the origin of the starch had an impact on the rheological and mechanical 
properties of the prepared films, which could be due to the different amylose content. Pea 
starch was shown to be a promising non-gelatin material for soft capsules, as the 
produced capsules were clear and shiny with good mechanical strength and elasticity. 
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However, the procedure for the production of hydrocolloid-containing films is rather 
demanding. Namely, hydrocolloids require a large amount of water for their full 
hydration. If the produced films are not sufficiently dried, the retained water reduces the 
film strength. Therefore, a very useful method for extracting a portion of water from the 
films was proposed by Archibald et al. (19). They used an extruder/dryer that included a 
series of individually controllable heating zones along its length. As the film-forming 
composition was heated and agitated in the extruder/dryer, the excess water was extracted 
through several water extraction ports. However, the extrusion process for the production 
of starch-based shell material with low water content was already introduced earlier by 
Broker et al. (14). 
Another interesting approach to overcome these water-related issues was suggested by 
Brown et al. (16). They used synthetic polymers, such as polyvinyl alcohol (PVA). As 
PVA lacks the gelling properties of hydrocolloids or gelatin, these authors suggested 
using preformed rolls of almost water-free films that could be fed into the rotary die 
encapsulation. Also recently, Reich et al. (41) evaluated polymer films made of Kollicoat 
Protect® (coating polymer mixture comprising PVA-PEG graft copolymers and PVA; 
BASF) using a small-scale casting drum. This casting device simulated the conditions of 
the rotary die machine and proved to be a useful laboratory tool for screening non-gelatin 
film-forming polymers. Kollicoat Protect® formed homogenous polymer films of well-
defined thickness, whose mechanical properties were dependent on water content. As a 
follow-up to this research, Meyer-Böhm et al. (42) studied various combinations of 
modified starch types (tapioca, corn, pea) and Kollicoat Protect®. They demonstrated that 
modified pea starch improved flexibility of the produced films compared to the starchless 
films.  
Research activities conducted in Swiss Caps AG (Kirchberg, Switzerland) resulted 
recently in a novel starch-based thermoplastic material that was obtained from a two-step 
extrusion process. The new shell material combines the thermoplastic properties of starch 
with the characteristics of PVA. In our first study we aimed to physically characterize the 
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novel starch-based PVA thermoplastic shell material (S-PVA) and to explore its 
pharmaceutical advantages over gelatin for soft capsule technology. 
Today, several types of plant-based soft capsules are commercially available. Table 2.2 
outlines the most common non-gelatin soft capsules on the market. Basically, both 
qualitative and quantitative compositions of the presented capsule prototypes are similar. 
The main difference is the water content in the finished product, due to the different 
manufacturing processes. 
 
Table 2.2: Overview of selected commercial non-gelatin soft capsules. 
 Composition Method of 
production 
Manufacturer Patent 
Vegicaps® Modified starch/iota 
carrageenan blend, 
plasticizer, water          
52.5% :37.5% :10% 
(w/w) 
Melt-on-
demand, 
casting and 
rotary die 
method 
Catalent US 6,884,060 
US 6,340,473  
US 6,582,727 
VegaGels® Potato starch, 
glycerol, sorbitol, 
carrageenan, and 
water 66% : 18% : 
10% : 1% : 5% (w/w) 
Extrusion 
and rotary 
die method 
Swiss Caps AG, 
member of 
AENOVA group 
US 6,790,495 
SeaGel® Kappa or iota 
carrageenan, starch, 
optionally a 
plasticizer, water  
Extrusion/ 
casting and 
rotary die 
method 
FMC Biopolymer US 7,807,194 
Until now, all plant-based soft capsules were intended only for healthcare and nutritional 
consumers. They are most commonly used for the encapsulation of simple lipophilic oils 
(vitamins A, E, vegetable oils), multivitamins and some herbals (Table 2.3).  
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Table 2.3: List of selected commercially available lipophilic oils encapsulated in non- 
gelatin soft capsules, in Europe, in 2013. 
Trade name Active ingredients/Dose Distributer 
Opti 3 Omega-3 EPA & 
DHA 
EPA (200 mg), DHA (400 mg), D3  
(5 µg) 
ESB Developments1 
Surbex Natopherol®   d-α tocopherol Abbott2 
Garlic pearls Pure concentrated garlic oil 
Omega 3,6,9 Organic Flaxseed Oil (1000 mg) 
VitaEPA  Omega-3 Fatty Acids (300 mg), EPA 
(180 mg), DHA (120 mg) and 
Natural Vitamin E (2 IU) 
Primolin gold Evening primrose oil (1000 mg), 
vitamin E 
VitaHealth2 
UltraClean Algal DHA 
and Omega 
Schizochytrium sp. (microalgae) and 
Hippophae rhamnoides (sea 
buckthorn), DHA (300 mg) 
BioCeuticals2 
Actilife Omega-3 DHA (250 mg), Migros3 
Omega 3 Linseed oil 
1000 
α Linolenic acid (500mg), Folic acid 
(600 µg), Vitamin B6 (4.2 mg), 
Vitamin B 12 (7.5µg) 
DM Drogeriemarkt3 
Marinalis, marine lipids Tuna fish oil (500 mg), DHA (120 
mg), EPA (30 mg) 
Sofinol3 
 
1SeaGel® FMC technology; 2Vegicaps® capsule; 3VegaGels® capsule; EPA-Eicosapentaenoic acid; DHA- 
Docosahexaenoic acid; IU-international units  
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2.3. Manufacturing methods  
In the early 19th century soft gelatin capsules were produced one at a time in individual 
moulds. As technology advanced, the individual moulds were replaced by multiple 
moulding units, which led to the development of plates containing die pockets (plate 
process) (3). As this method requires several operators and the equipment cannot be 
purchased any more, it is almost obsolete today. Up till now, several other methods (e.g. 
Norton, Accogel) have been invented, but are nowadays rarely employed. The 
commercially important equipment and processes in soft capsule technology that are used 
contemporarily will be described in the following paragraphs.  
2.3.1. Globex method 
Seamless, spherical soft gelatin capsules can be produced by the Globex method (Figure 
2.2). The lipophilic fill and the gelatin shell formulations are stored separately and kept at 
elevated temperatures (> 60° C) (43). 
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Figure 2.2: Process outline of the Globex method. Adapted from reference (44). 
 
They are both simultaneously pumped through a concentric double tube, with the fill in 
the inner one. The liquids are discharged into a cooling bath (e.g. liquid paraffin at 4° C) 
as droplets consisting of a liquid fill with a molten gelatin outer film. The droplets assume 
spherical shape, as the shell material possesses a higher surface tension compared to the 
surface tension of the fill. Upon cooling, gelatin congeals thereby forming a flexible and 
firm capsule shell. The produced capsules are collected, washed and dried. The main 
disadvantage of this method is the necessity of optimizing the surface tension between the 
fill and the shell material (44). 
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2.3.2. Rotary die method  
The rotary die method was invented in 1933 by Robert Pauli Scherer. To date, it has 
become the standard manufacturing procedure for encapsulation of liquids and semi-
solids in soft gelatin capsules. The illustration of the production process is shown in 
Figure 2.3.  
For the rotary die method, the fill and the shell material are prepared in separate 
containers. The shell formulation is made by initially mixing water and plasticizer(s) with 
gelatin in a suitable vessel at room temperature (RT). The mixture is then melted 
completely at high temperatures (~90-95° C) under vacuum with slow mixing, until a 
clear gel is obtained. The molten mass is transferred to heated tanks and kept at 57-60° C. 
From the tanks, the gelatin solution is fed into two spreader boxes placed above cooled 
rotating drums (13-14° C). The spreader boxes control the flow of the shell-forming 
material onto rotating casting drums. The thickness of the formed gelatin ribbons can be 
varied depending on the capsule application (from 600-1000 µm), but usually it is about 
800 µm. The formed ribbons are lubricated by feeding them over guide rolls through a 
mineral oil bath. Subsequently, they are guided over counter-rotating rolls that contain the 
shape forming dies. The die cavities on the left-hand roll form the left half of the capsule; 
the die cavities on the right-hand roll form the right half of the capsule. As the die rolls 
rotate, die cavities on the two rolls match and the two passing gelatin ribbons can be 
sealed and cut along the edge of the dies. As a result, the lower parts of the capsules are 
sealed. The filling material flows by gravity from a filling tank into a positive 
displacement pump. The pump accurately injects the fill through the wedge and into the 
partially sealed gelatin ribbons between the die rolls. As the die rolls continue to rotate, 
the filled capsules are completely sealed and cut out. The produced capsules have to be 
washed to remove the mineral oil lubricant (44). 
After encapsulation, the capsules are subjected to a two-step drying process (primary and 
secondary drying). During primary drying, capsules are transferred into rotating drums at 
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20-30° C until about 50-60% of the water content in the shell is removed. For secondary 
drying, capsules are placed in tunnel dryers at a relative humidity of 10-30% and 20-25° 
C until the equilibrium is reached. This might take from several hours to several days 
depending on the gelatin formulation used. The shell of the dried capsules at equilibrium 
normally contains 6-10% water, which is determined during quality control testing. 
Additional analysis, such as seam thickness and rupture tests, are also employed on the 
finished capsules. Afterwards, the capsules might be sent for ink printing (for 
identification purposes), enteric-coating (for modified-release dosage forms) or directly to 
packaging into blisters (3, 44). 
 
 
Figure 2.3: Illustration of the rotary die method. Adapted from reference (44). 
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The rotary die method has several advantages over the Globex method. For example, 
there are no restrictions regarding the fill (other than compatibility with the shell). It also 
enables the production of capsules of different shapes, sizes, or even colours. 
Additionally, the manufacturing rates are faster so that up to 100 000 capsules per hour 
can be produced. However, the costs are higher due to the large amount of shell waste, 
and machinery maintenance. Another disadvantage of the rotary die method is the risk of 
leakage through imperfect seams, which is avoided by the Globex method as the 
produced capsules are seamless. In line with these different technological aspects, the 
rotary die method is the most commonly used process today for the production of soft 
gelatin capsules. 
2.3.3. Production of non-gelatin soft capsules  
As shown in Table 2.2, the shell formulations of non-gelatin soft capsules are usually 
starch-based. Accordingly, the machinery for the production of shell ribbons was adjusted 
to the existing rotary die method. For example, Vegicaps® are produced using melt-on-
demand and casting technology coupled with the rotary die method (17). For this 
technology, the film-forming material is prepared in bulk (allowed to solidify), and is 
transferred to tanks. Only the required amount of solid shell formulation from the tanks is 
melted in the melt-on-demand device and transported under pressure to the casting drum. 
The casted ribbons are further guided over rolls to rotating dies and the fill is 
encapsulated. 
The manufacturing process of SeaGel® capsules was patented recently by FMC 
Biopolymer (18). Firstly, all components of the shell-forming material are heated, 
hydrated, mixed, solubilized and de-aerated in a suitable double jacketed vessel at 90-95° 
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C. In the next step, the molten mass can be formed into a film either by casting the 
mixture onto a cooling drums or by passing the mixture through an extruder. The formed 
films are used for encapsulation using the conventional rotary die process. 
In contrast to Vegicaps® and SeaGel® capsules, the shell material of VegaGels® is 
produced in a two-step extrusion process, as presented in Figure 2.4. In the first step, the 
shell formulation is mixed by means of a double-screw extruder at 130-140° C under high 
pressure of 115-120 bar to form granules. Formed granules can be stored in plastic tanks 
or mixed with colourants and used immediately for the second extrusion process. For this 
subsequent extrusion, a single-screw extruder is employed at about 100-135° C. The 
obtained extrudate is pressed through a slit die at 115° C to form a shell ribbon used 
further on in the rotary die method. This manufacturing process was also used for the 
encapsulation of the novel starch-based PVA thermoplastic capsules (S-PVA-Cs) that are 
described in detail in Chapter 3. 
 
Figure 2.4: Schematic outline of the manufacturing process of VegaGels®. Reprinted 
from reference (14) with permission from Swiss Caps AG.  
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2.4. Comparison of soft gelatin capsules versus non-gelatin soft capsules 
The different shell capsule technologies can be compared by means of the shell material, 
processing characteristics as well as by considering biopharmaceutical aspects. Table 2.4 
provides such an overview of most relevant features of soft capsule technologies. 
 
Table 2.4: Soft gelatin capsules versus non-gelatin soft capsules. 
 Soft gelatin capsules Non-gelatin soft capsules 
Shell composition Animal origin 
Gelatin, plasticizer, water, etc. 
Plant-based 
Modified starch (potato), carrageenan 
(or PVA), plasticizer, water etc. 
 
Fill composition Type I-IV according to LFCS Type I-IV according to LFCS 
Potential improvement for type IIIB- 
IV 
 
Fill pH Slightly acidic to slightly basic Slightly acidic to highly alkaline 
 
Manufacturing  
process 
 
Rotary die method Melt-on-demand/casting/extrusion 
coupled with the rotary die method 
Fill temperature Maximum: 35-40° C 
(primarily liquids) 
Maximum: 65-75° C  
(for S-PVA-C: 100-140° C) 
(viscous liquids, semi-solids; high 
melting point formulations) 
 
Large scale 
manufacture and  
available marketed 
products 
Good technical feasibility with 
many market products 
(Pharmaceuticals and Health & 
Nutritional) 
 
Technical feasibility demonstrated 
with products on the market (OTC 
and Health & Nutritional; No 
pharmaceuticals) 
 
Shell compatibility 
with fill excipients 
Mostly lipophilic 
Limitations: hydrophilic 
excipients; low MW and 
short/medium-chain lengths 
 
Wide range: from lipophilic to 
hydrophilic 
Potentially less limitations 
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 Soft gelatin capsules Non-gelatin soft capsules 
Drug migration  Probable in the case of small 
acidic compounds 
 
Not expected 
Water migration Very dynamic system 
(potential limitation for 
hydrophilic formulations) 
 
Slight water migration 
Shell disintegration Fast Fast (for S-PVA-C: short lag-time) 
 
Dissolution Potential cross-linking No cross-linking 
 
 
LFCS - lipid formulation classification system; S-PVA-C - starch-based PVA capsule; OTC – over the counter 
 
2.5. Oral lipid-based formulations for poorly water-soluble drugs  
Poorly water-soluble drugs (PWSD) are typical outcomes of high throughput screening in 
drug discovery programmes. According to their permeability, these drugs can be 
categorized by the Biopharmaceutics Classification System (BCS) as class II (high 
permeable) or class IV (low permeable) compounds (Figure 2.5) (45). Additionally, this 
classification system includes highly soluble drugs and also differentiates them according 
to permeability (class I and class III). From a pharmaceutical perspective, poorly-soluble 
compounds (class II and IV) are especially challenging, but various formulation strategies 
can help in reducing biopharmaceutical issues. Particularly, in case of class II compounds, 
several formulation approaches exist to cope with a limiting solubility or a critical drug 
dissolution rate (46).  
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Figure 2.5: Biopharmaceutics Classification System according to Amidon et al. (45). 
 
Nowadays, oral lipid-based formulations (LBFs) have become one of the most interesting 
formulation strategies for PWSD. Their main advantage is that the drug remains in 
solution during its transit period in the lumen of the gastrointestinal tract (GIT). Although 
drug solubilization is the primary mechanism by which LBFs improve drug absorption, 
they may also protect the drug from chemical and enzymatic degradation in the GIT, as 
well as promote lymphatic drug transport (Figure 2.6). 
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Figure 2.6: Schematic diagram of intestinal drug transport from LBF via the portal and 
the mesenteric lymphatic routes. (A) Increased membrane fluidity facilitating 
transcellular absorption, (B) opening of tight junctions to allow paracellular 
transport, (C) inhibition of P-gp and/or CYP450 to increase intracellular 
concentration and residence time, and (D) stimulation of 
lipoprotein/chylomicron production. ABL-aqueous boundary layer; D-drug; 
D¯-ionized drug; FA MG-fatty acid monoglyceride; LCFA-long-chain fatty 
acid; ME-microemulsion; SEDDS-self-emulsifying drug delivery system; 
TG-triglyceride; TJ-tight junction. Reprinted from reference (47) with 
permission from Elsevier. 
 
LBFs range from simple oils to complex mixtures comprising oils, lipophilic and 
hydrophilic surfactants, and hydrophilic co-solvents (48). In 2000, Pouton proposed the 
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Lipid Formulation Classification System (LFCS) to categorize LBFs into classes based on 
the polarity of excipient blends (Table 2.5) (49). Type I formulations are simple, non-toxic 
solutions of the drug in oils (e.g. triglycerides, mixtures of mono- and diglycerides). They 
generate coarse oil droplets upon dispersion and would have to be digested to free fatty 
acids and 2-monoglycerides to further promote drug absorption. Due to their lipophilicity 
they are particularly appropriate for drug compounds with rather high lipophilicity, e.g., 
log P>4. Type II formulations are combinations of oils and lipophilic surfactants (e.g. 
lecithin, Labrafil® M1944CS) and they are employed when higher drug solubility in a 
formulation is needed. These formulations spontaneously self-emulsify upon gentle 
agitation. Fine emulsions (0.25-2 µm) are generated and they are usually digested thereby 
enhancing drug absorption. Type III formulations contain oils, hydrophilic surfactants 
(e.g. Gelucire® 44/14, Cremophor® RH 40), and co-solvents (e.g. PEG, propylene glycol), 
which may further facilitate the self-emulsification process in the GIT. Depending on the 
oil content in type III formulations, we can differentiate type IIIA formulations (up to 
80% w/w oil) and type IIIB formulations (< 20% w/w oil). While type IIIB formulations 
form smaller particles (<50 nm) compared to type IIIA formulations (100-250 nm), they 
also present a greater risk of drug precipitation upon aqueous dispersion due to a loss of 
solvent capacity. In 2006, Pouton introduced an updated version of the LFCS that 
contained an additional category (type IV formulations) (50). These formulations are oil-
free and represent the most hydrophilic lipid-based formulations comprised only of 
hydrophilic surfactants and co-solvents. Type IV formulations commonly offer increased 
drug payloads and produce micellar structures when introduced in aqueous media. It has 
been suggested that this in turn led to rapid drug release and increased drug absorption 
(51). However, adding more hydrophilic excipients may also foster drug precipitation 
upon formulation dispersion, therefore some care is needed when using this type of lipid-
based system. 
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Table 2.5: Composition of lipid-based formulations (%, w/w) according to LFCS (50). 
Excipient Type  
I 
Type  
II 
Type 
IIIA 
Type 
IIIB 
Type  
IV 
Oils 100 40-80 40-80 <20 - 
Lipophilic surfactants (HLB<12) - 20-60 - - 0-20 
Hydrophilic surfactants (HLB>12) - - 20-40 20-50 30-80 
Co-solvents - - 0-40 20-50 0-50 
 
HLB - hydrophilic-lipophilic balance 
In this thesis particular interest was directed towards the encapsulation of hydrophilic 
lipid-based formulations, such as self-microemulsifying drug delivery systems 
(SMEDDS), since they present a special challenge in terms of capsule compatibility. 
Therefore the following paragraph describes these systems in more detail.  
2.6. Self-microemulsifying drug delivery systems (SMEDDS) 
Self-microemulsifying drug delivery systems (SMEDDS) are defined as 
thermodynamically stable isotropic mixtures of oil, surfactant/co-surfactant, and a 
solubilized drug. These formulations rapidly and spontaneously form transparent o/w 
microemulsions (droplet size <50 nm) in contact with aqueous media (52). Upon oral 
administration, SMEDDS are easily dispersed in the gastrointestinal fluids, as the motility 
of the stomach and small intestine endows the gentle agitation needed for emulsification 
(53). Recently, the name SMEDDS has been challenged because obtained colloidal 
dispersions may not necessarily be true microemulsions but nano-emulsions instead (54). 
The latter system is only kinetically stable and is not a thermodynamically stable system 
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like microemulsions. The definition of microemulsions as thermodynamically stable 
systems was proposed already in 1981 by Danielsson and Lindman (55). Some authors 
preferred to use the name self-nanoemulsifying system (SNEDDS) but this does not help 
as long as the true nature of the colloidal dispersion has not been identified, which most 
scientific reports do not clarify. A very recent article proposed a guideline for 
differentiating the different types of nano-dispersion (56). However, such experimental 
differentiation is primarily of academic interest because it is most likely of lesser 
importance from a biopharmaceutical perspective. 
2.6.1. Excipients in SMEDDS 
The primary aim in the selection of adequate excipients for self-emulsifying formulations 
is finding an excipient or combination of excipients that will enable the solubilization of 
the entire drug dose (57). A major concern represents the chemical and physical stability 
of the drug in the formulation, which both have to be monitored during formulation 
development. Another important criterion in excipient selection is the toxicity and safety 
that are evaluated by regulatory authorities. “Generally recognised as safe” (GRAS) 
excipients are excipients tested by the United States Food and Drug Administration 
(FDA) and they are considered as non-toxic to humans and animals (58). The FDA also 
recommends the accepted amounts of excipients in the Inactive Ingredient Database 
(IID), where they publish qualitative and quantitative compositions of approved drug 
products on the US market (59). 
Medium-chain triglycerides (MCT; e.g. Miglyol® 812 N, coconut oil) and long-chain 
triglycerides (LCT; e.g. olive oil, peanut oil) are the most commonly used oils for the 
formulation of SMEDDS (60). To empower rapid and facile dispersion in the GIT, 
SMEDDS require the incorporation of large amounts of surfactants (up to 50% w/w) that 
possess relatively high HLB (hydrophilic-lipophilic balance) values. Since surfactants 
often have potential toxic effects, particularly when they are used at high amounts, it is 
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important to consider the oral tolerability these excipients. Therefore, non-ionic 
surfactants are usually favoured over their ionic counterparts, as they have been reported 
to have minimal toxicity. Also, surfactants of natural origin (e.g. lecithin or Peceol®) are 
generally less toxic compared to synthetic surfactants (e.g. Tween 80®). Such natural 
surfactants may, however not always exhibit the same performance of self-emulsification 
as compared to synthetic amphiphile. In addition, surfactants can facilitate drug 
absorption via reversibly changing of the intestinal permeability (61). Formulations 
comprising of oils and hydrophilic surfactants might not have sufficient solubilizing 
capacity for some drugs. In such cases, the addition of hydrophilic co-solvents (e.g. 
ethanol, propylene glycol, glycerol, PEG) is needed (50). However, since these excipients 
normally change their solubilizing properties following dispersion in GI fluids, the risk of 
drug precipitation raises (62). Therefore, hydrophilic co-solvents should be added 
carefully. 
Ternary phase diagrams typically help to find optimum concentrations or suitable 
concentration ranges of the excipients in the final formulation. Each point in the phase 
diagram corresponds to a certain combination of oil, surfactant, and co-surfactant. 
Usually, all combinations of different amounts of excipients are evaluated for their self-
emulsification properties by mixing with aqueous media (e.g. water, buffers or 
biorelevant media) in biopharmaceutically relevant ratios (e.g. 1:200 v/v). The resulting 
dispersions are checked visually and analysed by dynamic light scattering for particle 
size, enabling the identification of those combinations that form nano-dispersions. An 
example of such a ternary phase diagram is presented in Figure 2.7 (63), where 
combinations of medium-chain or long-chain triglycerides (lipid phase), Cremophor® RH 
40 (surfactant), and Akoline MCM or Peceol® (co-surfactant) are examined. The area 
within the dotted line represents the microemulsion region for different mixtures of these 
excipients dispersed in 250 mL water at 37° C (particle size <100 nm). 
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Figure 2.7: The marked area in the ternary phase diagram represents microemulsions 
obtained upon dispersion of 1 g of SMEDDS containing surfactant 
(Cremophor® RH40), oil (MCT or LCT) and co-surfactant (Akoline MCM or 
Peceol®) in 250 mL water. Droplet size of microemulsions was less than 100 
nm. MCT-medium-chain triglycerides, LCT-long-chain triglycerides. Adapted 
from reference (63). 
 
Although phase diagrams are of great interest to formulators, there is much time needed 
for experimental construction of such diagrams. Therefore, much effort was directed in 
recent years to shorten the formulation selection process. This involved development of 
artificial neural network models for computer simulation and optimization of 
microemulsion systems to minimize the experimental workload (64-67). 
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2.6.2. In vitro testing of SMEDDS 
In vitro testing of selected formulations is often used to help predict the fate of the drug 
upon formulation dispersion and digestion in the GIT. There are several useful in vitro 
analyses that are commonly employed, such as dilution, dispersion, and in vitro lipolysis 
(68). Firstly, simple and fast dilution tests are normally used to evaluate the formulation 
performance in contact with aqueous media (69). Visual assessment of the diluted systems 
seems to be reliable for the estimation of oil droplet size (52, 63, 70). Namely, transparent 
to slightly bluish, opalescent dispersions possess oil droplets between 20-40 nm, whereas 
larger oil droplets (≥100 nm) are characteristic of opaque, milk-white dispersions.  
In comparison to simple aqueous dilution, in vitro dispersion testing better mimics the 
physiological conditions in the GIT. A compendial dissolution apparatus (United States 
Pharmacopoeia-USP 2) and various biorelevant media are often used to simulate gentle 
agitation of the GIT and its physiological environment. The general method for this test is 
analogous to dissolution testing, i.e. samples are taken from the vessels at various time 
points, and before assaying they are filtered or centrifuged to remove any precipitated 
drug. In vitro dispersion testing is of major importance particularly for hydrophilic LBF. 
The hydrophilic formulation components are likely to partition in the aqueous bulk, 
which in turn decreases the solubilization capacity of the formulation and increases the 
risk of drug precipitation. Formulations can be analysed regarding particle size in the 
course of their aqueous dispersion (usually at fixed time points) (71). Measuring particle 
size in formulations dispersions may detect drug precipitates but are often just meant to 
characterize the type of lipid-based formulations. However, the importance of droplet size 
is a debated topic when comparing different nano-dispersions (72). Most important is 
certainly drug solubilization. 
As soon as the dispersed formulation enters the upper small intestine, the digestion of 
formulation components begins. The solubilizing properties of LBFs can change 
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dramatically following dispersion and digestion, so the fate of the drug depends on more 
factors than just the initial droplet size upon dispersion. In vitro lipolysis testing is 
generally of high importance for the development of LBFs (73, 74). However, it can be 
argued that for SMEDDS, the influence of digestion is often limited. Especially for this 
formulation type, rather simple dispersion tests may provide a good first estimate of the 
biopharmaceutical performance. 
There are some specific factors to consider in the development of LBF with weak bases. 
Namely, weak bases may be dissolved at the low pH in the stomach, but when they enter 
the intestinal environment, they could precipitate. The fate of the weak base in the 
intestinal fluid will greatly depend on the solubilization capacity of the formulation or the 
intestinal mixed micelles. In the last decade, in vitro tests simulating drug transfer from 
the stomach to the intestine showed that the precipitation of weak bases depends on the 
rate of gastric emptying (75, 76). Therefore, for weak base formulations additional in 
vitro tests which mimic gastric emptying would be useful.  
As mentioned earlier, the primary mechanism through which LBFs promote drug 
absorption is by providing a high concentration of solubilized drug in the GI lumen. 
However, depending on the LBF composition, the solubilization capacity of the 
formulation may decrease following dispersion and digestion and this creates the risk of 
drug precipitation. In the following paragraph drug precipitation, and focused beam 
reflectance measurement (FBRM) an in vitro analytical technique for studying drug 
precipitation, will be discussed.  
2.7. Drug precipitation  
Drug precipitation is a complex process that involves three phases (77). In the first phase, 
a drug is in a supersaturated solution, i.e. the actual concentration of solubilized drug 
exceeds its equilibrium solubility. Such a supersaturated solution is associated with an 
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increased chemical potential (µ) compared to a thermodynamically stable, saturated 
solution (µeq). The difference in this chemical potential (Δµ = µ - µeq) is the driving force 
for drug precipitation. If we assume that there is no difference in the activity coefficients 
of the solute in the supersaturated and saturated state, the relationship between the 
difference in chemical potential (Δµ) and supersaturation (S) can be presented as follows: 
Δµ = kTln(S), where k presents Boltzmann constant, T the temperature, and S the 
supersaturation ratio (78). Once a critical supersaturation is reached, the second phase of 
the drug precipitation process (nucleation) begins. It is important to differentiate between 
“primary” and “secondary” nucleation (Figure 2.8). In absence of solid drug, primary 
nucleation can occur, whereas secondary nucleation describes that nuclei are often formed 
in close proximity of crystals already existing in a supersaturated solution (79). 
 
Figure 2.8: Schematic diagram of nucleation nomenclatures. Adapted form reference 
(77). 
 
During this nucleation phase, drug molecules form small clusters/aggregates, which grow 
to macroscopic crystals (crystal growth) in the third phase of precipitation. As presented 
in Figure 2.9, precipitation from a supersaturated solution is thermodynamically favoured 
(decrease in Gibbs free energy). However, the nucleation step requires activation energy. 
During the nucleation phase, small aggregates grow until they become critical in size 
(with a critical radius r*). Such critical nucleus size is required for further particle growth. 
If this activation energy is too high, new crystals will not be formed and the 
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supersaturated solution will remain in a metastable zone (for a certain period of time) 
(79). 
 
Figure 2.9: Schematic diagram of the Gibbs free energy of dissolved molecules in 
supersaturated solution. Adapted from reference (79). 
 
Homogeneous nucleation may occur at rather high supersaturation, but is rarely found at 
comparatively lower supersaturation and in presence of impurities and other foreign 
particles. In the GI lumen, mostly heterogeneous nucleation may occur, which can be 
influenced by excipients such as surfactants (79). 
Once the activation energy is reached (stable nuclei with critical radius r* are formed), 
critical clusters can grow to macroscopic crystals. Crystal growth is the last phase of the 
precipitation process and consists of two steps: diffusion of molecules from the 
supersaturated solution to the crystal interface, and integration of the molecule in the 
crystal lattice (79). 
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2.8. Focused beam reflectance measurement (FBRM)  
Focused beam reflectance measurement (FBRM) is a rather novel in vitro analytical 
technique for real time in situ analyses. Gao et al. were first to use this technique for 
studying drug precipitation during LBF dispersion (80). FBRM utilizes a focused beam of 
laser light that scans across a particle passing in front of the probe window (Figure 2.10). 
Based on the back-scattered light, the chord length distribution of particles is determined 
(81). The lowest detectable chord length of the particles is around 1µm. In this PhD thesis 
(Chapter 5) FBRM was successfully employed for the detection of the onset of drug 
precipitation following aqueous dispersion of solid lipid-based systems. This technique 
offers several advantages, such as ease of use, minimum maintenance requirements and, 
as mentioned beforehand, capability of in-situ measurements. In addition, FBRM can be 
coupled with other analytical techniques (e.g. Raman or infrared spectroscopy) for better 
characterisation of formed precipitates (82, 83). 
 
 
Figure 2.10: In-process probe for focused beam reflectance measurements 
(Source: Mettler-Toledo, Switzerland). 
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2.9. Drug supersaturation  
2.9.1. Drug supersaturation triggered by oral administration of LBF 
The intraluminal concentration of a drug is not necessarily limited by its solubility in GI 
fluids. Drugs may be in solution in a supersaturated state, which means at a concentration 
above their saturation solubility (Ceq). However, as mentioned earlier, a supersaturated 
drug solution is thermodynamically unstable and has the tendency to return to the 
equilibrium state by drug precipitation. This period of drug supersaturation is of major 
importance from a biopharmaceutical perspective. Namely, if it is sufficiently long, it may 
enable drug absorption and prevent intestinal drug precipitation. Additionally, it would be 
beneficial if drug supersaturation occurs close to the site of absorption. Recent studies 
showed that LBFs could be a successful formulation strategy in this respect, since they 
induce moderate supersaturation within the GI lumen. Four different mechanisms have 
been suggested by which LBFs generate supersaturation along the GIT (84). Dispersion-
triggered supersaturation (mechanism 1) usually appears when LBFs that contain high 
amounts of water-miscible co-solvents and hydrophilic surfactant are employed (85). In 
case the decreased solubilization capacity of the dispersed formulation does not 
immediately result in drug precipitation, the solubilized drug can reside in a 
supersaturated state. Similarly, excipient digestion can also induce drug supersaturation 
(mechanism 2) as digestion products are less lipophilic and a drop in formulation 
solubilization capacity is expected (86). Interestingly, Yeap et al. (87, 88) demonstrated 
that further dilution of digestion products with bile salt also caused a decrease in drug 
solubility (mechanism 3) and this was particularly crucial for basic drugs. Finally, drug 
supersaturation can also be generated at the intestinal unstirred water layer, which is more 
acidic compared to the bulk lumen (pH 5.5 vs. 6.5). This acidic microclimate promotes 
fatty acid absorption, since they become protonated and dissociate from bile salt mixed 
micelles. As a consequence, supersaturation is induced, since fatty acids are no longer 
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accessible for drug solubilization (mechanism 4) (89). In summary, LBFs present a 
promising formulation approach not only to promote GI drug solubilization, but also to 
enhance drug absorption by generating moderate supersaturation within the GIT. 
The degree of supersaturation can be defined by the supersaturation ratio (SR): 
 
eq
so
C
CSR    (2.1) 
where Csol represents the actual concentration of solubilized drug, and Ceq the equilibrium 
solubility of the drug. According to the degree of supersaturation, a system can be 
unsaturated (SR<1), saturated (SR = 1), or supersaturated (SR>1) (79). As the SR value 
exceeds 1, there is an increasing likelihood of drug precipitation. As mentioned earlier, 
drug supersaturation is a typical outcome of LBF dispersion and lipolysis. Therefore, 
research effort has been recently directed in determining the critical SR for a range of 
PWSD formulated using various LBFs. It has been demonstrated that drug precipitation 
was unlikely to occur in a physiologically relevant time span when SR<2 was obtained 
upon formulation dispersion (85, 86). However, this limit might not be a general rule, 
since another study presented drug precipitation at lower SR values (90). The critical SR 
value could be considerably different upon formulation digestion, especially in the case of 
type I, II, and IIIA formulations, as their solubilizing properties change tremendously 
upon hydrolysis. Recent studies for a range of PWSD and LBFs reported that the risk of 
drug precipitation following digestion is high when the SR determined in digestion 
medium was higher than 3 (91). The determination of the critical SR value following 
dispersion and digestion might be a useful tool for comparison of different formulations 
and drug-loads. However, some care is needed as it seems that these values are rather 
drug-specific. Moreover, for the prediction of the risk of drug precipitation in vivo, an 
absorptive environment should be considered (92). 
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2.9.2. Supersaturatable (S-SEDDS) and supersaturated (super-
SNEDDS) drug delivery systems 
In the last decade, the concept of supersaturation in the GIT as a formulation strategy to 
promote the intestinal absorption of PWSD has raised a lot of interest. To utilize drug 
supersaturation it is important to generate supersaturation and to maintain the metastable 
supersaturated state for a sufficient period of time. Yet, for some highly permeable drugs, 
the induction of supersaturation is more critical than stabilization of the supersaturated 
state (93, 94). Guzman et al. proposed the “spring and parachute” approach where a high 
energy form of the drug (“spring”) is generated and in the presence of precipitation 
inhibitors (“parachutes”) these drugs are kept in a metastable supersaturated state (Figure 
2.11) (93). Based on the supersaturating strategy, Gao et al. introduced supersaturatable 
self-emulsifying drug delivery systems (S-SEDDS), which differ from the standard 
SEDDS as they contain a reduced amount of surfactant and a polymeric precipitation 
inhibitor (95). SEDDS have a high surfactant quantity to assure drug solubilization 
following formulation dilution and digestion in GI fluids. However, as mentioned earlier 
these high surfactant levels can lead to undesirable toxic effects. Smaller amounts of 
solubilizing excipients in S-SEDDS normally result in lower toxicity.  
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Figure 2.11: Schematic presentation of the “spring and parachute” approach of 
supersaturatable drug delivery systems. A high energy form of the drug (e.g. 
crystalline salt, the “spring”) provides the driving force to solubilize the drug 
at a concentration greater than its equilibrium solubility (Ceq). Some 
excipients can act as a “parachute” and inhibit and/or retard drug 
precipitation. Adapted from reference (93). 
 
Several additives from different groups of pharmaceutical excipients (e.g. polymers, 
surfactants, and cyclodextrins) exhibited the function of drug precipitation inhibitors 
when incorporated into S-SEDDS. From the group of polymers, water-soluble cellulosic 
polymers (e.g. HPMC-hydroxypropyl methylcellulose, MC-methylcellulose) were 
reported to be the most effective at supressing drug precipitation (79, 96, 97). The 
underlying mechanisms by which they inhibit precipitation were proposed by Raghavan 
et al. (98). The authors suggested a mechanism based on hydrogen bonding between drug 
molecules and the polymer, which increased the activation energy for nucleation. 
Additionally, HPMC molecules adsorbed on the crystal surface (via hydrogen bonds), 
which hindered crystal growth. Other studies demonstrated that low concentrations of 
some surfactants (Pluronics- ethylene oxide/propylene oxide block copolymers, TPGS- d-
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alpha tocopheryl polyethylene glycol 1000 succinate) also successfully prevented drug 
precipitation (99, 100). These surfactants might have improved the solvation of dissolved 
drug, and hence increased the activation energy required for desolvation during 
nucleation and crystal growth. Recently, Brewster et al. studied the influence of 
cyclodextrins (HPβCD-hydroxypropyl-β-cyclodextrin, SBEβCD-sulfobutylether-β-
cyclodextrin) on stabilization of supersaturated drug solutions (100). These cyclodextrins 
were shown to be more effective in drug precipitation inhibition compared to the tested 
surfactants. The authors suggested that cyclodextrins might have acted as surfactants here 
and improved the solvation of the dissolved drug. In addition, they also behaved similarly 
to polymers, as they formed hydrogen bonds with drug molecules and therefore decreased 
both nucleation and crystal growth. To date, only a few animal studies have correlated in 
vitro supersaturation with in vivo intestinal drug absorption. However, they all inevitably 
showed that S-SEDDS provide higher oral bioavailability when compared to the standard 
SEDDS (101). 
Another interesting supersaturation formulation approach was recently proposed by 
Müllertz et al. (102). These authors developed a supersaturated self-nanoemulsifying drug 
delivery system (super-SNEDDS), where the drug in the formulation was already present 
in a supersaturated state. Although these systems are thermodynamically unstable, the 
supersaturation could have been maintained for several months. These findings 
emphasized the potential for a higher drug loading capacity of super-SNEDDS. In a 
pharmacokinetic study in beagle dogs, these systems showed considerably higher 
bioavailability than multiple units of conventional SNEDDS (with the same dose) (103). 
However, uncertain long-term stability of the super-SNEDDS might limit them from 
becoming commercially viable delivery systems. 
Z. Misic, K. Muffler, G. Sydow, and M. Kuentz. Novel starch-based PVA thermoplastic capsules 
for hydrophilic lipid-based formulations. Journal of Pharmaceutical Sciences. 101:4516-4528 
(2012). 
 
Chapter 3 
 
Novel starch-based PVA thermoplastic 
capsules for hydrophilic lipid-based 
formulations 
 
Summary 
For decades, gelatin has been used in the rotary die process as a shell-forming material of 
soft capsules because of its unique physicochemical properties. However, with respect to 
the encapsulation of comparatively hydrophilic lipid-based formulations, gelatin has one 
considerable drawback: Immediately after production, the capsule shell contains a large 
amount of water (up to 35% w/w). There is the potential for water to migrate from the 
capsule shell into the formulation, which will lead to a decrease in drug solubility and, in 
turn, the potential for drug crystallization. The present study introduces a novel capsule 
material that was obtained from extrusion. The starch-based polyvinyl alcohol 
thermoplastic capsules (S-PVA-Cs) mainly comprised a blend of starch and PVA. Gelatin 
and the novel material were used to encapsulate a hydrophilic lipid-based system of 
fenofibrate. Considerable water migration was observed from the soft gelatin shell to the 
hydrophilic formulation during drying and drug crystallization resulted in soft gelatin 
capsules. In contrast, S-PVA-Cs displayed no substantial water exchange or drug 
crystallization upon storage. The thermoplastic capsule material further exhibited larger 
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surface roughness and higher resistance to mechanical deformation compared with 
gelatin. In conclusion, S-PVA-C provided a robust drug product following encapsulation 
of a rather hydrophilic lipid-based formulation. 
3.1. Introduction 
The production of soft capsules from gelatin has a long tradition in pharmaceutics (25). 
However, gelatin also has a number of drawbacks: Ingestion of gelatin as an animal-
derived material can be an issue for patients living under religious or dietary (vegetarians 
or vegans) restrictions. Moreover, identification of transmissible spongiform 
encephalopathies in animals (especially bovine spongiform encephalopathy, first case in 
UK, 1986) raised anxiety among gelatin manufacturers and consumers. Today, most 
national and international authorities have guidelines (i.e., in the EU EMA/410/01 rev.3, 
(31)) that ensure the safety of gelatin raw material by inspecting the geographical origin, 
the manufacturing method, and the quality system. 
Another potential issue of unmodified gelatin is its susceptibility to cross-linking. It can 
affect in vitro drug release depending on whether or not the dissolution medium contains 
enzymes that are able to digest gelatin (e.g., pepsin). This in vitro effect of gelatin 
capsules seems, however, to be of lesser importance for drug absorption in vivo (104). 
Another critical aspect of gelatin is that its mechanical properties depend greatly on 
temperature and moisture content. Thus, climatic conditions of hot and humid regions can 
soften capsules, which is unfavourable for their handling by patients (105). A 
considerable drawback of soft gelatin capsules (SGCs) is also the potential migration of 
the drug into the shell. This diffusion depends on the amount of water in the shell, the 
formulation, as well as the properties of the drug (6). Such drug migration may be 
promoted by marked water partitioning between the capsule shell and a hydrophilic lipid-
based formulation. Apart from the drug migration, the water exchange between the shell 
and the formulation can also be critical. Substantial water partitioning is especially 
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expected with gelatin shells and hydrophilic formulations. Even temporary water uptake 
of the formulation is a risk for drug precipitation in the fill mass. Small amounts of water 
can already be sufficient to greatly reduce the drug solubility in the formulation (13). 
To overcome the disadvantages of gelatin, a great deal of effort has gone into finding 
gelatin substitutes for soft capsules during the last decade. However, only a few non-
gelatin soft capsule prototypes and methods of encapsulation have been patented so far. 
All materials were based on plant-derived hydrocolloids, except one that mainly 
comprised a synthetic polymer. In 2002, the patent by Tanner et al. (15) was granted for 
combining iota carrageenan and modified starch to produce mechanically strong, elastic 
films. After the casting of polymer bands, the rotary die process was employed for 
encapsulation. Later Brocker et al. (14) described in their patent the production of soft 
capsules that were mainly based on potato starch with special amylopectin content. They 
suggested a single screw-type extruder for producing polymer films that directly feed into 
a conventional rotary die process. As a result of this research on thermoplastic shell 
materials, VegaGels® were introduced to the market as the first starch-based vegetarian 
soft capsule (106). In 2005, Fonkwe et al. (39) proposed another hydrocolloid based film 
consisting of iota and kappa carrageenan, and the subsequent research activities focused 
on the production of this shell formulation. It appears that options for manufacturing 
capsules from carrageenan or starch-based materials are limited due to the technical 
difficulties. Carrageenan, like other hydrocolloids, requires a large fraction of water for 
full hydration, which in turn reduces the strength of the film. Therefore, Archibald et al. 
(19) presented a method for extracting a portion of water from the film-forming 
composition, leading to the production of a dried film with 8-25% w/w water. To avoid 
these water-related complications, as early as 2002, Brown proposed using polyvinyl 
alcohol (PVA) for the encapsulation process (16). Although PVA is less hygroscopic than 
hydrocolloids or gelatin, it lacks the gelling properties. Therefore, Brown suggested using 
preformed rolls of almost water-free films that can be fed into the rotary die 
encapsulation. 
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In summary, the research of novel shell materials has brought to light the difficulties of 
replacing gelatin. In particular, the production step remains a technical challenge for 
alternative materials. Further, it remains uncertain as to whether such alternative soft 
capsules have any pharmaceutical advantages other than their non-animal origin. This 
stresses the need for more pharmaceutical research in the area of identifying new shell 
materials. A particular rationale for new material is to obtain a robust drug product for the 
encapsulation of comparatively hydrophilic lipid-based formulations, such as self-
microemulsifying drug delivery systems (SMEDDS). Such preconcentrates exhibit 
favourable dispersion behaviour when in contact with water or gastrointestinal fluids, but 
it comes at the cost of employing large amounts of hydrophilic surfactant(s) and/or 
cosolvent(s). Thus, an optimal formulation is often incompatible with gelatin, so that 
current capsule technology actually limits the freedom to select the best system from a 
biopharmaceutical viewpoint. It would be desirable first to focus on the development of 
an optimal formulation with respect to drug absorption and stability and then still have a 
sufficient choice of a viable capsule technology. 
This article describes a new soft capsule material that is extruded to films for the 
subsequent rotary die encapsulation process. The starch-based PVA (S-PVA) material 
combines the thermoplastic properties of starch with the characteristics of PVA. We 
expected this material to be specifically suited for encapsulation of hydrophilic lipid-
based formulations.  
More recently, there has been an increasing interest in “hydrophilic formulations” of 
PWSD. These lipid-based formulations containing a high proportion of hydrophilic 
surfactant and cosolvent are classed as type IIIB and type IV of the lipid formulation 
classification system (LFCS) proposed by Pouton in 2006 (50). The addition of small 
amounts of water to these systems can lead to the loss of drug solubility in the 
formulation. SGCs bear a particular risk of drug crystallization in such a hydrophilic fill 
because of water uptake from the shell during production (2, 13). 
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The present work compared the encapsulation of a rather hydrophilic SMEDDS (type 
IIIB formulation) in starch-based PVA thermoplastic capsules (S-PVA-Cs) and SGCs. We 
aimed to determine whether the novel shell material is associated with less water 
exchange between the capsule shell and the fill compared to gelatin, thus, preventing drug 
precipitation in the fill mass. Other potentially beneficial physical properties of the novel 
shell material were analysed as well. 
3.2. Materials and methods 
3.2.1. Materials 
Fenofibrate (Sigma–Aldrich, St. Gallen, Switzerland) was selected as a poorly water-
soluble model drug. Solvents for Karl Fischer titrimetry [HYDRANAL®-Formamide dry, 
HYDRANAL® Solvent, HYDRANAL®-Composite 5, and dimethyl sulphoxide (DMSO)] 
and ammonium acetate were purchased from Sigma–Aldrich, Buchs, Switzerland. 
Polyoxyethylene (80) sorbitan monooleate (Tween® 80), medium-chain triglycerides 
(Miglyol® 812), and sodium dodecyl sulphate (SDS) were supplied by Hänseler AG, 
Herisau, Switzerland. Transcutol® HP [2-(2-ethoxyethoxy)ethanol] was obtained from 
Gattefosse, Nanterre, France, and hydrochloric acid (0.1N) was purchased from Scharlab 
Ltd., Barcelona, Spain. Acetonitrile of high-performance liquid chromatography (HPLC) 
grade was purchased from Mallinckrodt Baker, St. Louis, Missouri. 
3.2.2. Methods 
3.2.2.1. Production and physical characterization of the S-PVA and soft gelatin films 
The S-PVA films were manufactured using extrusion technology. These films were a 
mixture of potato starch, PVA, and plasticizers (sorbitol solution and glycerol) in a ratio 
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of 40%:30%:30% (w/w). First, potato starch and PVA were premixed in a blender. This 
mixture was then mixed with the plasticizers by constant feeding of a double-screw 
extruder at approximately 135° C under high pressure of 115-120 bar to form granules. 
Formed granules were again extruded using a single-screw extruder at approximately 
100-135° C at 22 rpm. The obtained extrudate was pressed through a slit die at 115° C to 
form an S-PVA film.  
Gelatin films were obtained using casting technology. A mixture of bovine gelatin (type 
B, Bloom 160 limed bone/limed hide), glycerol, and water (47.4%:17.1%:35.5%, w/w) 
was heated while stirred gently in a stainless-steel vessel at approximately 55-65° C for 
approximately 60 min. Subsequently, the heated gelatin solution was poured onto a 
cooled casting drum using a spreader to form a homogeneous gelatin film. 
Both S-PVA and gelatin films were left in a climate chamber for at least 2 weeks at 20° 
C/40% relative humidity (RH) to equilibrate. The film properties of both materials were 
subsequently analysed using various physical methods. 
3.2.2.1.1. Surface texture measurements 
Surface texture was assessed using a confocal laser scanning microscope (CLSM, LEXT 
OLS3100; Olympus, Southend-on-Sea, Essex, UK). The CLSM was equipped with a 
semiconductor laser at a wavelength of λ=408±5 nm. Magnification of ×1200 with a field 
of view of 256 × 256 µm2 was used. Both films were cut into rectangular pieces (2 × 4 
cm2). These samples were then fixed to glass slides with transparent tapes to avoid any 
curvatures caused by the film specimens. Each film was scanned at six different positions 
in one line. The noise signal arising from flat surfaces in the three-dimensional images 
was removed, and the plane roughness was calculated using the LEXT OLSTM software 
(Olympus). For each region of interest, the following roughness parameters were 
calculated in accordance with DIN EN ISO 4287 (107): 
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 Average roughness (SRa) defined as the arithmetic average of absolute profile 
ordinate values Z (x) within the analysed area. 
 Root mean square roughness (SRq) defined as the root mean square value of 
profile ordinate values within the analysed area. 
 Maximum peak height (SRp) defined as the maximum profile peak height within 
the analysed area. 
 Maximum valley depth (SRv) defined as the maximum profile valley depth within 
the analysed area. 
The SRa is a representative estimate of surface roughness, but it does not provide explicit 
information about variation in peak height and depth of the valleys. Therefore, it is 
important to calculate other roughness parameters, such as SRq that is more influenced by 
the high amplitudes of peaks and valleys in the surface. Moreover, the extreme values 
were assessed in terms of the SRp and SRv. 
3.2.2.1.2. Residual water content 
Karl Fischer titrimetry was used for residual water determination. HYDRANAL®-Solvent 
(Sigma-Aldrich) (20 mL) and HYDRANAL®-Formamide dry (Sigma-Aldrich) (20 mL) 
were added to a heated titration vessel (50° C), and HYDRANAL®-Composite 5 (Sigma-
Aldrich) was titrated to assure initial dryness. A gelatin sample (200 mg) was accurately 
weighted, and its water content was titrated with HYDRANAL®-Composite 5 (Sigma-
Aldrich). Because a S-PVA sample (200 mg) could not be dissolved in the same solvents 
as a gelatin sample, it was prepared by dissolving in 2 mL of DMSO for 1 h in an 
ultrasonic bath at 60° C. Finally, the water content of DMSO was measured for correction 
of the sample values. 
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3.2.2.1.3. X-ray diffraction (XRD) 
X-ray diffraction was used to determine which excipient contributed the most to 
crystallinity in an S-PVA film. A diffractometer Phaser D2 (Bruker, Karlsruhe, Germany) 
with LYNXEYE detector and the EVA software application was employed. The source of 
radiation was Co Kα at 30 kV, 10mA, and the measurement range was 2θ 7°–40°. The 
sample was automatically rotated on a holder at 15 rpm.  
X-ray diffraction was also used to determine crystallinity of fenofibrate after precipitation 
caused by water in the formulation. Fenofibrate (60 mg/mL) was dissolved in the mixture 
of Miglyol® 812, Tween® 80, and Transcutol® HP (15%:60%:25%, w/w) by stirring at 
800 rpm at room temperature (RT). Water was added to the formulation at a concentration 
of 32% w/w, which was still a realistic amount that can occur during production of SGC 
(consistent with method in the section 3.2.2.2.1.). The mixture was gently mixed and left 
at 5° C for 24 h. In the second step, the mixture was stirred at 800 rpm and RT for 5 days. 
These sample conditions were used to increase the crystallization yield. After this cyclic 
test the mixture contained crystals, which were analysed by X-ray diffraction in the 
measurement range 2θ 5-40° without sample rotation. Subsequently, a fenofibrate 
reference was analysed and the diffractograms were compared. 
3.2.2.1.4. Differential scanning calorimetry (DSC) 
A differential scanning calorimeter DSC 30 (Mettler Toledo, Greifensee, Switzerland) 
was used to characterize the thermal properties of the PVA, potato starch, and S-PVA 
shell materials. Samples of PVA and potato starch (average weight: 9 mg) were placed in 
hermetically sealed aluminium pans (40 µL) and heated at 10° C min−1 from 25° C to 
300° C in an inert environment (100 mL min−1 Ar). Moreover, samples of S-PVA (average 
weight: 20 mg) were placed in bigger hermetically sealed aluminium pans (160 µL) and 
also heated at 10° C min−1 from 25° C to 300° C in an inert environment. Melting 
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temperature (Tm) and heat of fusion (ΔHf) of the S-PVA samples were determined from 
the peak maximum and the area under the peak, respectively. Finally, the degree of 
crystallinity of S-PVA was calculated using the following equation (108): 
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where Xc is the degree of crystallinity (%), ΔHf is the latent heat of fusion of the S-PVA 
sample (J/g), ΔHf100 is the latent heat of fusion of a PVA with 100% crystallinity (161 J/g) 
(109) and w is the weight fraction of PVA in the S-PVA film. 
3.2.2.2. Solubility studies and excipients phase behaviour 
3.2.2.2.1. Solubility studies of fenofibrate in excipients and mixtures with water  
The solubility of fenofibrate in Miglyol® 812, Tween® 80, Transcutol® HP, and their 
mixture (i.e., 15%:60%:25%, w/w) was determined as follows: 
An excess amount of compound was added to 1 mL of each sample and the mixture was 
constantly stirred (750 rpm) in a glass vial at RT for 24 h and 7 days. The time point at 7 
days was taken to assure that equilibrium was reached. The samples were then 
centrifuged at 13,362 g for 20 min using a Centrifuge 5415 R (Eppendorf AG, Hamburg, 
Germany). Finally, the concentration of the compound in the supernatant was determined 
after diluting the supernatant with acetonitrile (1:1000, v/v) by HPLC analysis (section 
3.2.2.4.). 
Drug solubility was also determined in the placebo formulation (Miglyol® 812, Tween® 
80, and Transcutol® HP, 15%:60%:25%, w/w) with varying amounts of water at RT. The 
added water reflected a possible state after soft capsule production. Batches of SMEDDS 
(3 g in total) were prepared (in triplicate) to contain the following water levels: 1%, 2%, 
4%, 8%, 16%, or 32% w/w. There was no visible change in mixtures containing 1%, 2%, 
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and 4% of water. The mixture with 16% w/w water showed more clouding than the 
mixture with 8% w/w water. In the mixture with 32% w/w water, phase separation was 
visible. An excessive amount of fenofibrate was added to each mixture and the glass vials 
were vortexed for 30 s. To mimic possible shipment and storage conditions, all mixtures 
were stored at 5° C for 24 h and then equilibrated at RT for 60 h under continuous stirring 
at 750 rpm. An aliquot (1 mL) was taken from each vial and centrifuged at 13,362 g for 
20 min. The clear supernatant was diluted with acetonitrile (1:200, v/v) and the 
fenofibrate content was analysed using HPLC assay (section 3.2.2.4.). 
 
3.2.2.2.2. Preparation of the SMEDDS and particle size measurements 
Mixtures of Miglyol® 812, Tween® 80, and Transcutol® HP (Table 3.3) were compounded 
in glass vials by weight using an analytical balance (Mettler Toledo AB204-S; Mettler 
Toledo). The aim was to find SMEDDS resulting in a small particle size after aqueous 
dispersion (up to 50 nm) and at the same time to reach sufficient fenofibrate solubility. 
Quaternary mixtures containing oil, surfactant, cosolvent, and water (representing the 
lipid formulations after dilution) were prepared by the addition of water to a primary 
blend of oil, surfactant, and cosolvent (1:200, v/v). An aliquot (100 µL) of each mixture 
obtained from a calibrated automatic pipette Eppendorf Research® plus (Eppendorf) (20-
200 µL) was diluted with 20 mL of water in a glass vial and gently mixed. Phase 
behaviour was assessed initially by visual observation, classifying the dispersion samples 
as either single phase or multiphasic (turbid) mixtures. Subsequently, all mixtures were 
analysed by means of dynamic laser light scattering using a Zetasizer Nano ZS (Malvern 
Instruments, Malvern, Worcestershire, UK). The mean particle size (Z-average diameter) 
was calculated from the volume size distribution. All experiments were repeated in 
triplicates from fresh samples at ambient temperature. 
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3.2.2.3. Characterization of the S-PVA-Cs and a comparison with SGCs 
3.2.2.3.1. Production of the S-PVA-Cs and SGCs 
A continuous rotary die process was used for production of both S-PVA-Cs and SGCs at 
Swiss Caps (Kirchberg, Switzerland). For encapsulation of the S-PVA-Cs, an extrusion 
process was coupled with the capsule manufacture. Before encapsulation, the same 
granules used for the S-PVA films (section 3.2.2.1.) were extruded in two single-screw 
extruders (one for each half of the capsule shell) at approximately 135° C at 22 rpm, and 
ribbons were formed using flat film extrusion dies. These ribbons were feeding into the 
rotary die process. In the case of SGCs manufacture, the same gelatin solution as used for 
the production of gelatin films (section 3.2.2.1.) was used for the gelatin ribbons. 
Both SGCs and S-PVA-Cs were filled with the same batch of fenofibrate formulation 
(drug concentration 60 mg/mL). The drug formulation (7.5 kg for each capsule type) was 
prepared in a stainless-steel vessel by mixing all excipients and fenofibrate at 20-25° C 
for 120-150 min using a paddle agitator. Subsequently, the formulation was transferred 
into the filling tank above the die rolls. Two ribbons (either S-PVA or gelatin) were 
continuously and simultaneously fed into the rotary die process. The formulation was 
injected between the converging ribbons and sealing of the capsules followed in matching 
dies of the counter-rotating rolls. The capsule size for both batches was 15 minims (R.P. 
Scherer volume units; 1 minim = 0.0616 mL). Gelatin capsules were filled with 1.0 g of 
drug formulation, whereas S-PVA-Cs contained 0.85 g of the drug formulation because of 
the less flexible material in comparison with gelatin. Each batch consisted of about 1000 
capsules that were initially left for 50 h in a tumbler at RT/45% RH. Afterward, all 
capsules were stored in a climate chamber at 20° C/ 40% RH before analysis. 
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3.2.2.3.2. Drying kinetics-water activity measurement  
During the drying process, samples of SGCs and S-PVA-Cs were taken at predetermined 
time points. Each capsule was opened with scissors and the fill mass was manually 
removed from the capsule shell. The shells were thoroughly dried with a cotton cloth. 
Both capsule shell and fill mass were used for analysis of water activity (aw) using a 
LabMaster-aw (Novasina AG, Lachen, Switzerland). The aw is defined as the ratio of the 
water vapour pressure of the sample to that of pure water, which equals the relative 
equilibrium humidity (%) of the sample. The aw values of the formulation fill and the 
capsule shells were measured in triplicates in the airtight chamber of the instrument. 
The water activity was also measured in the mixtures of the drug-containing formulation 
(60 mg/mL of fenofibrate in a mixture of Miglyol® 812, Tween 80, and Transcutol® HP, 
5%:60%:25%, w/w) with different amounts of water. The mixtures (10 g in total) 
contained the following water levels: 1%, 2%, 4%, 8%, 16%, or 32% w/w and, like in 
section 3.2.2.2.1., they reflected a possible state during soft capsule production. 
3.2.2.3.3. Determination of the dissolved drug concentration in the capsule 
formulation  
The concentration of fenofibrate in the formulation was determined immediately after the 
production and was used as the reference. The concentration of dissolved drug in SGC 
and S-PVA-C was determined after storing the capsules openly in a climate chamber and 
closed in glass vials for 4 months at 20° C/40% RH. The formulation was removed from 
each capsule (n = 5) and centrifuged. The clear supernatant was diluted with acetonitrile 
(1:200, v/v) and used for HPLC assay (section 3.2.2.4.). 
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3.2.2.3.4. Texture analysis  
A texture analyzer (TAXT2i; StableMicro Systems, Godalming, UK) was used to study 
the capsule rupture strength. This mechanical test for soft capsules determines the 
bursting point of the film at the point of contact with a defined probe. The apparatus was 
equipped with a 5 kg load cell and fitted with a flat-bottomed cylindrical stainless-steel 
probe (P/2, 2mm in diameter). The capsule was placed in the centre of the testing 
platform with the capsule seam positioned perpendicularly to the probe. The speed of the 
probe was 1.0 mm/s until the surface of capsule was detected at the force of 0.049 N 
(threshold value for triggering the onset of texture analysis). The probe then penetrated 
the capsule to a maximal depth of 8 mm with a speed of 2.0 mm/s. The force dropped 
when the capsule was ruptured and the probe was automatically withdrawn at a speed of 
10.0 mm/s. Tensile force (force applied at the rupture point) was recorded as an indicator 
of compressive capsule strength. From the area under the force-displacement curves, we 
obtained the work (W) required to rupture the capsules. Both SGCs and S-PVA-Cs filled 
with fenofibrate formulation were tested (n = 4), and the mechanical properties compared, 
that is, tensile forces, rupture distances, as well as the work required to rupture the 
capsules. 
3.2.2.3.5. In vitro disintegration and drug release testing 
Disintegration times of SGCs and S-PVA-Cs were determined with six capsules in 
distilled water at 37 ± 0.5° C using a DT-3 disintegration tester (SOTAX, Basel, 
Switzerland) according to United States Pharmacopeia (USP) 34 (110). Disintegration 
time was defined as the time necessary for complete opening of the capsules. A digital 
stopwatch was used, and only one capsule was analysed at a time. All results are 
presented as mean value ± SD (n = 6). Release testing with both capsule types was 
performed in 1000 mL of 0.05 M SDS in water using the USP dissolution apparatus II 
(DT 600; Erweka, Heusenstamm, Germany). The paddles were rotated at 75 rpm, and the 
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medium was heated to 37 ± 0.5° C. At predetermined time points, a 2-mL sample of 
medium was drawn and centrifuged, and clear supernatant was subjected to drug analysis 
without dilution using HPLC analysis (described in the section 3.2.2.4.). The removed 
volume was replaced each time with 2 mL of fresh medium. 
3.2.2.4. HPLC method 
High-performance liquid chromatography analysis employed a LiChrospher 60, RP select 
B 125-4 (5 µm) column (Merck, Darmstadt, Germany). The mobile phase consisted of 
acetonitrile and 25 mM ammonium acetate buffer, pH = 3.5 (65:35, v/v). Flow rate was 
1mL/min with the injection volume of 20 µL and the detection wavelength was 287 nm 
(111). 
3.2.2.5. Data analysis 
The concentration of dissolved drug in SGC and S-PVA-C stored openly and closed in 
glass vials for 4 months at 20° C/40% RH was analysed with n = 5, and the results were 
expressed as mean values with lower and upper limits. The Statgraphics Centurion XVI 
ed. Professional Program from Statpoint Technologies Inc. (Warrenton, Virginia) was 
used for the analysis of variance (ANOVA) calculations. Significance was assumed if the 
p value was less than 0.05. 
 
3.3. Results 
3.3.1. Physical characterization of the S-PVA and gelatin films 
3.3.1.1. Surface texture measurements 
To analyse the surface morphology of the different polymer materials (S-PVA and 
gelatin), confocal microscopy was used. Figure 3.1a presents the three-dimensional 
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surface profile of a soft gelatin film, which appeared to be less rugged and smoother than 
the surface of the S-PVA material (Figure 3.1b). This finding was also reflected by the 
calculated surface roughness parameters (Table 3.1). Thus, the SRa of the SPVA film was 
almost four times higher than the corresponding value of gelatin. Even though the SRa is 
the most widely used surface roughness parameter, it was also important to measure SRq. 
This SRq is more affected by rather high peaks and deep valleys on a surface compared 
with the SRa. The SRq also exhibited differences between the materials, but these were not 
more pronounced than with SRa. This result already indicated that the difference in 
surface roughness was not because of few extreme profile values, but the result of a high 
number of peaks and valleys. To explore them more thoroughly, we studied the highest 
peak (SRp) and the lowest valley (SRv). The latter value of SRv demonstrated a greater 
difference between the materials than in terms of SRp. Figure 3.1b reveals that the surface 
roughness of S-PVA was to a great extent determined by valleys, which appeared to be 
characteristic for the new material. 
 
Figure 3.1: The three-dimensional surface profiles of (a) soft gelatin film (produced by 
casting) and (b) S-PVA film (extruded from a mixture of PVA, potato starch, 
and plasticizers, 40%:30%:30%, w/w) by using confocal laser scanning 
microscopy. 
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Table 3.1: Comparison of surface roughness parameters of soft gelatin and starch-based 
PVA (S-PVA) films (mean ± SD, n=6) calculated by confocal laser scanning 
microscopy (CLSM). 
 
  
  
SRa (μm)* SRq (μm)* SRp (μm)* SRv (μm)* 
soft gelatin 0.089 ± 0.010 0.131 ± 0.024 1.875 ± 0.995 0.971 ± 0.231 
S-PVA 0.327 ± 0.057 0.435 ± 0.066 2.546 ± 0.242 2.719 ± 0.450 
* Surface roughness parameters: SRa: the arithmetic average of absolute profile ordinate values Z (x) within 
the analysed area. SRq: the root mean square value of profile ordinate values within the analysed area. SRp: 
the maximum profile peak height within the analysed area. SRv: the maximum profile valley depth within 
the analysed area. 
 
3.3.1.2. Residual water content  
Both soft gelatin and S-PVA films were stored for two weeks at 20° C/40% RH, and were 
then analysed for residual water content by Karl Fisher titrimetry. As a result, the soft 
gelatin film provided a mean value of 10.4 ± 0.5%, whereas the S-PVA film contained 
less water, that is, 7.4 ± 0.1%. These values represent a total amount of water, which may 
be different from the fraction of water available for partitioning between the shell and the 
fill mass or the environment (112). 
3.3.1.3. X-ray diffraction (XRD) 
Figure 3.2 shows X-ray patterns of a PVA, a potato starch, and an S-PVA film. The main 
diffraction peak of PVA was at around 22.5°, which was already observed 2007 by Pal et 
al. (113). This peak was very intense indicating a highly crystalline structure of PVA. As 
expected, the diffractogram of the S-PVA film showed the peak at 22.5° as well. The 
distinct peaks of pure potato starch were observed at around 17° and 20°. This was in 
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agreement with van Soest et al. (114), who confirmed these peaks in potato starch back in 
1996. They prepared thermoplastic starch from native starch by different manufacturing 
processes (i.e. kneading, extrusion, compression moulding, and injection). These process 
conditions were shown to affect the degree of starch crystallinity. In the present study, the 
absence of characteristic peaks of potato starch in the S-PVA films was interpreted as a 
lack of starch crystallinity following the extrusion process. Thus, crystallinity of the S-
PVA film was obviously mainly because of the PVA. 
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Figure 3.2: X-ray diffractogram patterns of PVA (red line), potato starch (black line), and 
S-PVA film (green line). 
 
3.3.1.4. Thermal analysis by DSC 
Differential scanning calorimetry thermogram of potato starch exhibited two 
characteristic endothermic peaks (Figure 3.3). The first broad peak at about 100° C was 
attributed to the loss of adsorbed water, whereas the second peak (at about 280° C) 
corresponded to the melting of crystallites in starch, which was followed by immediate 
degradation. These findings were in good agreement with Zhao et al. (115). The melting 
point of PVA was observed at about 200° C and the same endothermic peak (at 200° C) 
was found in the S-PVA films (Figure 3.3). For calculation of the crystalline fraction in S-
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PVA, the contribution of starch to crystallinity was neglected. This was based on the 
results of X-ray diffraction, where no distinct peaks were arising from starch. Therefore, 
only the contribution from pure PVA was considered for estimating crystallinity of the 
novel capsule material. The calculation in Eq. 3.1 (108) used the reference heat of fusion 
from pure PVA. Accordingly, the Xc of S-PVA yielded 38.3 ± 2.3% (n = 4), which 
indicated that a considerable fraction of the S-PVA polymer film was indeed crystalline. 
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Figure 3.3: Differential scanning calorimetry thermograms of S-PVA film (green line),  
PVA (red line), and potato starch (black line). 
 
3.3.2. Solubility studies and excipients phase behaviour 
A broad range of excipients was initially evaluated with respect to maximal drug 
solubility. For this screening of excipients, fenofibrate was gradually added and solubility 
was visually assessed with respect to an onset of turbidity (data not shown). On the basis 
of this initial testing, favourable excipients (Miglyol® 812, Tween® 80, and Transcutol® 
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HP) were selected and the solubility of fenofibrate was then determined using HPLC 
analysis (section 3.2.2.4.). Table 3.2 displays the obtained fenofibrate solubilities in the 
chosen excipients (Miglyol® 812, Tween® 80, and Transcutol® HP). Miglyol® 812 and 
Tween® 80 demonstrated remarkable drug solubility, which was in agreement with the 
data previously reported by Patel and Vavia (116). However, Transcutol® HP exhibited the 
highest capacity to dissolve fenofibrate. 
Our next step was to find the model formulation that had self-microemulsifying properties 
(particle size upon aqueous dispersion with a diameter of ≤50 nm) and the capability of 
dissolving rather large amounts of fenofibrate. To meet these two criteria, comparatively 
higher amounts of the cosolvent Transcutol® HP were considered. Mixtures of Miglyol® 
812 (5-20% w/w), Tween® 80 (50-90% w/w), and Transcutol® HP (5-30% w/w) (Table 
3.3) were prepared and dispersed in water at a physiologically relevant dilution level 
(1:200, v/v) to check for potential self-microemulsification. Within the tested ranges, 
excipients could be freely mixed resulting in macroscopically homogenous solutions. 
Dynamic laser light scattering was used to assess a range of microemulsification. Table 
3.3 shows particle size results of obtained colloidal systems together with their 
polydispersity index.  
The formulation with 15% w/w Miglyol® 812, 60% w/w Tween® 80, and 25% w/w 
Transcutol® HP was selected as a model system because of a very small particle size upon 
aqueous dispersion. Moreover, the composition contains good solvents of fenofibrate in 
rather high amounts and the surfactant concentration was limited to 60% w/w. The 
selected model formulation falls in category type IIIB of the LFCS and is rather 
hydrophilic compared with other lipid formulations (49, 50). 
Experimental section 62 
Table 3.2: Solubility of fenofibrate in Miglyol® 812, Tween® 80, Transcutol® HP, and 
their mixture (i.e. 15% : 60% : 25%, w/w) at RT after 24 h and 7 days under 
constant stirring at 750 rpm (n=3). 
 drug solubility in mg/mL 
 24 h 7 days 
Miglyol® 812 80.4 ± 2.6 84.3 ± 3.4 
Tween® 80 61.9 ± 2.9 61.1 ± 1.5 
Transcutol® HP 160.3 ± 8.9 160.7 ± 3.8 
Mixture* 91.2 ± 9.7 90.4 ± 2.4 
* Mixture with the following content: Miglyol® 812, Tween® 80, 
and Transcutol® HP (15% : 60% : 25%, w/w) 
Table 3.3: Particle size (Z-average diameter) of the microemulsions prepared by gentle 
mixing of lipid components with water (1:200 v/v) at RT and measured by 
dynamic laser light scattering using a Zetasizer Nano ZS (Malvern). 
Miglyol® 812 
(% w/w)  
Tween® 80 
(% w/w) 
Transcutol® HP 
(% w/w) 
Z-average 
(nm) PDI
a 
5 90 5 9.6 0.06 
5 80 15 9.7 0.04 
20 60 20 38.8 0.52 
20 55 25 110.4 0.27 
15 60 25 15.9 0.17 
5 65 30 10.6 0.03 
20 50 30 109.7 0.27 
The microemulsion indicated bold contains the optimal ratio of cosolvent and surfactant  
and was selected for encapsulation of S-PVA-C and SGC. 
aPDI, polydispersity index. 
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To assess the relevance of water migration from capsule shell to formulation, we studied 
the effect of added water to the formulation regarding fenofibrate solubility. Thus, drug 
solubility was determined in mixtures of the model formulation (Miglyol® 812, Tween® 
80, and Transcutol® HP, 15%:60%:25%, w/w) with water (1%, 2%, 4%, 8%, 16%, or 
32% w/w). We found that solubility of fenofibrate decreased nonlinearly with increasing 
water content in the formulation (Figure 3.4). A first-order model was selected to describe 
the solubility decay in line with previous work reported by Serajuddin et al. (13). In our 
study, an excellent model fit with an R2 value of 0.992 was obtained. 
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Figure 3.4: Solubility of fenofibrate in placebo formulation-water mixtures stored at 5° C 
for 24 h, and then equilibrated at RT for 60 h under continuous stirring at 750 
rpm. Placebo formulation was mixture of Miglyol® 812, Tween® 80, and 
Transcutol® HP (15%:60%:25%, w/w). An exponential model was fitted 
(solid line). Data are presented as mean ± SD (n = 3). 
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3.3.3. Characterization of the S-PVA-Cs and a comparison with SGCs 
3.3.3.1. Drying kinetics-water activity measurement 
Drying kinetics of SGCs is displayed in Figure 3.5a. Initially pronounced water 
partitioning between capsule shell and formulation was observed, which continued 
gradually until an equilibration of shell with environment was reached. In contrast to that, 
water migration between the S-PVA shell and the formulation was rather slight (Figure 
3.5b).  
The obtained RH data indicated that even after 50 h of drying, equilibrium had not been 
reached in both capsule types. Subsequently, the capsules were stored openly in a climate 
chamber at 20° C/40% RH. Measurements after 3 months exhibited that equilibrium was 
finally reached. Water activity (aw) of the shell and the fill of both capsule types was then 
~ 0.4, that is, equal to the RH of the environment. 
 
 
Figure 3.5: Measured water activity (aw) during drying of (a) drug formulation (blue line) 
with soft gelatin shell (green line) and (b) drug formulation with S-PVA shell 
(red line). In both capsule types the equilibrium was not reached within 50 h 
of observation time. Data are presented as mean ± SD (n = 3). 
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To link the water activity measurements (Figure 3.5) with the drug solubility in the 
formulation (Figure 3.4), we further measured the water activity of the drug containing 
formulation with different water amounts added (Figure 3.6). Because the water activity 
of the formulation in SGCs after encapsulation was around 0.7, the corresponding water 
content was roughly 8% w/w in the formulation. Therefore, drug solubility in the 
encapsulated formulation decreased temporarily close to about 60 mg/mL, which means 
close to the solubility limit with the given drug load. 
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Figure 3.6: Water activity measurements of mixtures of drug-containing formulation (60 
mg/mL of fenofibrate in a mixture of Miglyol® 812, Tween® 80, and 
Transcutol® HP, 15%:60%:25%, w/w) and water. Data are presented as mean 
± SD (n = 3). Standard deviations are included within the labels. 
 
3.3.3.2. Determination of the dissolved drug concentration in the capsule 
formulation 
Soft gelatin capsules and S-PVA-Cs were stored openly and closed in glass vials for 4 
months at 20° C/40% RH. Visual observation of the formulation in SGCs, stored both 
openly and closed, revealed drug precipitation. This physical instability was best observed 
after centrifugation. In contrast, the drug-containing formulation in S-PVA-Cs, stored 
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openly or closed, remained clear without visual signs of any drug precipitation. The 
concentration of dissolved drug in the formulation of both capsule types was analysed and 
compared with the initial drug content in the formulation, which was determined 
immediately after the production (60.6 ± 1.6 mg/mL) (Table 3.4). A reduced content of 
dissolved drug in SGCs was found for both storage conditions, whereas S-PVA-Cs always 
maintained the drug quantitatively in solution. The ANOVA demonstrated a significant 
effect of the shell material (p < 0.0001) and the storage conditions (p = 0.0008). 
Moreover, a significant factor interaction was revealed (p < 0.0001; Table 3.4). Thus, the 
stability effect of the shell material was depending on storage conditions or vice versa. 
The storage conditions obviously did not affect the drug content of S-PVA-Cs, whereas 
the drug content of SGCs was even lower after storing the capsules in the closed 
condition than after storing them openly.  
Table 3.4: The concentration of dissolved drug in SGC and S-PVA-C stored openly and 
closed in glass vials for 4 months at 20° C/40% RH (n=5) with 95% 
confidence interval. 
Storage 
condition Mean (%) 
Lower 
limit (%) 
Upper 
limit (%) 
Open    
S-PVA-C 99.46 98.05 100.87 
SGC 86.64 85.23 88.05 
Closed    
S-PVA-C 100.62 99.21 102.03 
SGC 80.00 78.59 81.41 
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To study the solid state of precipitated material, X-ray analysis was conducted. Because 
the analysis required larger amounts of the solid material than obtained from the SGCs, 
water was added to the drug formulation as outlined in the method section 3.2.2.1.3. The 
diffractograms in Figure 3.7 demonstrate analogous distinct peaks from the precipitated 
material in the formulation as compared with a reference sample of crystalline 
fenofibrate. Thus, most of the precipitated material was obviously crystalline fenofibrate.  
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Figure 3.7: X-ray diffractogram patterns of fenofibrate powder as reference (F ref.) 
(black line), fenofibrate precipitated (FF prec.) from the formulation with 
32% (w/w) (red line), and formulation without fenofibrate (vehicle) (blue 
line). FF prec. after preparation was stored for 24 h at 5° C, then left for 5 
days at RT continuously stirring at 750 rpm and analysed. Formulation 
without fenofibrate (vehicle consisted of Miglyol® 812, Tween® 80, and 
Transcutol® HP (15%:60%:25%, w/w). 
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3.3.3.3. Texture analysis 
To study the mechanical properties of SGCs and S-PVA-Cs, texture analysis was used. 
Four important parameters were considered: elastic stiffness (slope of linear region of the 
curve), tensile force (force applied at the rupture point), elongation at break (deformation 
at which a capsule breaks), and the area under the force-displacement curve (work 
required to rupture the capsules). These mechanical properties were obtained from force-
displacement profiles of both capsule types (Figure 3.8). Comparison of the slopes of 
linear portion of the profiles of SGCs and S-PVA-Cs revealed lower elasticity of SGCs 
than of S-PVA-Cs. The tensile force at rupture point was about the same (SGC, F = 40.8 
± 3.1 N; S-PVA-C, F = 37.0 ± 2.3 N) indicating similar strength of both capsule types. 
Elongation at break was considerably greater with S-PVA-Cs, showing that these capsules 
accommodated more deformation before the rupture point was reached compared with 
SGC (S-PVA-C, d = 6.8 ± 0.2 mm; SGC, d = 3.7 ± 0.3 mm). The amount of W required to 
rupture the capsules was higher for S-PVA-C than determined with SGC (S-PVA-C, W = 
107.8 ± 7.9 Nmm; SGC, W = 61.0 ± 9.9 Nmm). 
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Figure 3.8: Comparison of the force-displacement profiles of SGCs (green lines) and S-
PVA-Cs (blue lines), both filled with fenofibrate formulation and equilibrated 
for 2 weeks at 20° C/40% RH before measurements. Profiles of n = 4 for each 
capsule type were measured. 
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3.3.3.4. In vitro disintegration and drug release testing 
For disintegration testing, we measured the time necessary for complete opening of the 
capsules in water at 37° C. SGCs showed much faster disintegration (3.2 ± 0.5 min) than 
S-PVA-Cs (15.4 ± 0.4 min). This was partially attributed to the higher amount of work 
required to rupture the S-PVA-Cs than SGCs. We observed that S-PVA-Cs were first 
swelling before rupture at the seam occurred. On the contrary, SGCs exhibited fast 
opening when in contact with the disintegration medium. The different disintegration 
behaviour was also reflected by the drug release profiles. Figure 3.9 depicts the 
dissolution behaviour of both capsules types in 0.05 M SDS. The SGCs showed almost 
immediate drug release during first 15 min of analysis. A short lag time was noted for the 
S-PVA-Cs, which was due to the delayed opening time of these capsules.  
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
0 20 40 60 80 100 120
0
20
40
60
80
100
SGC
S-PVA-C
 
Figure 3.9: Drug release profiles of fenofibrate formulation encapsulated in SGCs and S-
PVA-Cs in United States Pharmacopeia (USP) 2 in 0.05 M SDS, 75 rpm, at 37 
± 0.5° C. 
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3.4. Discussion 
One of the most critical points for encapsulating a hydrophilic lipid-based formulation in 
SGCs is water partitioning between the capsule shell and the fill (2). Water in the 
formulation typically reduces the solubility of poorly soluble drugs (13). In the present 
study, this reduction was shown to obey an exponential decay so that already small 
amounts of water in the formulation greatly lowered fenofibrate solubility (Figure 3.4). 
However, a precipitation is only observed when drug supersaturation occurs in the 
formulation for a sufficient time to induce nucleation of drug molecules and 
particle/crystal growth (117). The fenofibrate concentration of approximately 60 mg/mL 
was considerably lower than the solubility value of the water-free formulation. However, 
Figure 3.4 indicates that water concentrations higher than approximately 8% w/w in the 
formulation would lead to supersaturation of fenofibrate. It was possible to relate the 
amount of water in the formulation to the water activity of the formulation (Figure 3.6). 
Thus, the water activity of about 0.7 would already correspond to the solubility limit of 
fenofibrate in the formulation. During the SGCs manufacture, the high water activity of 
the gelatin shell decreased and approached that of the formulation (~0.6-0.7). This value 
was much higher than the water activity of around 0.3 that was obtained during the 
production of S-PVA-Cs. Only the SGCs exhibited a greatly reduced solubility that was in 
proximity of the drug loading. Any further reduction in solubility due to the temperature 
decrease or migration of the cosolvent to the gelatin shell would result theoretically in 
drug precipitation. Instead, much more robustness was expected for the S-PVA drug 
product based on the observed water activity changes during its soft capsule production.  
On the basis of the observed water exchange pattern of SGC, it was not surprising to find 
precipitated drug in these capsules following production and storage. Such drug 
precipitation is in any case considered as a serious quality defect. It can influence the in 
vivo drug release even though the effects may not always be seen under in vitro release 
testing conditions. Especially a crystalline precipitate is problematic from a 
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biopharmaceutical viewpoint. It was proven by solid-state analysis that most of the solid 
material in the SGCs was indeed crystalline fenofibrate. The redissolution of this dose 
fraction is expected to be critically slow so that incomplete drug absorption can result. 
Drug precipitation, as a consequence of water migration during the SGCs production, is 
even problematic when it is only temporary. It can be argued that drying upon storage can 
reduce the water content in the formulation and, therefore, the solubility would be shifted 
to a higher value allowing the precipitate to redissolve. However, such redissolution in an 
unstirred, viscous formulation is rather slow. Because any partitioning of water affects the 
equilibrium, it is expected that also packaging conditions influence the water content in 
the formulation and thereby also affect drug solubility. For example, fast packaging in 
hermetically sealed blisters may stop initial drying under open environment, thus keeping 
the water contained in the formulation. 
For more formulation robustness, soft capsules should exhibit another water migration 
pattern. Our study suggested an advantage for the S-PVA-Cs compared with SGCs. By 
measuring the water activity of the shell and the fill in both capsule types, it was possible 
to monitor water migration during drying and storage (Figure 3.5). In SGCs, the initial 
fast water partitioning between the shell and the formulation was followed by a slow 
equilibration with the shell and the environment. This process may take days, and the 
final water content in a hydrophilic lipid-based formulation is typically higher than that 
measured before encapsulation. In line with the concerns of losing drug solvent capacity 
in the formulation, differences were found in the stability data of the two capsule types. 
Visual observation of the drug formulation in the SGCs (stored openly and in closed glass 
vials for 4 months at 20° C/40% RH) revealed drug crystallization, which was further 
confirmed by HPLC analysis (Table 3.4). In contrast, S-PVA-Cs exhibited only slight 
water partitioning between the shell, the formulation, and the environment leading to slow 
equilibration. Another benefit of the S-PVA-Cs is that the low water activity 
(approximately 0.4) is close to a typical environmental humidity at RT, which enables S-
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PVA-Cs to be packaged shortly after production. Such fast packaging is not possible with 
the SGCs, so the novel capsule material enables a faster production of the final dosage 
form. 
It was mentioned before that the SGCs demonstrated a lacking robustness of the drug 
product with the given hydrophilic lipid-based formulation. The water-exchange pattern 
was shown to reduce the fenofibrate solubility close to the given drug loading in the 
formulation. It was assumed that an additional migration of a hydrophilic excipient into 
the gelatin shell occurred. Especially, the cosolvent Transcutol® HP was a candidate for 
such solute diffusion because of its hydrophilic nature and because of a comparatively 
small molecular size. Migrations of excipients or of the drug into the gelatin shell were 
reported earlier (6, 8). The authors studied the diffusion of solutes through interstices in 
the gelatin matrix (8). They proved these interstices were too large to act as physical 
barriers to diffusing molecules. Our study results could indicate that the thermoplastic 
shell material had an advantage over gelatin regarding solute diffusion. However, it is 
theoretically also possible that similar amounts of the cosolvent diffused from the 
formulation to the shell, but given the different water exchange patterns, only the SGCs 
exhibited drug crystallization during storage. 
The capsule materials also differed in their mechanical behaviour. As shown by the force-
displacement profiles (Figure 3.8), tensile force for both types of capsules was about the 
same indicating similar compressive strength. The typical force-displacement profile for 
soft capsules consists of an initial linear range, followed by a nonlinear behaviour (118). 
The linear range presented deformation according to Hook’s law, indicating that the 
applied compression force was directly proportional to probe displacement. This part of 
the profile represents the elastic range of deformation, which is followed by irreversible 
plastic deformation. Interestingly, the S-PVA-Cs accepted more deformation than SGCs 
and had larger elongation at break. Moreover, the work required to rupture the S-PVA-Cs 
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was considerably higher than that of SGCs. Such mechanical robustness of S-PVA-Cs is 
advantageous for direct bulk storage on trays or storage in large bins after capsule filling. 
Apart from the mechanical differences between the capsule types, surface morphology 
differed as shown in Figure 3.1. The films of S-PVA were considerably rougher than those 
of gelatin, which may be beneficial for capsule coating. S-PVA-C has the potential for 
simpler and more robust coating than SGC because of the slow water migration, high 
temperature resistance (up to 150° C), and rougher surface (Table 3.1). However, further 
technical studies are needed to better understand the relevance of the different capsule 
properties for additional manufacturing steps such as coating. 
3.5. Conclusion 
We have successfully introduced a novel thermoplastic material for soft capsules. The S-
PVA-Cs were manufactured on a pilot scale using a coupled extrusion and rotary die 
encapsulation. The water migration pattern of these thermoplastic capsules was markedly 
superior to that of SGCs. The novel shell material was found to be suitable for 
encapsulation of a hydrophilic lipid-based formulation (SMEDDS, type IIIB) without 
exhibiting any drug crystallization. Thus, a promising soft capsule technology was 
obtained for the production of a stable drug product when using hydrophilic lipid-based 
formulations that may otherwise not be suitable for SGCs. Moreover, the high resistance 
to mechanical deformation of the novel shell material may shorten manufacturing times 
as compared with the soft capsules made of gelatin. Other characteristics of the new 
material, such as surface roughness and thermal stability can be advantageous for a 
subsequent coating step.  
The hydrophilic lipid-based system in this study profited from the new capsule 
technology, but other formulations might be less critical with respect to encapsulation. 
Future studies are needed to investigate more formulations with different drugs at varying 
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dose strengths. Especially, the effects of cosolvent migration would have to be studied to 
finally assess the potential of the novel thermoplastic S-PVA-C in pharmaceutics. 
Z. Misic, R. Urbani, T. Pfohl, K. Muffler, G. Sydow, and M. Kuentz. Understanding biorelevant 
drug release from a novel thermoplastic capsule by considering microstructural formulation 
changes during hydration. Pharmaceutical Research. 31:194-203 (2013). 
 
Chapter 4 
 
Understanding biorelevant drug release 
from a novel thermoplastic capsule by 
considering microstructural formulation 
changes during hydration 
 
Summary 
The objective of this study was to explore the biorelevant drug release from novel starch-
based polyvinyl alcohol capsules (S-PVA-Cs). The effect of the shell material is studied 
by considering microstructural formulation changes during hydration. Two different self-
emulsifying systems containing either fenofibrate or probucol were filled in S-PVA-Cs, as 
well as capsules of gelatin (SGCs) and starch (VegaGels®). Release analysis employed a 
BioDis® apparatus, while disintegration was studied by texture analysis. For 
microstructural analysis we used small angle x-ray scattering (SAXS). 
S-PVA-Cs opened only partially in biorelevant media compared to completely opened 
SGCs and VegaGels®. In case of the fenofibrate formulation, this opening mechanism 
caused only a short lag time, while the probucol formulation in S-PVA-Cs resulted in a 
sustained release. The latter formulation demonstrated much higher viscosity upon 
hydration compared to the fenofibrate system. Such a rheological effect on drug release 
was barely noted for SGCs or VegaGels® and SAXS revealed differences in the hydrated 
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microstructure. Even though S-PVA-Cs are highly attractive for encapsulation of rather 
hydrophilic formulations, some care is needed regarding an immediate release form. The 
type of formulation hydration must be considered for adequate selection of the capsule 
material. 
4.1. Introduction 
There has been a great interest in finding gelatin substitutes for soft capsules in the last 
decade. This is due to known gelatin drawbacks, for example animal sources, potential 
issues of cross-linking, drug migration, or high water exchange during drying between a 
hydrophilic fill mass and the gelatin shell (25). Recently, we introduced (thermoplastic) 
starch-based polyvinyl alcohol capsules (S-PVA-Cs) in pharmaceutics (119). This soft 
capsule technology appeared to be especially promising for encapsulation of rather 
hydrophilic lipid-based systems. A typical problem of many self-microemulsifying or 
nano-emulsifying drug delivery systems is that the presence of hydrophilic formulation 
components can lead to issues of capsule compatibility when gelatin is used as shell 
forming material. The problem might be alleviated by addition of excipients to the soft 
gelatin shell, but a more versatile alternative is to employ the novel S-PVA-C technology. 
This thermoplastic capsule material was found to be suitable for rotary die encapsulation 
and the previous study demonstrated adequate drug release in a quality-control (QC) drug 
release test (119). 
Compendial drug release methods are used either in QC testing or to predict in vivo drug 
release with regards to the absorption process. Depending on the focus, the appropriate 
dissolution media and conditions need to be selected. For example, simplified aqueous 
media are typically used for routine QC purposes and more complex media might be 
required for predicting in vivo absorption (120). Such more complex media are especially 
needed for lipid-based formulations. The presence of bile salts and phospholipids, as 
natural surfactants, has a special importance in these drug release media. Due to their 
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amphiphilic nature, there can be an effect on drug solubilization as well as on reduction of 
interfacial oil/water tension, which would affect formulation dispersion. To better 
simulate the environment of gastro-intestinal (GI) fluids, many biorelevant dissolution 
media have been developed and tested over the last decade (21). Moreover, standard 
dissolution methodology (paddles or baskets) may not adequately mimic the 
hydrodynamics occurring in the GI tract, which was one of the reasons to develop the 
reciprocal cylinder, i.e. USP apparatus 3 (BioDis®). Although it is the most attractive 
method for testing extended-release products, some immediate release products were also 
successfully analysed (121). It seems to be attractive for in vivo absorption prediction to 
combine the use of a USP apparatus 3 with selecting biorelevant media. This is especially 
the case for poorly soluble, lipophilic drugs as demonstrated by Jantratid et al. (20, 122). 
One could argue that the most physiological for lipid-based systems is to test in vitro 
lipolysis (26, 123). Such tests are advantageous with formulations that are extensively 
digested. However, there is currently no standardized vessel defined for lipolysis testing 
so that hydrodynamics may differ from one equipment to another. Another drawback 
compared to compendial testing is that the final dosage form cannot be assessed with 
current lipolysis assays. Since we focused rather on the effect of the shell material on 
drug release, we selected biorelevant media in a USP apparatus 3. 
In the last decade self-emulsifying lipid-based systems have attracted increasing interest 
among scientists. These systems are dosed as pre-concentrates in a capsule and upon 
administration they disperse to microemulsions with a large surface area. The process of 
self-emulsification is a complex and still debated topic. Excellent reviews on the 
mechanisms of spontaneous emulsification were written by Lopez-Montilla et al. and 
others (124-127). Three principal mechanisms have been proposed for spontaneous 
emulsification. A first mechanism is based on interfacial turbulence, while another is 
called “diffusion and stranding” and finally, the transient occurrence of a negative 
interfacial tension has been discussed. It is also possible that combinations of these 
principal mechanisms dominate the aqueous dispersion of a self-emulsifying formulation.  
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The aqueous dilution of a pre-concentrate can possibly exhibit a phase separation along 
the dilution line. Interesting is the work of Regev et al. (128) who demonstrated that even 
in case of a resulting one-phase system, the aqueous dilution of the pre-concentrate 
typically passes through liquid crystalline structures and/or a bicontinuous microemulsion 
area. Only recently, small angle x-ray scattering (SAXS) was used in pharmaceutics to 
study the intermediate hydration phases of self-emulsifying drug delivery systems (129-
132). 
In the present work, we addressed the need to study the biorelevant drug release from S-
PVA-Cs. Self-emulsifying systems were used as model formulations and results were 
compared to the release from soft capsules made of gelatin and of a thermoplastic starch 
(VegaGels®). A particular aim was to evaluate the interaction of the shell material and the 
type of formulation hydration by studying microstructural changes. 
4.2. Materials and methods 
4.2.1. Materials 
Fenofibrate (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) and probucol 
(Euroasian Chemicals Pvt Ltd, Mumbai, India) were selected as poorly water-soluble 
model drugs. Medium-chain triglycerides (Miglyol® 812) were supplied by Hänseler AG 
(Herisau, Switzerland), soybean oil refined from Georges Walther AG (Pfäffikon, 
Switzerland) and Transcutol® HP (2-(2-ethoxyethoxy)ethanol) by Gattefosse (Lyon, 
France). Imwitor® 742 (medium-chain partial glyceride) was obtained from SASOL 
(Witten, Germany) and macrogol-glycerolhydroxystearat (Cremophor® RH 40) from 
BASF (Ludwigshafen, Germany). Polyoxyethylene (80) sorbitan monooleate (Tween® 
80) and acetonitrile of high-pressure liquid chromatography (HPLC) grade were 
purchased from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland).  
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For the preparation of the fasted state simulated gastric fluid (FaSSGF) and the fasted 
state simulated intestinal fluid (FaSSIF), we purchased sodium chloride and sodium 
hydroxide from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland), pepsin and maleic 
acid from Hänseler AG (Herisau, Switzerland), sodium taurocholate from Prodotti 
chimici e alimentari S.p.A. (Basaluzzo, Italy), phosphatidylcholine from Lipoid GmbH 
(Ludwigshafen, Germany), and hydrochloric acid (1 N) and sodium hydroxide (1 N) from 
Scharlab (Barcelona, Spain).  
The air-filled and oil-filled capsules (Table 4.1), used for the release testing, and the 
disintegration testing, were produced at the technical facility at Swiss Caps AG , 
(Kirchberg, Switzerland).  
 
Table 4.1: Characteristics of different capsule types. 
Type of 
capsule Capsule shell material 
Method of 
production  
Fill mass1 
Soft gelatin 
capsules 
bovine gelatin, glycerol, and 
water                                             
47.4%: 17.1%: 35.5% (w/w) 
casting and rotary 
die method2  
soybean oil 
VegaGels® 
potato starch, glycerol, sorbitol, 
carrageenan, and water                 
66%: 18%: 10% : 1% : 5% 
(w/w) 
extrusion and 
rotary die method3 
soybean oil 
S-PVA-Cs4 
potato starch, PVA, plasticizers 
(sorbitol solution and glycerol)     
40 % : 30% : 30% (w/w) 
extrusion and 
rotary die method2  Miglyol
® 812 
 
1 Fill mass for those capsules used for the texture analysis of dosage form disintegration  
2 Methods of production are described in Misic et al. (119). 
3 Method of production of VegaGels® is the same as for S-PVA-Cs. 
4 S-PVA-Cs: starch-based polyvinyl alcohol thermoplastic capsules 
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4.2.2. Methods 
4.2.2.1. Preparation and hydration of the formulations 
Two different self-emulsifying systems consisting of Tween® 80, Transcutol® HP, 
Miglyol® 812, Imwitor® 742 (45%: 15%: 20%: 20% w/w; TTMI) and Cremophor® RH 
40, Transcutol® HP, Miglyol® 812 (60%: 25%: 15% w/w; CrMTrans) were used as model 
formulations. Since lipid-based systems are generally tailor-made for each drug 
substance, we also employed two different formulations for the active substances, i.e. 
TTMI for fenofibrate and CrMTrans for probucol. Both mixtures (TTMI and CrMTrans) 
were compounded in glass vials (by weight) using an analytical balance (Mettler Toledo 
AB204-S). A magnetic stirring was employed at 40° C until a clear solution was obtained. 
We carefully checked for the absence of residual particles following the cooling at room 
temperature. The prepared formulations were hydrated with deionized water at water 
levels in the range of 5-90% w/w and stored for 24 h at room temperature (RT) before 
analysis. 
4.2.2.2. Preparation of drug-containing formulations (solubility studies) 
For the system of fenofibrate in TTMI as well as probucol in CrMTrans, an excess 
amount of drug was added. The mixtures were constantly stirred (750 rpm on a magnetic 
stirrer) in glass vials at RT. To ensure that equilibrium was reached, the solubility was 
determined after 18 h, 24 h, and 72 h. The samples were then centrifuged at 13,362 g for 
20 min using a Centrifuge 5415 R (Eppendorf AG, Hamburg, Germany). Finally, the 
concentrations of the active compounds in the supernatant were determined after diluting 
the supernatant with acetonitrile (1:500 v/v) by HPLC analyses. 
Drug-containing formulations were prepared by adding fenofibrate to a clear solution of 
TTMI (FF-TTMI), and probucol to CrMTrans (Pro-CrMTrans), both in drug 
concentration of 60 mg/mL. 
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4.2.2.3. Characterisation  
4.2.2.3.1. Particle size measurements  
Particle size of the diluted self-emulsifying systems was analysed by means of dynamic 
laser light scattering using a Zetasizer Nano ZS (Malvern, Worcestershire, United 
Kingdom). For individual measurements, an aliquot (100 μL) of each preconcentrate was 
obtained from a calibrated automatic pipette Eppendorf Research® plus (20-200 μL) and 
dispersed in 20 mL of water using a glass vial. Both formulations were assessed for their 
ease of self-emulsification and qualitatively described as “good”, “moderate” or “poor” 
(129). The diluted samples were measured in dynamic light backscattering (173° angle) 
and the mean particle size (Z-average diameter) was calculated from the volume size 
distribution. All experiments were repeated in triplicates from fresh samples at RT. 
4.2.2.3.2. Rheological studies  
The rheological properties of low-viscous lipid-containing colloids can be difficult to 
measure. For adequate measurements using a cone-plate rheometer, there must be a 
uniform force transmission in the sample. A loss of grip between the cone and the sample 
shear plane is a problem that especially occurs at comparatively high shear forces. For the 
measurements of the hydrated formulations, we therefore employed a new mechanical 
chip-based (MEMS) capillary rheometer (mVROC™ RheoSence, San Ramon, CA, 
USA). m-VROC™ (Viscometer-Rheometer-on-Chip) is a microfluidic slit rheometer 
used for fast and accurate measurements of the viscosity of microliter sample volume 
solutions. It measures the viscosity from the pressure drop of a sample as it flows through 
a rectangular slit. The glass syringe (Hamilton 1010 C SYR 10 mL or Hamilton 81260 
SYR 500 μL, depending on the viscosity of the sample) was loaded with sample and 
placed inside of the thermal jacket (25 ± 0.5° C). When the measurement temperature was 
stable, the sample was pumped to flow (at shear rate 200 s-1) through the flow channel of 
the chip. The pressure drop was detected by a sensor (cell m-VROC A-10 or D-10) and 
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the viscosity was calculated using m-VROC Control Software™. The viscosities of TTMI 
and CrMTrans were measured for hydration levels of 5-90% w/w. Results were based on 
experiments in triplicates.  
4.2.2.3.3. Small angle x-ray scattering (SAXS) studies  
SAXS was measured using a Bruker NANOSTAR setup with an Incoatec IμS-microfocus 
Cu-Kα anode (wavelength 1.54 Å) and a Bruker VANTEC-2000 detector. The samples 
were measured in flame-sealed glass capillaries with a diameter of 1.5 mm and a wall 
thickness of 1 μm. The 2D detector images were taken at ambient temperatures and were 
azimuthally averaged to produce 1D intensity profiles.  
Fitting. The SAXS data were fitted using a Teubner-Strey model for microemulsions 
(131, 133). The Teubner-Strey model is based on the Landau theory for microemulsions, 
where the order parameter is associated with the “water-to-oil ratio” (133). This model 
predicts a single broad maximum and a q-4-dependance towards higher q-values (higher 
scattering angles).  
Within this model the scattering intensity has the following form: 
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Here, d is the domain size (or periodicity) whereas ξ is the correlation length, both 
together providing an indication of the order in the system. The ratio ξ/d is a measure of 
the correlation length in units of the periodicity.  
4.2.2.3.4. Biorelevant drug release studies 
Drug release was studied using the BioDis® apparatus (RRT 8, CALEVA Ltd, Dorset, 
England) at 37 ± 0.5° C using 220 mL of test medium in each vessel, mesh sizes of 420 
μm for both the top and bottom mesh of the glass cylinders and a dip rate of 10 dpm or 30 
dpm, respectively (134, 135). Prior to each experiment, the air-filled capsules were 
weighed before and after manual filling with FF-TTMI or Pro-CrMTrans, to obtain an 
exact fill mass in each capsule. The experimental set-up in this study was supposed to 
mimic the fasted gastrointestinal tract (GIT). Therefore we used FaSSGF (30 min) 
followed by FaSSIF (60 min), prepared as described by Jantratid et al. (136). At 
predetermined time points, a 2-mL sample was taken by a syringe, immediately filtered 
through a 0.45 μm Nylon filter (Titan 2 Syringe Filter, SUN SRi, Rockwood, TN, USA) 
and analysed by HPLC. The removed volume was replaced each time with 2 mL of fresh 
medium. All experiments were performed in triplicates.  
4.2.2.3.5. Texture analysis of dosage form disintegration  
A texture analyzer (TAXT2i; Stable Micro Systems, Surrey, United Kingdom) was 
assembled with a disintegration rig (originally developed for fast-melting tablets) to study 
the disintegration of capsules. This mechanical test mimics the gastric disintegration 
conditions, while constantly maintaining the force and measuring the distance as the 
sample disintegrates. The apparatus was equipped with a 5 kg load cell and fitted with a 
20 mm diameter cylindrical probe. The capsule was attached with a strip of 3 mm wide 
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double-sided tape to the underside flat region of the probe end. Each capsule type was 
filled with oil at the technical facility of Swiss Caps AG , (Kirchberg, Switzerland) (Table 
4.1) and was analysed in triplicates. A double-jacketed glass vessel was connected with 
tubes to a thermostat system to keep the disintegration medium (FaSSGF, 100 mL) at 37 
± 0.5° C. On the bottom of the double-jacketed glass vessel was a (30 mm diameter) 
platform, which was perforated to allow ingress of water beneath the capsule. The speed 
of the probe with an attached capsule was initially 2.0 mm/s until the surface of 
perforated platform was detected at the force of 0.029 N (threshold value for triggering 
the onset of texture analysis). Subsequently, the force of the probe was 0.098 N with a 
speed of 3.0 mm/s and the distance was measured to obtain a capsule disintegration 
profile. The time of analysis was 30 min (consistent with section 4.2.2.3.4.). All capsules 
were produced either on pilot- (S-PVA-Cs) or on a production-scale (SGCs, VegaGels®) 
using rotary die filling machines at the Swiss Caps facility in Kirchberg, Switzerland 
(Table 4.1).  
4.2.2.4. HPLC method  
The drug content of each sample was determined by HPLC (Agilent Technologies 1200 
Series) using a degasser (G1379 B), an isocratic pump (G1310A), an autosampler 
(G1329A), a variable wavelength detector (G1314B), and a LiChrospher 60, RP select B 
125–4 (5 μm) column (Merck, Darmstadt, Germany) at a flow rate of 1 mL/min. The 
HPLC conditions are described in Table 4.2. 
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Table 4.2: Overview of HPLC methods used for active compounds quantification. 
Active 
compound Mobile phase 
Injection 
volume 
UV 
detection 
Fenofibrate 
Acetonitrile : ammoniumacetate 
buffer (pH 3.5; 25 mM) (65:35, 
v/v) 
20 μL 287 nm 
Probucol Acetonitrile : water (90:10, v/v) 10 μL 241 nm 
 
4.3. Results 
4.3.1. Characterization 
4.3.1.1. Particle size measurements 
The self-emulsifying systems (CrMTrans and TTMI) used in our study showed different 
spontaneous dispersion behaviour in water (ratio 1:200 v/v) at room temperature. We 
checked each of the evolving dispersions visually and qualitatively classified the ease of 
their self-emulsification as “good”, “moderate” or “poor”. Since TTMI spontaneously 
formed a transparent dispersion, it was categorized as “good” emulsifying system. This 
ease of spontaneous self-emulsification behaviour was already described by Groves and 
Pouton (137, 138). In contrast to that, the formulation CrMTrans was rated as rather 
“poor” emulsifier, since it formed flakes upon gentle agitation, while following short 
vigorous stirring, the mixture became completely transparent. This result was obviously 
caused by the formation of viscous structures, which required higher shear forces to 
disperse the system. Despite the differences in their ease of self-emulsification, both 
systems resulted in nanodroplets. The droplet sizes of CrMTrans and TTMI were found to 
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be 23.0 ± 1.6 nm (PDI = 0.15) and 17.9 ± 1.7 nm (PDI = 0.07), respectively. A 
statistically significant difference between the droplet sizes of diluted formulations was 
confirmed with p<0.01 (t-test following an F-test that demonstrated the homogeneity of 
sample variances). 
4.3.1.2. Rheological studies 
Figure 4.1 shows differences in viscosities of the hydrated self-emulsifying systems 
(TTMI and CrMTrans). We observed that, in the case of CrMTrans, the viscosity at lower 
water contents (10-25% w/w) increased with dilution. It may be related to the swelling of 
the amphiphilic film as part of the generated microstructure. This increase in viscosity, 
caused by instantaneous formation of a transparent gel upon hydration, was already 
visually observed during sample preparation. With further increase in water volume 
fraction, continuous hydration of the structure was observed. There was a sharp increase 
in viscosity observed with the CrMTrans system demonstrating a maximum at 30% w/w 
water, followed by a decrease with further hydration. In contrast, TTMI exhibited only a 
slight increase in viscosity at the hydration levels of 40-50% (w/w). 
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Figure 4.1: Viscosity profiles of the self-emulsifying systems upon hydration measured at 
200 s-1 and 25° C by m-VROC™ rheometer [CrMTrans (red line), TTMI 
(blue line)]. The lines are presented as guides to the eye. 
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4.3.1.3. Small angle x-ray scattering (SAXS) 
SAXS was used to study microstructural changes in hydrated formulations over the whole 
hydration range. We did not expect a marked effect of the compounds on hydration, 
because both drugs are neutral, highly lipophilic and low concentrated. Therefore, the 
controlled hydration was studied using placebo formulations. The peak positions of 
hydrated TTMI shifted to smaller q-values with increasing water content and became 
narrower up to 55 % w/w water content (Figure 4.2). For the hydrated CrMTrans, with 
the increasing water content from 10 to 25% w/w, a shift of the peak to lower q-values 
and a narrowing of the peak could be observed. The narrowest peak was obtained at a 
water content of 30% w/w. Further water increase resulted in only slight shifts of the peak 
positions, while a broadening of the peak with increasing water content was noted. Both 
formulations exhibited at higher hydration levels (for TTMI from 60% up to 90% w/w 
and for CrMTrans from 35% to 70% w/w) an additional change in SAXS intensity for 
smaller q values (0.01-0.02 Å-1). The appearance of an additional SAXS signal can be 
attributed to a coexistence of an additional colloidal phase with the general 
microemulsion structure. 
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Figure 4.2: SAXS intensity profiles (logarithmic scale) for microemulsions consisting of 
(a) TTMI and water and (b) CrMTrans and water. The numbers next to the 
each curve indicate different water concentrations in the mixtures. Each curve 
is shifted by one order of magnitude with respect to the previous one.  
 
The calculated domain sizes d and correlation lengths ξ are shown in Figures 4.3 and 4.4. 
For CrMTrans hydrated from 15% to 25% w/w, and from 45% up to 60% w/w an increase 
in d was found, which was followed by a slight decrease for water contents up to 90%. In 
contrast to that, a strong (linear) increase of the correlation length ξ with increasing water 
content from 10% to 30% w/w could be seen. After reaching a maximum in ξ at 30% w/w 
water content (ξ ≈ 190 Å), ξ sharply decreased between 30% and 65% w/w with a 
subsequent slower decrease towards higher water contents. Both the calculated domain 
size d and the correlation length ξ of hydrated TTMI demonstrated a linear increase with 
rising water content up to 50% w/w, followed by slight decrease at higher water contents. 
The exception was at 65% w/w hydration level when d showed some increase compared 
to other hydration levels. 
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Figure 4.3: Plot of domain size (periodicity) d versus hydration levels for both model 
formulations (TTMI and CrMTrans). [CrMTrans (red line), TTMI (green 
line)]. The lines are presented as guides to the eye to point at increase in 
periodicity. 
Both formulations exhibited a maximum value in d as well as with respect to the 
correlation length ξ. This scattering behaviour was reflecting a hydration process that 
induced the formation of a more ordered phase. Following the maximum domain size and 
correlation length, a reverse trend in the swelling process started, which can be viewed as 
a phase transition. Thus, dominance of a bicontinuous microemulsion structure (with 
possible existence of local lamellar structures) was receding to evolving colloids of a 
droplet type. 
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Figure 4.4: Plot of correlation length ξ versus hydration levels for both model 
formulations (TTMI and CrMTrans). The connecting lines are for the ease of 
visualization. 
 
4.3.1.4. Analysis of capsule disintegration and drug release 
To better characterize the mechanical changes of the shell material, we used a capsule 
disintegration testing rig of texture analysis. Thus, the capsule filled with oil (Table 4.1) 
was placed in biorelevant test medium (FaSSGF) at 37 ± 0.5° C and a plate was kept at 
constant force to monitor changes in distance. Such changes of displacement were caused 
by the specific hydration and capsule disintegration mechanisms (Figure 4.5). Both S-
PVA-Cs and VegaGels® were first swelling before rupture at the seam occurred. For S-
PVA-Cs partial opening at the seam was noticed by visual observation, whereas for 
VegaGels® there was a fast and complete opening along the seam. This difference in 
opening can also be seen in their disintegration profiles. VegaGels® appeared to 
disintegrate in a two-steps process. A first stage corresponded to the opening at the 
capsule seam, while the second stage was given by the disintegration of the residual 
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capsule halves. SGCs exhibited a very fast and complete opening prior to dissolution of 
the gelatin fragments. 
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Figure 4.5: Comparison of disintegration profiles of oil-filled SGC, VegaGels®, and S-
PVA-C analysed by texture analyzer in biorelevant medium (FaSSGF) at 37 ± 
0.5° C. Each curve is a single representative example of n = 3 experiments. 
The different disintegration behaviour was also reflected by the drug release profiles. 
Figure 4.6 depicts the release behaviour of fenofibrate formulation (FF-TTMI) in all three 
capsule types using the biorelevant media. SGCs and VegaGels® showed an almost 
immediate drug release within the first 10 min, which was in agreement with the 
disintegration profiles confirming a complete capsule opening. A short lag time was noted 
for the S-PVA-Cs, which was due to the partial opening of these capsules. 
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Figure 4.6: Release behaviour (n = 3 ± SD) of fenofibrate formulation (FF-TTMI) from 
S-PVA-Cs, SGCs, and VegaGels® using the BioDis® apparatus in biorelevant 
media at 37 ± 0.5° C, 10 dpm (shaded part represents drug release in FaSSGF, 
and non-shaded in FaSSIF). 
 
Figure 4.7 presents the release behaviour of the probucol formulation (Pro-CrMTrans) in 
all three capsule types using biorelevant media. The drug release of Pro-CrMTrans filled 
in S-PVA-Cs in FaSSGF was incomplete with high variations (10-30%). A subsequent 
change to FaSSIF exhibited sustained and comparatively slow drug release also with high 
variability. This observation may be attributed to the differences in viscosity of Pro-
CrMTrans compared to FF-TTMI. The drug release of Pro-CrMTrans filled in SGCs and 
VegaGels® was complete after 30 min with a short delay. 
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Figure 4.7: Release behaviour (n = 3 ± SD) of the probucol formulation (Pro-CrMTrans) 
from S-PVA-Cs, SGCs, and VegaGels® using the BioDis® apparatus in 
biorelevant media at 37 ± 0.5° C, 10 dpm (shaded part represents drug release 
in FaSSGF, and non-shaded in FaSSIF). 
To evaluate the effect of mechanical force on release behaviour of the probucol 
formulation in S-PVA-Cs, we increased the dipping rate from 10 dpm to 30 dpm. A rate of 
10 dpm provided an agitation that is generally considered as physiological for dosage 
form release in the USP 3 (139). An increase of the dip rate was therefore primarily of 
interest to mechanistically study the probucol system. We targeted higher shear forces 
caused by an increased agitation of the reciprocal cylinder. However, the probucol 
formulation CrMTrans barely revealed a difference in drug release when comparing the 
two dip rates (Figure 4.8). 
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Figure 4.8: Effect of the mechanical force on release behaviour of probucol formulation 
(Pro-CrMTrans) in S-PVA-C in BioDis® apparatus in the biorelevant media at 
37 ± 0.5° C (shaded part represents drug release in FaSSGF, and non-shaded 
FaSSIF). 
 
4.4. Discussion 
For any new capsule technology it is important to study drug release not only in standard 
buffer solutions but also using biorelevant media. Although these media only approximate 
the composition of gastro-intestinal fluids, they still contain the most important 
components, namely bile salts and phospholipids, which facilitate solubilization of 
lipophilic drugs in micelles. So the release of poorly soluble, lipophilic drugs is usually 
enhanced compared to the release rate in simple aqueous solutions (20). 
In our previous work we focused on manufacturability and general characterization of the 
novel thermoplastic soft capsules (S-PVA-Cs). Benefits were shown for the encapsulation 
of rather hydrophilic formulations and drug release was studied in water only (119). 
Considering the importance of more physiological drug dissolution, we focused in the 
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present study on biorelevant drug release using the USP apparatus 3. A special aim was to 
better understand how the shell material affects drug release by considering changes in 
the hydrated microstructure of selected self-emulsifying formulations. 
4.4.1. Effect of the shell material 
Disintegration in a compendial sense is defined as the state in which any residue of the 
unit, except fragments of the capsule shell, is a soft mass having no palpably firm core 
(140). The process of disintegration consists theoretically of two steps: opening of the 
capsules and the disintegration of the capsule shell, which may overlap in time. In case of 
the gelatin capsules, the opening process was usually fast (within the first 5 min) and 
seemed not to limit the drug release. In contrast to gelatin, there was a general lack of 
knowledge about disintegration of thermoplastic capsules or their drug release in 
biorelevant media. This was not only true for the novel S-PVA-Cs but also for other 
thermoplastic capsules such as VegaGels®. Since the thermoplastic capsules may have a 
specific opening mechanism, depending on the nature of the polymer, their disintegration 
profiles can vary. Both VegaGels® and S-PVA-Cs are starch-based thermoplastic capsules 
that are similar in their qualitative composition (Table 4.1). Their similarity was also 
reflected by the observed disintegration profiles in biorelevant media. Texture analysis of 
their disintegration process revealed a swelling (pre-disintegration) before a rupture 
occurred at the seam of the capsules (Figure 4.5). Following an initial swelling, 
VegaGels® demonstrated a step-wise disintegration pattern. It was clearly possible to 
distinguish a complete opening of the capsule from the disintegration of the residual shell 
material. In contrast to that, S-PVA-Cs first partially opened and then started to 
disintegrate, while they continued to open. This different opening pattern was visually 
observed and was supported by the texture analytical profiles. Moreover, this finding was 
in agreement with the observed release profiles of S-PVA-Cs. In the case of the 
fenofibrate formulation, a short lag time was noted, which was attributed to the partial 
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capsule opening. For the probucol formulation, the interaction of the opening mechanism 
and poor formulation dispersibility resulted in sustained and comparatively slow drug 
release. Furthermore, there was no influence noted of a varied hydrodynamics on the 
release profile (Figure 4.8). This was similar to the results of a previous study in which a 
difference in typical dip rates of the USP apparatus 3 barely affected drug release of 
tablets (141). A complete and fast opening of SGCs and VegaGels® assured an immediate 
drug release, which was not depending on the nature of the formulation with its hydration 
process. 
In summary, the fenofibrate system easily self-emulsified and drug release was therefore 
practically independent of the used capsule shell. However, the model formulation of 
probucol was critically depending on the type of capsule opening. The partial opening of 
the S-PVA-Cs in combination with the highly viscous hydrated formulation obviously 
sustained the drug release. Such hindered drug diffusion was not observed with the same 
formulation using the other tested capsules that opened rapidly along their entire seam. 
4.4.2. Effect of microstructural formulation change  
The results of the capsule opening as well as the drug release testing showed, especially 
for S-PVA-Cs, that formulation changes during water hydration can be critical. To better 
understand such effects during self-emulsification, we studied the preconcentrates at 
different hydration levels. The drug-free formulations were studied while assuming that 
the compounds would have a neglectable effect on hydration at the rather low 
concentrations used in this study. 
Both model formulations (CrMTrans and TTMI) exhibited along the different hydration 
levels some similarities. Until the viscosity maximum was reached, the system remained a 
clear single phase. The drop of viscosity in both systems resulted in slightly turbid 
mixtures that became practically transparent as the water hydration levels increased. The 
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probucol system (CrMTrans) revealed a sharp increase in viscosity at an intermediate 
hydration (10-25%, w/w), which was quite different from the hydrated fenofibrate system 
(TTMI). Such a viscosity peak was previously observed by Fanun (142) in hydrated 
preconcentrates that were fully dilutable (as a single-phase). It was assumed that 
structural transitions occurred from water-in-oil to bicontinuous to oil-in-water 
microemulsions. This view of structural transitions has also been reported by other 
authors who studied similar self-emulsifying formulations (85). However, the 
microstructural changes may still be specific for a given system so that different 
rheological properties evolve during hydration. 
For the swelling of an amphiphile, the polar head group is expected to play a key role. 
Both model systems comprised rather hydrophilic surfactants with a substantial amount 
of ethylene oxide units. However, the Cremophor-containing formulation (CrMTrans) had 
a much higher surfactant concentration than the Tween-system (TTMI). This probably 
contributed to the more viscous structures that were formed upon water addition. 
Unfortunately, we could not compare surfactant effects at the same concentration levels, 
because of the individual phase behaviour of the formulations that were tailor-made for 
the different model drugs. 
A better understanding of the microstructure was targeted by the analysis of SAXS data. 
Both systems demonstrated a typical peak for the hydrated systems as it has been 
observed before in hydrated microemulsion preconcentrates (130-132). Recently, Patil et 
al. discussed the possibility that at least a part of such structure was consisting of local 
lamellar structures (131). Such structures can be viewed as small stacks of randomly 
oriented lamellar structures. Local lamellar structures were initially reported in 
microemulsions by Cabos et al. (143). Since there is a lack of long-range and 
orientational order, no macroscopic birefringence would be expected. Kogan et al. 
described the existence of “ordered bicontinuous structures” as bicontinuous 
microemulsions based on lamellar phases that have lost the long-range order due to 
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thermal distortions but kept the short-range order (144). In our case, the SAXS 
diffractograms of both systems developed comparatively ordered structures at an 
intermediate hydration regime. This increase in ordering has been seen in a shift of the 
peak maxima to the lower angles (q) and a sharpening of the peaks. The samples at 
intermediate hydration levels were also examined by a polarized light microscope and did 
not reveal any birefringence, which indicated that no marked liquid crystalline structures 
were present. The obtained structures were considered to be microemulsions with some 
short-range order. For such intermediate hydration levels, a bicontinuous microemulsions 
type is expected. Our data showed in case of TTMI some linearity of d as a function of 
different water amounts. More complex were changes in the domain size of the CrMTrans 
system upon addition of water. This formulation showed a maximum in ξ ≈ 190 Å at 30% 
w/w, whereas TTMI exhibited a strong linear increase and reached its maximum only at ξ 
≈ 110 Å at 55% w/w. It was a notable finding that the maximum in the correlation length 
of the CrMTrans system corresponded to the observed sharp viscosity peak. In contrast to 
that, hydrated TTMI demonstrated neither a sharp peak in correlation length nor in 
viscosity. 
Our systems also exhibited a typical bell-shaped curve of ξ as a function of the hydration 
level (Figure 4.4). As earlier reported by Fanun (132, 142) this behaviour could be 
correlated with structural transitions. Another interesting property is the ratio of the 
correlation length to the domain size ξ/d, which indicates a length of order that is relative 
to a typical domain size. It has been argued that the product 2π times ξ/d might be used to 
differentiate a bicontinuous microemulsion from another type of a Windsor type IV 
system (128). However, some care is needed with this theoretical argument because real 
Windsor type IV systems can be difficult to assign to an ideal structural type. Structures 
of different colloidal nature can also co-exist. As explained earlier, it is well possible that 
stacks of local lamellar structures were present in our model systems. However, they 
could have been part of a bicontinuous microemulsion at intermediate hydration levels. 
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A co-existence of different structures was also an interpretation of the additional SAXS 
features at very low q, which was observed at relatively higher water amounts in both 
systems. This signal was likely due to larger colloidal structures such as oil-swollen 
micelles. Hence, it may hold for the onset of a transition to oil in water microemulsion. 
In summary, the SAXS data demonstrated clear differences in the microstructures of the 
model systems in terms of how the domain size d and the correlation length ξ changed at 
different hydration levels. Interesting was the more complex hydration process of the 
CrMTrans system, which was inferred from the non-linearity of d as a function of 
increasing water amounts. Our data suggested that different colloidal structures can co-
exist in hydrated self-emulsifying systems. The higher structural ordering might have 
caused an increased viscosity. Although, the microstructural analysis using SAXS 
effectively complemented the rheological studies of the hydrated formulations, it did not 
fully explain the huge differences in viscosity between the two hydrated systems. More 
research is needed to better understand how the microstructure of hydrated self-
emulsifying systems is affecting rheological properties. 
4.5. Conclusions 
This study focused on the biorelevant drug release from S-PVA-Cs. Texture analysis of 
capsule disintegration revealed interesting findings. A clear difference was noted in the 
mechanism of how the novel S-PVA-Cs opened compared to soft capsules of gelatin or of 
another thermoplastic material (VegaGels®). The different opening mechanism was 
relevant for the drug release depending on the given formulation. We studied two model 
formulations which were both preconcentrates of microemulsions, but they significantly 
differed in their hydrated microstructure. A better understanding of these microstructures 
was achieved by SAXS analysis. An interaction of the hydrated structures and the shell 
material was identified for the drug release from the novel thermoplastic capsules.  
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Our results support the view that a capsule shell material may not be freely selectable for 
a given formulation. While initial formulation development is typically optimizing the 
biopharmaceutical performance, some care is needed with selecting an appropriate 
capsule technology. The choice of a suitable shell material has to be based on improved 
knowledge of formulation characteristics. Quality control failures in drug release can be 
avoided by a better understanding of the mechanisms of capsule opening and the 
microstructural formulation changes during hydration. Ultimately, such knowledge 
contributes to designing quality into a capsule dosage form. This is a step in the right 
direction towards the desired state of the quality by design initiative as it is targeted by 
regulatory authorities as well as by developers of drug products. 
  
Chapter 5 
 
Understanding interactions of oleic acid 
with basic drugs in solid lipids on 
different biopharmaceutical levels 
 
Summary 
Recently, the impact of intestinal supersaturation on absorption of poorly water-soluble 
drugs has raised much interest among researchers. A focus has been mostly to study 
excipient effects on maintenance of drug supersaturation. The aim of the present study 
was to better understand the effects of drug-excipient interactions on different levels, i.e., 
in the anhydrous formulation, upon dispersion in simple buffer media and, in particular, 
regarding precipitation kinetics. As a model system a solid lipid-based formulation was 
developed, comprising PEG-32 stearate and oleic acid (OA) (8:2 w/w). Loratadine (pKa = 
4.33) and carvedilol (pKa = 8.74) were chosen as basic drugs. UV/FTIR spectroscopy and 
viscometry were used to characterize drug-OA molecular interactions in solution, while 
solid formulations were studied using x-ray diffraction, thermal analysis and van’t Hoff 
solubility-temperature plots. Precipitation kinetics of drug formulations was real-time 
monitored in phosphate buffer (pH = 6.5) by focused beam reflectance measurements. It 
was found that the addition of OA in the formulations resulted in substantial drug 
solubility increase. Although the drug-OA interactions appeared to be partially lost upon 
formulation dispersion, the extent of precipitation was markedly lowered compared to the 
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formulations without OA. A Precipitation number (Pnc) was introduced as a ratio of a 
relevant residence time of drug in the gastrointestinal tract (GIT) to the induction time 
(the onset time of crystalline precipitation). Without OA, Pnc was already taking critical 
values (>1), while the anhydrous formulation was still below saturation for both model 
drugs. Interestingly, the addition of OA resulted in amorphous instead of crystalline 
precipitates, which is advantageous for drug absorption. In conclusion, this study provides 
an improved understanding of OA and basic drug interactions on different levels of in 
vitro performance for more rational oral formulation development.  
5.1. Introduction 
Poorly water-soluble drugs (PWSD) present a challenge for drug development because of 
a typically reduced systemic exposure upon oral administration. A key approach to 
enhance oral bioavailability of PWSD is to employ lipid-based formulations (LBFs) that 
may consist of oils, surfactants, and co-solvents (26). The latter excipients are often added 
to solubilize the dose of rather hydrophobic drugs, while primarily lipophilic compounds 
may be incorporated in oils alone. A high solvent capacity of the anhydrous formulation 
generally decreases upon formulation dispersion and digestion in the gastrointestinal tract 
(GIT), thereby resulting in drug supersaturation. This supersaturated state is 
thermodynamically unstable and its extent constitutes the driving force for drug 
precipitation. In the last decade, there has been a growing interest in: 1) development of 
different types of supersaturating drug delivery systems (SDDS) (79, 145) that stabilize 
supersaturation, and also in 2) understanding the mechanisms by which LBFs generate 
supersaturation (84, 87, 89). Maintenance of drug supersaturation upon aqueous 
formulation dispersion was demonstrated in several studies by inclusion of some 
polymers (96, 97), surfactants (99), and cyclodextrins (100) in drug formulations. As a 
result of a sufficiently long and stable period of drug supersaturation, intestinal drug 
absorption and oral bioavailability can be enhanced (101).  
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Many studies on drug supersaturation are not mechanistically oriented and there is a need 
to better differentiate excipient effects on drug solubility (upon dispersion) from an 
influence on the kinetics of drug precipitation. Much needed is a better holistic 
understanding of drug-excipient interactions starting already on the level of the anhydrous 
formulation to the fate of the drug delivery system in vitro and in vivo. Such a systematic 
study of drug-excipient interactions, to the best of our knowledge, has not been reported 
for solid lipid-based formulations. The present study is following such an approach by 
studying the excipient interactions up to an in vitro level as outlined in Figure 5.1. 
This study employs a solid lipid-based excipient that has recently been introduced for oral 
use. Polyethylene glycol 32 stearate (PEG-32 S) is a waxy lipid-based excipient, with a 
melting point of 48° C and a HLB of 16. It belongs to a group of the polyoxyl stearates, 
consisting of PEG-32 mono- and diesters of mainly stearic (octadecanoic), and/or 
palmitic (hexadecanoic) acid, and free PEG-32 (146). Since PEG-32 esters are 
hydrophilic surfactants and free PEG-32 is a hydrophilic solvent, this excipient alone 
would correspond to a type IV formulation of Lipid Formulation Classification System 
(50).  
The present study is focused on the mechanistic understanding of oleic acid (OA) and 
basic drug interactions in anhydrous solid lipid-based formulations, and upon aqueous 
dispersion of these systems. In particular, drug-excipient interactions were studied with 
respect to drug precipitation kinetics. Since it has been demonstrated earlier that various 
hydrodynamics may have an impact on precipitation kinetics (147), a comparison 
between two different mixing techniques was made (magnetic stirring and standard USP 3 
apparatus). As a model system, we developed a solid lipid-based formulation, comprising 
PEG-32 stearate and OA in the optimal ratio. Loratadine (pKa = 4.33, logP = 4.55) (148) 
and carvedilol (pKa = 8.74, logP = 3.42) (149) were selected as basic drugs and were 
incorporated at different saturation levels in LBFs with and without OA. The formulations 
were dispersed in phosphate buffer (pH = 6.5) and the precipitation kinetics was studied 
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using a laser scanning technique (focused beam reflectance measurement, FBRM). Gao 
and co-workers (80) were first to use this technique to analyse drug precipitation. 
Compared to commonly used light scattering techniques (e.g. nephelometry), FBRM 
allows in situ monitoring of both dimension and number of precipitated particles. Finally, 
we introduced the concept of a biopharmaceutically relevant parameter, i.e. a 
Precipitation number (Pnc), by the ratio of a relevant residence time of drug in the 
gastrointestinal tract (GIT) to the induction time (the onset time of crystalline 
precipitation).  
 
 
Figure 5.1: Scheme highlighting the different biopharmaceutical levels of formulation in 
vitro performance. 
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5.2. Materials and methods 
5.2.1. Materials 
Loratadine and carvedilol were purchased from AK Scientific Inc. (Union city, CA, USA) 
and PEG-32 stearate was a gift from Gattefosse SAS (Lyon, France). Oleic acid vegetable 
(extra pure) was supplied by Merck (Darmstadt, Germany). Sodium phosphate monobasic 
anhydrous and sodium hydroxide (pellets) were obtained from Sigma-Aldrich (Steinheim, 
Germany), hydrochloric acid (0.5 M) from J. T. Baker (Deventer, Holland), and 
potassium phosphate monobasic from Sigma-Aldrich (St. Louis, MO, USA). Acetonitrile 
of high-pressure liquid chromatography (HPLC) grade was purchased from Sigma-
Aldrich Chemie GmbH (Buchs, Switzerland). The air-filled thermoplastic capsules 
(VegaGels®), used for the drug release testing (5.2.2.6.2.), were produced at Aenova 
facility at Swiss Caps AG (Kirchberg, Switzerland). 
5.2.2. Methods 
5.2.2.1. Preparation of solid systems 
Mixtures of PEG-32 S with OA at different weight ratios (10:0, 9:1, 8:2, 7:3, 6:4) were 
prepared by heating 20° C above their melting points, mixing and cooling to room 
temperature (RT). The other ratios of PEG-32 S and OA did not solidify and remained 
liquid or semisolid at RT, which were therefore not further considered in this study. 
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5.2.2.2. Characterization of solid systems 
5.2.2.2.1. X-ray diffraction (XRD) 
XRD of PEG-32 S and of PEG-32 S/OA mixtures was analysed at RT using a 
diffractometer Phaser D2 (Bruker, Karlsruhe, Germany) with LYNXEYE detector and the 
EVA software application. The source of radiation was Co Kα at 30 kV, 10 mA, the 
measurement range was 5-50° 2θ using a step size of 0.02° and a count time of 0.5 s per 
step. The sample was automatically rotated on a holder at 15 rpm. We also used XRD and 
polarizing light microscopy PLM (Olympus BX61, Tokyo, Japan) to determine the solid-
state properties of precipitated drugs upon formulation dispersion in phosphate buffer.  
5.2.2.2.2. Differential scanning calorimetry (DSC) 
The thermal characteristics of PEG-32 S and of the solid mixtures were determined using 
a differential scanning calorimetry (DSC 8500, Perkin Elmer, Santa Clara, CA, USA). 
Samples (average weight: 8 mg) were accurately weighed in hermetically sealed 
aluminium pans (50 µL), held at initial temperature (20° C) for 5 min, and then heated at 
10° C min-1 from 20° C to 80° C under nitrogen gas purging (20 mL/min). We also used 
DSC to examine the drug-loaded formulations (saturation level S = 1.5; i.e. 150% w/w of 
drug equilibrium solubility at 37° C) to detect any crystalline drug. 
5.2.2.2.3. Particle size measurements following aqueous dispersion of solid systems 
The PEG-32 S and PEG-32 S/OA mixtures were dispersed in 0.025 M HCl (pH = 1.6), or 
in phosphate buffer (pH = 6.5) at 37° C to measure particle size. Dynamic laser light 
scattering was used with a Zetasizer Nano ZS (Malvern, Worcestershire, United 
Kingdom). Each sample was accurately weighed in a dust-free glass vial and 20 g of 
dispersion medium (heated at 37° C) was added (1:200 w/w). Prior to measurements, we 
mixed the dispersions for 10 min at 100 rpm in a water bath (37° C), and passed the 
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dispersions through a coarse filter (0.45 µm) to assure absence of dust particles. The mean 
particle size (Z-average diameter) of each dispersed sample was calculated from the 
volume size distribution. For these measurements aqueous viscosity provided a good 
approximation of the diluted dispersions. All experiments were repeated in triplicates 
from fresh samples. This method was also used to examine the particle size of dispersed 
drug-loaded PEG-32 S/OA (8:2 w/w) formulations (at saturation level S = 0.8). 
5.2.2.3. Spectroscopic and rheological characterization of drug-excipient molecular 
interactions 
5.2.2.3.1. UV spectroscopy 
The UV spectra of OA and of drug-OA mixtures were scanned using a SpectraMax M2e 
microplate reader (Molecular Devices, Sunnyvale, CA, USA). Both loratadine and 
carvedilol were mixed in dark glass vials with OA at 80% w/w of their Seq (equilibrium 
solubility in OA at 37° C), purged with nitrogen, and left for one hour at 37° C while 
magnetically stirring (300 rpm). An aliquot (300 µL) of each sample was added to a 96-
well microplate and UV spectra were recorded over a wavelength range of 200-700 nm. 
Additionally, UV spectroscopy was employed to examine the drug-OA molecular 
interactions in dispersed formulations (at saturation level S = 0.8). 
5.2.2.3.2. Mechanical chip-based rheology 
The viscosity profiles of drug-OA mixtures were analysed using a new mechanical chip-
based (MEMS) capillary rheometer (mVROC™ RheoSence, San Ramon, CA, USA). It 
measures the viscosity from the pressure drop of a sample as it flows through a 
rectangular slit. Each drug was dissolved in OA in dark glass vials at following 
concentrations: 0%, 5%, 10%, 15%, 20%, and 25% w/w. The mixtures were purged with 
nitrogen and left for one hour at 37° C on magnetic stirrers at 300 rpm. A glass syringe 
(Hamilton 81260 SYR 500 μL) was loaded with the sample and placed inside of the 
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thermal jacket (25 ± 0.5° C). When the measurement temperature was stable, the sample 
was pumped to flow (at shear rate 500 s−1) through the channel of the chip. The pressure 
drop was detected by a sensor (cell m-VROC A-10) and the viscosity was calculated 
using the m-VROC Control Software™. All experiments were conducted in triplicates. 
5.2.2.3.3. FTIR 
The infrared spectra of the drugs, OA, and of both drug-OA mixtures (prepared as 
described in section 5.2.2.3.1.) were recorded using a Diamond ATR (attenuated total 
reflection) accessory (MKII Golden GateTM, Specac Inc, Woodstock, GA, USA) on a Bio-
Rad Excalibur FTS 3000 MX spectrophotometer (Bio-Rad, Cambridge, MA, USA). The 
drug-OA interactions in dispersed formulations (at saturation level S = 0.8) were also 
studied using FTIR. The analysis depth of the surface was approximately 1 µm and all 
spectra were calculated from 32 scans, (each containing 2038 points) in the wavelength 
number range of 645-4000 cm-1. Data were acquired with the Resolutions Pro software 
(version 5.2.0; Agilent Technologies, Santa Clara, CA, USA).  
5.2.2.4. Testing of the anhydrous drug-loaded solid systems 
5.2.2.4.1. Van’t Hoff solubility study 
The PEG-32 S/OA mixture (8:2 w/w), which upon dispersion resulted into the smallest 
particle size with lowest polydispersity index (PDI) was selected for the solubility study. 
Drug solubility was determined at different temperatures (55° C, 60° C, 65° C, and 70° 
C), and the value at 37° C was extrapolated using vanʼt Hoff plots. An excess amount of 
loratadine or carvedilol was added to dark glass vial containing approximately 5 g of 
melted vehicle. The vials were tightly closed with rubber cap under nitrogen purging (2 
min). The mixtures were then left on magnetic stirrers at 300 rpm in water baths at 
controlled temperatures for 72 h. We measured drug solubility after 24 h, 48 h, and 72 h 
to assure that equilibrium was reached. Samples were withdrawn, filtered through 0.45 
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µm PVDF syringe filters (Titan3, SMI-LabHut LTD, Gloucester, UK), and diluted with 
phosphate buffer (20 mM, pH = 2.5; in weight ratios) for HPLC analysis. All solubility 
values were determined in triplicates. 
Loratadine solubility in OA was measured directly at 37° C, and these samples were 
prepared as for the drug solubility studies in the vehicles. In contrast to that, it was not 
feasible to determine carvedilol solubility in OA at 37° C using magnetic stirring in glass 
vials, due to the high viscosity of the mixture. Therefore, an excess amount of carvedilol 
was added to Eppendorf® tubes (1.5 ml) containing OA, and the mixtures were shaken 
using a Thermomixer comfort (Eppendorf AG, Hamburg, Germany) at 1400 rpm and 37° 
C for 72 h. Every 24 h, samples were centrifuged (n = 3) at 16 100 x g (37° C, 30 min) 
using a Centrifuge 5415 R (Eppendorf AG, Hamburg, Germany). Finally, the 
concentration of the compound in the supernatant was determined by HPLC analysis 
following dilution. 
The maximum supersaturation ratios, SRM, of the dispersed formulations in phosphate 
buffer (pH = 6.5) were calculated according to SRM = C/C*, where C is the maximum 
concentration of solubilized drug and C* is the solubility in the dispersion of formulation 
in phosphate buffer (1:100 w/w), respectively (150).  
5.2.2.4.2. Drug loading of solid systems 
The drug-loaded systems were prepared as follows: The PEG-32 S and PEG-32 S/OA 
mixture (8:2 w/w) were heated 20° C above their melting point, and added to previously 
weighed drug in dust-free dark glass vials. Following a heating phase (1 h at 80° C while 
stirring with magnetic stirrer), the samples were cooled to RT (102). Drug loads are 
expressed as saturation levels (S) referring to the equilibrium solubility of loratadine or 
carvedilol (in the formulation at 37° C), respectively. 
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5.2.2.5. Zeta potential measurements of dispersed drug-loaded solid systems  
For measurements of zeta potential we used a Zetasizer Nano ZS (Malvern, 
Worcestershire, United Kingdom). The PEG-32 S/OA (8:2 w/w), drug-free and drug-
loaded (at 80% w/w of Seq), were dispersed (1:200 w/w) in 0.025 M HCl (pH = 1.6) or in 
phosphate buffer (pH = 6.5) at 37° C for 10 min at 100 rpm. Each dispersed sample was 
passed through a coarse filter (0.45 µm), poured in a transparent cuvette with electrodes at 
each ends, and inserted in a slit through which was laser beamed. As an electric field was 
applied to the cell, the Zetasizer measured the electrophoretic mobility of particles. The 
zeta potential was calculated and all measurements were done in triplicates at 37° C.  
5.2.2.6. Drug precipitation testing upon dispersion and release from capsules  
5.2.2.6.1. Drug precipitation upon aqueous dispersion 
Drug precipitation upon dispersion in phosphate buffer (pH = 6.5, 1:100 w/w) was 
analysed using a Lasentec FBRM D600L probe (Lasentec, USA). This laser scanning 
technique employs an in-process probe, which detects the chord length distribution of 
particles. The general measurement principle of focused beam reflectance measurements 
(FBRM) was described by Ruf et al. (81). The detection is limited to particles with a 
chord length 1 µm. For calculation of the induction time, we monitored only chord length 
of less than 10 µm in order to follow the number of evolving particles over time, while 
avoiding the noise from counts of aggregated particles. In contrast to that, when we 
studied the effect of OA on precipitation, all chord lengths and their particle size 
distributions (PSD) were considered. Both PEG-32 S and PEG-32 S/OA (8:2 w/w) were 
loaded with loratadine or carvedilol at the following saturation levels: 0.6, 0.7, 0.8, 0.9, 
1.0, 1.1, 1.3, 1.5, and 1.7. Due to the ranges of interest, these saturation levels were non-
equally distributed. The probe was positioned at an angle of 30° in a thermostated glass 
vessel (37° C) and the accurately weighed drug formulation was added to the dispersion 
medium. The dispersion was stirred at 500 rpm and the particle size of precipitated drug 
was recorded every 2 s for 8 h using the iC FBRM software (version 4.0; Mettler-Toledo 
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AutoChem, Columbia, MD, USA). All formulations were dispersed and measured in 
triplicates. From each precipitation curve, the onset time of crystalline precipitation 
(induction time, τind) was determined at the crossing point of the tangent of the 
precipitation curve and the time axis. Subsequently, the Precipitation number (Pnc) was 
defined for each saturation level as follows: 
 
ind
res
nc
tP    (5.1) 
where tres is a relevant drug residence time in the gastrointestinal tract (GIT) and is 
approximated with 180 min according to Amidon et al. (45).  
5.2.2.6.2. Drug release testing 
Compendial release testing from soft capsules was determined regarding a potential effect 
of the different hydrodynamics or of the shell material on drug precipitation kinetics. 
Drug formulations (PEG-32 S and PEG-32 S/OA (8:2 w/w)) loaded with loratadine or 
carvedilol were studied both at saturation level of 1.5. A reciprocal cylinder BioDis® 
apparatus (RRT 8, CALEVA Ltd, Dorset, England) was thermostated at 37±0.5° C. Each 
vessel contained 200 mL of phosphate buffer (pH = 6.5). A mesh size of 420 μm was 
selected (top and bottom mesh) for the glass cylinders that were dipping at a rate of 20 
dpm. Two manually filled soft capsules were placed in each glass cylinder, due to their 
lower fill mass (~ 0.6 g) compared to the capsules obtained from a machine-filling 
process (~ 1.0 g). Prior to each experiment, the air-filled capsules were weighed before 
and after manual filling with the drug formulations to determine an exact fill mass in each 
capsule. At predetermined time points, a 1-mL sample was taken by a syringe, 
immediately filtered through a 0.45 µm PVDF syringe filter (Titan3, SMI-LabHut LTD, 
Gloucester, UK) and analysed by HPLC. The removed volume was replaced each time 
with 1 mL of fresh medium. The total time of analysis was 180 min with respect to a 
relevant residence time of the drug in the GIT. All experiments were performed in 
triplicates. 
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5.2.2.7. HPLC method 
High-performance liquid chromatography analysis employed a LiChrospher 60, RP select 
B 125-4 (5 µm) column (Merck, Darmstadt, Germany), a degasser (G1379 B), an 
isocratic pump (G1310A), an autosampler (G1329A), and a variable wavelength detector 
(G1314B). The mobile phase consisted of acetonitrile and 20 mM phosphate acetate 
buffer, pH = 2.5 (40:60, v/v). Flow rate was 1 mL/min with the injection volume of 10 µL 
and the detection wavelengths were 248 nm and 280 nm for loratadine and carvedilol, 
respectively. 
5.2.2.8 Data analysis 
The temperature-dependent drug solubility in solid systems (PEG-32 S and PEG-32 S/OA 
(8:2 w/w)) was analysed at different temperatures with n = 3. The Statgraphics Centurion 
XVI ed. Professional Program from Statpoint Technologies Inc. (Warrenton, Virginia, 
USA) was used for van’t Hoff linear regression and prediction of the drug solubility at 
37° C. A good correlation was assumed if the R2 value was higher than 0.99. 
5.3. Results 
5.3.1. Characterization of solid drug-free systems 
In preliminary experiments, OA was incorporated in PEG-32 S at different w/w ratios to 
determine the physical consistency of the mixtures at RT. Visual observation of the 
mixtures (stored for two days at RT) indicated that when the concentration of OA was not 
higher than 40% w/w, the mixtures solidified and no phase separation occurred, whereas 
higher concentrations of the liquid OA were deemed less suitable for a solid lipid-based 
formulation. 
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5.3.1.1. X-ray diffraction (XRD) 
Figure 5.2 displays x-ray diffractograms of PEG-32 S and PEG-32 S/OA mixtures. The 
presence of peaks in the mixtures at the same angle (2θ) as those of PEG-32 S confirmed 
that crystallinity of PEG-32 S was maintained in the formulations. We observed a gradual 
decrease in peak heights as the concentration of OA increased. This can be interpreted as 
lowering the concentration of crystalline lipid phase by increasing the amount of OA. The 
extent of crystallinity of PEG-32 S in PEG -2 S/OA mixtures could be approximated by 
the crystallite size(s). Determination of crystallite size(s) from XPD patterns are based on 
the widths of the diffraction peaks but due to the complexity of added OA, this task was 
beyond the scope of the present work. However, observations made by Patel et al. (151) 
could suggest that the addition of OA results in decrease of the crystallite size. 
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Figure 5.2: X-ray diffraction patterns of the solid systems containing different 
concentrations of oleic acid in PEG-32 S/OA mixtures (w/w). Oleic acid 
concentrations: (a) 0%, (b) 10%, (c) 20%, (d) 30%, and (e) 40% (w/w). 
 
5.3.1.2. Differential scanning calorimetry (DSC) 
The DSC thermogram of PEG-32 S exhibited a characteristic endothermic peak at 47° C 
(Figure 5.3a). We observed a gradual decrease in the onset of melting endotherms (Figure 
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5.3), as the concentration of OA in the mixtures with PEG-32 S increased. Similar 
changes were also observed for the melting peak maximum of the mixtures. 
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Figure 5.3: Differential scanning calorimetry (DSC) thermograms of the solid systems 
containing different concentrations of OA in PEG-32 S/OA mixtures (w/w). 
Oleic acid concentrations: (a) 0%, (b) 10%, (c) 20%, (d) 30%, and (e) 40% 
(w/w). 
 
5.3.1.3. Particle size measurements following aqueous dispersion of solid systems 
To select the optimal ratio of PEG-32 S and OA, we considered aqueous formulation 
dispersions. A minimal particle size and polydispersity index of prepared dispersions of 
PEG-32 S/OA mixtures were viewed as desirable from a biopharmaceutical viewpoint. 
Two aqueous media were selected that were mimicking an acidic stomach environment 
and an intestinal pH. As evident from the Figure 5.4, PEG-32 S : OA w/w ratio had a 
substantial influence on both particle size and polydispersity. The dispersed mixture with 
20% w/w OA exhibited the smallest particle size, as well as the lowest polydispersity, in 
both dispersion media and was therefore selected for further evaluations.  
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Figure 5.4: Effect of PEG-32 S : OA ratio on particle size and polydispersity index (PDI) 
analysed in (a) 0.025 M HCl (pH = 1.6) and in (b) phosphate buffer (pH = 
6.5) (n = 3). The particle size is specified only for systems with a PDI ≤ 0.3. 
5.3.2. Characterization of solid drug-loaded systems 
5.3.2.1. Drug-excipient interaction in oily mixtures  
Loratadine and carvedilol typically absorb in organic solvents (e.g. methanol) at 288 nm 
and at 242 nm, respectively (152, 153). In the present study both drugs were dissolved in 
OA and a considerable shift in the peak maxima and a broadening of the UV bands, 
compared to the pure OA was revealed (Figure 5.5a). This indication of a molecular 
interaction between the excipient and the basic drugs was also supported by a rheological 
study. An increase in viscosity was noted for rising amounts of drug (Figure 5.5b). The 
oily system was probably becoming a partially organized system due to the interaction, 
which was more pronounced in the case of carvedilol- compared to loratadine-OA 
solutions. These findings indicated a molecular complex in oily mixtures. 
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Figure 5.5: Shift of the maximum in UV spectrum and a broadening of the UV bands (a), 
and increase in viscosity profiles (b) indicate the presence of loratadine-OA 
and carvedilol-OA molecular complexes (n = 3, error bars are within 
markers). 
The IR spectrum of OA showed characteristic vibrational bands at 1700 cm-1 (C=O 
stretching vibrations) and at 3000-2700 cm-1 (O-H stretching vibrations) (Figure 5.6). No 
changes for hydroxyl group band were observed in both spectra of drug-OA molecular 
complexes (lor-OA and car-OA). In contrast to that, the drug-OA interaction could be 
proposed from the changes of both drug spectra. In lor-OA spectrum we noted shifting 
and broadening of the characteristic bands at 1200 cm-1 and 1700 cm-1, which represent 
stretching vibrations of C-O and C=O, respectively. Broadening/shifts of bands around 
1200 cm-1 could also indicate changes in amine (1250-1020 cm-1) and aromatic amine 
(1342-1266 cm-1) groups of loratadine. Additionally, changes in the 1700 cm-1 region 
could be attributed to the stretching of the C=N group. This could suggest that the “basic” 
groups of the drug were also involved in some kind of interactions with OA, most 
probably hydrogen bonds with carboxyl groups of OA. In case of carvedilol, the relevant 
N-H bonds at 1600 cm-1 and below 3500 cm-1 practically disappeared in car-OA 
spectrum. Moreover, the car-OA spectrum displayed the changes in the region between 
1200 cm-1 and 1000 cm-1 that correspond to C-O stretching in ethers and primary 
Experimental section 117 
alcohols. Both of these changes strongly indicate the interaction between ether and amino 
groups in carvedilol and carboxyl group of OA. 
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Figure 5.6: FTIR spectra of loratadine, carvedilol, OA and of their binary drug-OA 
mixtures (bands of interest are indicated by arrows). 
 
5.3.2.2. Solubility study 
PEG-32 S and PEG-32 S/OA (8:2 w/w) were solid at RT as well as at 37° C. To determine 
the drug solubility in these solid systems, it was measured at elevated temperatures and 
extrapolated to lower temperature by the vanʼt Hoff model (Figures 5.7 and 5.8) (154). 
The extrapolated solubility at a temperature of 37° C was of interest regarding the 
biopharmaceutical fate of the formulation.  
Table 5.1 displays the extrapolated drug solubility values in PEG-32 S and PEG-32 S/OA 
(8:2 w/w), as well as the drug solubility in OA determined at 37° C. OA demonstrated 
remarkable drug solubility for both loratadine and carvedilol. 
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Figure 5.7: Plot of vanʼt Hoff model of loratadine solubility in (a) PEG-32 S  
(linear regression, R2= 0.9969; p<0.05) and in (b) PEG-32 S/OA (8:2 w/w)  
(linear regression, R2= 0.9944; p<0.05). Outer lines show 95% prediction 
limits. 
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Figure 5.8: Plot of vanʼt Hoff model of carvedilol solubility in (a) PEG-32 S 
(linear regression, R2 = 0.9944, p<0.05) and in (b) PEG-32 S/OA (8:2 w/w) 
(linear regression, R2 = 0.9927, p<0.05). Outer lines show 95% prediction 
limits. 
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Table 5.1: Comparison of carvedilol and loratadine solubility in PEG-32 S, OA, and 
PEG-32 S/OA (8:2 w/w) at 37° C. 
Solubility (mg/g) 
 Carvedilol Loratadine 
PEG-32 S * 117.7 ± 4.8 53.4 ± 1.7 
OA 372.8 ± 11.3 253.2 ± 0.5 
PEG-32 S/OA  
(8:2 w/w)* 
153.9 ± 6.5 73.1 ± 4.3 
* extrapolated by linear van’t Hoff regression from higher temperatures 
Following solubility study, drug-loaded formulations at different saturation levels were 
prepared. The formulations loaded with drugs at supersaturated level (S = 1.5) were 
analysed using DSC for the presence of crystalline drugs. The characteristic drug melting 
peaks in all tested formulations were not observed (Figure 5.9), which confirmed the 
absence of crystalline drug.  
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Figure 5.9: Differential scanning calorimetry (DSC) thermograms of the supersaturated 
solid lipid-based formulations (S = 1.5) show the absence of the crystalline 
drug 2 h upon loading. 
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Drug-loaded PEG-32 S/OA formulations (S = 0.8) were analysed for the particle size 
following aqueous dispersion. In contrast to the dispersed drug-free formulation, an 
increased polydispersity index (PDI = 0.4 for pH = 1.6, and PDI = 0.32 for pH = 6.5) and 
similar Z-average were observed for all examined dispersion. This indicated that the 
presence of the drug probably disturbed the optimized structure of the drug-free system. 
5.3.3. Zeta potential measurements of dispersed drug-loaded systems 
To explore the drug-OA interactions during an aqueous dispersion process, UV/FTIR 
spectroscopy and zeta potential were employed using drug-loaded and drug-free 
formulations. UV spectra of all drug-free and drug-loaded dispersed systems 
demonstrated no significant shift of the peak maximum, indicating probably a different 
quality of the drug-OA interactions (data not shown). Regarding FTIR, recorded spectra 
did not show any representative band either of the drugs or of oleic acid, suggesting that 
the analysis was not sensitive enough for this high dilution ratio. Therefore, we studied 
zeta potential of the dispersed systems (Table 5.2). Loratadine is a weak base (pKa = 4.33) 
and is expected to have a neutral form in phosphate buffer (pH = 6.5). The zeta potential 
of dispersed lor-PEG-32 S/OA in phosphate buffer was negative. The result was similar to 
the negative zeta potential of the drug-free formulation under the same conditions. In 
contrast to that, the dispersed carvedilol-loaded formulation (car-PEG-32 S/OA; 
carvedilol pKa = 8.74, OA pKa = 9.85 (155)) resulted in a neutral zeta potential in 
phosphate buffer. A positive zeta potential was determined in 0.025 M HCl for both drug 
formulations, which was in line with the expected protonation and charge of the basic 
drugs at such a low pH. For the drug-free system dispersed in the acidic medium (HCl) 
zeta potential was almost neutral.  
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Table 5.2: Zeta potential of drug-free and drug-loaded PEG-32 S/OA (8:2 w/w), dispersed 
(1:200 w/w) in phosphate buffer (pH = 6.5) and 0.025 M HCl (pH=1.6) at 37° C. 
 Zeta potential (mV) 
 
PEG-32 S/OA  
(8:2 w/w) 
PEG-32 S/OA (8:2 
w/w) loaded with 
loratadine (S = 0.8) 
PEG-32 S/OA (8:2 
w/w) loaded with 
carvedilol (S = 0.8) 
Phosphate buffer 
(pH = 6.5) 
-7.9 ± 1.0 -6.6 ± 1.5 -0.1 ± 0.1 
0.025 M HCl 
(pH = 1.6) 
-0.8 ± 0.5 3.9 ± 0.5 11.2 ± 0.4 
 
5.3.4. Drug precipitation testing upon dispersion and release from 
capsules 
5.3.4.1. Drug precipitation upon aqueous dispersion 
We monitored drug precipitation by means of FBRM upon formulation dispersion in 
phosphate buffer (pH = 6.5). As a control, drug-free PEG-32 S and PEG-32 S/OA (8:2 
w/w) were also dispersed, but either no FBRM signal or a very low signal (up to 50 
counts) was detected. The drug-containing dispersion samples were analysed to determine 
the induction times that marked the onset of drug precipitation. Results for the dispersions 
of the formulations without OA are depicted in Figure 5.10. A decrease in the induction 
time was observed for both drugs with rising drug saturation. For loratadine loaded in 
PEG-32 S, the lowest saturation level in the anhydrous formulation to exhibit 
precipitation upon dispersion was 0.7 (considering 8 h limit of measurement). The 
corresponding results of carvedilol showed that only at a (formulation) drug saturation of 
0.9 and beyond, there was a precipitation detected within the observation time. 
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Considering the physiologically relevant residence time of 180 min, it was possible to 
extrapolate a critical formulation saturation level for which drug precipitation is expected. 
These critical values were about 0.65 for the formulation of loratadine and 0.85 in case of 
the PEG stearate mixture with carvedilol.  
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Figure 5.10: Effect of different saturation levels in the anhydrous formulation of (a) 
loratadine and (b) carvedilol on the induction times upon dispersion (pH = 
6.5). The horizontal line presents a relevant residence time tres (180 min) of 
the drug in the gastrointestinal tract. The vertical line determines the critical 
saturation level in the formulation for which drug precipitation starts within 
tres.  
Subsequently, dispersions of PEG-32 S/OA (8:2 w/w) were analysed to explore the effects 
of OA on drug precipitation. Formulations of both drugs did not show any precipitation in 
the range of unsaturated formulations. This marked effect of OA as potential precipitation 
inhibitor was also of interest to explore with supersaturated systems. A reference drug 
saturation of 1.5 was selected and FBRM results of the dispersions can be inferred from 
Figure 5.11. The particle size distribution (PSD) profiles from the supersaturated systems 
indicated that incorporation of 20% w/w of OA lowered the extent of drug precipitation 
but could not prevent it entirely. This effect was more pronounced in case of carvedilol 
formulations, as illustrated by Figure 5.11b. The chord length counts were greatly reduced 
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in the formulation containing OA and the maximum particle size may have been slightly 
shifted to ~10 µm (at t = 3h). In case of loratadine, particle size distributions appeared to 
be very similar for both tested formulations (Figure 5.11a). Addition of OA demonstrated 
also in this system a reduction in the extent of drug precipitation.  
Particle size (m)
co
un
ts
/s
0 50 100 150 200
0
100
200
300
400
PEG-32 S
PEG-32 S/OA
a)
Particle size (m)
co
un
ts
/s
0 50 100 150 200
0
200
400
600
PEG-32 S
PEG-32 S/OA
b)
 
Figure 5.11: Mean particle size distribution (PSD) profiles observed at t = 3h upon 
dispersion of solid lipid-based formulations loaded with (a) loratadine and (b) 
carvedilol at S = 1.5. 
The reference formulation at a drug saturation level of 1.5 was further explored regarding 
time evolution of particle counts. Counting of primarily short chord lengths (< 10 µm) 
focused on the early particle growth phase with minimal noise from potential aggregates. 
Interestingly, a spontaneous nucleation was observed for both drugs loaded in PEG-32 
S/OA (8:2 w/w). Figure 5.12a shows the precipitation kinetics of the dispersed loratadine 
formulation (S = 1.5). A high initial count rate was detected that slowed down to a much 
lower plateau as compared to the formulation without OA. Also carvedilol in PEG-32 
S/OA (8:2 w/w) (S = 1.5) demonstrated only a high initial rate that was followed by 
almost constant count rates after about 20 min. The count rate plateau from this OA-
containing formulation was again substantially lower than observed with carvedilol-
loaded PEG-32 S. Interestingly, these mixtures of PEG stearate and drugs did not 
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precipitate spontaneously, but appeared to have short induction times. Therefore OA 
influenced the extent of drug precipitation and also the type of its kinetics.  
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Figure 5.12: The effect of the drug-OA interaction on the type of precipitation kinetics of 
(a) loratadine and (b) carvedilol, both loaded at saturation level of 1.5 in PEG-
32 S and PEG-32 S/OA (8:2 w/w), respectively. 
 
Regarding oral drug delivery it was important to also analyse the solid-state properties of 
the precipitated drugs. Figure 5.13 displays the X-ray diffraction patterns of the 
precipitates and of crystalline drugs as used in the solid formulations (S = 1.5, at t=3h). 
These X-ray patterns demonstrated that both drugs maintained their crystallinity 
following the precipitation of dispersed drug-loaded PEG-32 S. These precipitates were 
also investigated by polarizing light microscopy and no different crystal morphology was 
observed. We noticed birefringent needles and cubic shapes for loratadine and carvedilol 
precipitates, respectively. This situation was in contrast to adding OA, since the drug 
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precipitates from the dispersed PEG-32 S/OA (8:2 w/w) systems were amorphous 
according to X-ray patterns (Figure 5.13). However, in the case of loratadine precipitate 
some isolated crystals were also observed under polarized microscope, while no 
crystalline drug was found in the carvedilol precipitate. The amorphous precipitates 
demonstrated that OA not only changed the type of precipitation kinetics, but also 
influenced the solid state of both drugs upon dispersion. 
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Figure 5.13: X-ray diffraction patterns of (a) loratadine powder as reference (black line), 
loratadine precipitated from PEG-32 S (red line), and from PEG-32 S/OA 
(blue line), and (b) carvedilol powder as reference (black line) and carvedilol 
precipitated from PEG-32 S (red line), and from PEG-32 S/OA (blue line). All 
solid formulations were supersaturated (S = 1.5) and the precipitated drugs 
were analysed following 3 h of dispersion in phosphate buffer (pH = 6.5). 
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Tables 5.3 and 5.4 provide an overview of the drug saturation levels studied for their 
precipitation kinetics. For calculation of maximum supersaturation ratios (SRM) (150) 
determination of the equilibrium drug solubilities in the dispersion medium was needed. 
This solubility of loratadine was 0.25 ± 0.01 mg/mL and 0.52 ± 0.02 mg/mL for the 
dispersion medium containing PEG-32 S and PEG-32 S/OA (8:2 w/w), respectively. For 
carvedilol, the corresponding solubilities were 0.91 ± 0.03 mg/mL and 1.68 ± 0.06 
mg/mL, respectively. Additionally, for each studied saturation level, the Precipitation 
number (Pnc) was determined according to Eq. 5.1. This number assessed the 
biopharmaceutical relevance of a supersaturation following dispersion of a formulation. 
However, it is very important to note that we were focusing only on crystalline 
precipitates because amorphous precipitates were deemed as less problematic for drug 
absorption (102). For both drugs loaded in PEG-32 S, precipitation upon dispersion 
started already with anhydrous formulations below saturation. A critical saturation level 
was here for loratadine 0.7 and 0.9 for carvedilol. Observed drug precipitation within a 
relevant physiological time span was reflected by precipitation numbers becoming higher 
than unity as seen in Table 5.3 and 5.4.  
 
 
 
 
 
 
 
Experimental section 128 
Table 5.3: Loratadine doses, corresponding saturation levels of the anhydrous 
formulations, calculated maximum supersaturation ratios (SRM), and 
Precipitation numbers (Pnc) used for the drug precipitation analyses. 
Model 
formulation 
Dose 
(mg/g) 
Saturation level 
in anhydrous 
formulation (S) 
Maximum 
supersaturation 
ratio (SRM) 
upon dispersion  
Precipitation 
number (Pnc) 
32.0 0.6  1.3 < 1 (< 0.38)  
37.4 0.7 1.5 >1 (1.31 ± 0.10) 
48.1 0.9 1.9 > 1 (11.15 ± 1.51)  
58.8 1.1 2.4 > 1 (14.08 ± 2.95)  
69.4 1.3 2.8 > 1 (25.63 ± 4.41) 
80.0 1.5 3.2 > 1 (52.14 ± 7.53)  
Loratadine 
in PEG-32 S 
90.8 1.7 3.6 > 1 (64.00 ± 6.93)  
58.5 0.8 1.2 < 1 
65.8 0.9 1.3 < 1 
80.4 1.1 1.6 * 
95.0 1.3 1.9 * 
109.6 1.5 2.2 * 
Loratadine 
in PEG-32 
S/OA 
124.3 1.7 2.5 * 
* Different type of kinetics and an amorphous precipitate. 
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Table 5.4: Carvedilol doses, corresponding saturation levels of the anhydrous 
formulations, calculated maximum supersaturation ratios (SRM), and 
Precipitation numbers (Pnc) used for the drug precipitation analyses. 
Model 
formulation 
Dose 
(mg/g) 
Saturation level 
in anhydrous 
formulation (S) 
Maximum 
supersaturation 
ratio (SRM) upon 
dispersion 
Precipitation 
number (Pnc) 
94.2 0.8 1.0 <1 (< 0.38) 
105.9 0.9 1.2 > 1 (1.97 ± 0.16) 
117.7 1.0 1.3 > 1 (7.74 ± 0.50) 
129.5 1.1 1.4 > 1 (14.36± 1.81) 
153.0 1.3 1.7 > 1 (17.17± 0.82) 
176.5 1.5 2.0 > 1 (29.37 ± 2.91) 
200.1 1.7 2.2 > 1 (32.14 ± 4.18) 
Carvedilol in 
PEG-32 S 
223.6 1.9 2.5 > 1 (39.24 ± 6.17) 
153.9 1.0 0.9 < 1 
169.3 1.1 1.0 * 
200.1 1.3 1.2 * 
230.9 1.5 1.4 * 
261.6 1.7 1.6 * 
Carvedilol in 
PEG-32 S/OA 
292.4 1.9 1.7 * 
 
* Different type of kinetics and an amorphous precipitate. 
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5.3.4.2. Drug release testing 
Initial release tests (USP 3 apparatus) used anhydrous formulations with PEG-32 S or 
PEG-32 S/OA (8:2 w/w) that were below drug saturation. For both drug release tests, no 
drug precipitation was revealed (data not shown). It must be noted that the given aqueous 
formulation dilution (1:160 w/w), specific hydrodynamics, as well as the capsule made a 
difference to the dispersion experiments using FBRM. It was hence of primary interest to 
compare the formulations at a supersaturated reference level of 1.5. Figure 5.14 displays 
the drug release profiles of the formulations for the model drugs loratadine and carvedilol. 
Both drugs precipitated during the drug release testing and clear differences were 
obtained in the kinetic profiles. A fast dispersion was observed with the different 
formulations once the thermoplastic capsules opened. Therefore, systems had in common 
that the maximum drug concentration was reached within 30 min (Figure 5.14). The OA-
containing system reached a maximum of released drug at 90% for loratadine and for 
carvedilol it could be it levelled off at 70%. This plateau level of the drug concentration 
remained constant during the 3 h of analysis. In contrast to that, the maximum of released 
drug for PEG-32 S formulations was reached at around 60%, followed by fast drug 
precipitation and lowering of the drug concentration to 30% and 40% in case of loratadine 
and carvedilol, respectively. The resulting maximum supersaturation ratios (SRM) for both 
drugs during release testing were also calculated. For loratadine SRM values were 3.2 and 
2.1 for the PEG-32 S formulation and OA-containing formulation, respectively. For 
carvedilol, the corresponding values were 2.0 and 1.4, respectively.  
Experimental section 131 
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
0 30 60 90 120 150 180
0
20
40
60
80
100
PEG-32 S
PEG-32 S/OA
a) S=1.5
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
0 30 60 90 120 150 180
0
20
40
60
80
100
PEG-32 S
PEG-32 S/OA
b) S=1.5
 
Figure 5.14: Drug release profiles of (a) loratadine, and (b) carvedilol, formulated in 
PEG-32 S and PEG-32 S/OA (8:2 w/w) and encapsulated in VegaGels®, 
analysed in USP 3 apparatus in phosphate buffer (pH = 6.5), 20 dpm, at 37 ± 
0.5° C (n = 3). 
 
5.4. Discussion 
Mechanistic understanding of drug-excipient interactions on different biopharmaceutical 
levels could be a way to better develop oral dosage forms. However, until now there has 
been a lack of systematic studies of drug-excipient interactions in solid lipid-based 
systems. As detailed in Figure 5.1, we focused on OA interactions with basic drugs in the 
anhydrous formulation, upon aqueous dispersion, and particularly with respect to 
precipitation kinetics and the evolving solid state of the precipitate. 
1) Level of the anhydrous formulation 
Firstly, we developed the solid system containing PEG-32 S and OA in optimal ratio (8:2 
w/w), which demonstrated optimal dispersion with respect to particle size and 
polydispersity. The reduction of particle size could indicate forming of mixed micelles 
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that may be beneficial for robust drug absorption. We targeted smallest particle sizes, as it 
proved to be relevant for enhanced bioavailability of some PWSD (72). However, such 
size effects may not always be relevant for drug bioavailability (71).  
Secondly, we characterized the drug-OA interactions in oily mixtures. It is well known 
that the intermolecular forces are often strong enough to control physical properties such 
as viscosity (156). This effect was also confirmed in the present study. Namely, the 
pronounced intermolecular forces between OA and the basic drugs caused an increasing 
viscosity with rising amounts of both drugs (Figure 5.5a). The molecular interactions 
between OA and the model bases were also supported by the results of the spectroscopic 
studies. The shift and the broadening of the UV band of drug-OA mixtures clearly 
indicated interactions between the two components. The nature of the drug-OA 
interactions was further characterized using FTIR spectroscopy. As displayed in Figure 
5.6, there were no changes in the band of the hydroxyl group of OA (3000-2700 cm-1). 
This could be attributed to the higher OA content in the mixtures (~ 1:5 w/w drug : OA 
ratio). A first intuitive assumption is that organic bases (drug) interact with organic acids 
(OA) via amino and carboxyl groups, where amino groups act as a proton acceptor and 
carboxyl groups as a proton donor. However, the complex systems such these may exhibit 
more complex interactions. Tertiary amines (as in loratadine) show no characteristic 
bands, but in case of their protonation, they would become secondary and the matching 
bands would appear. In the present study this was clearly not the case. We observed in the 
lor-OA spectrum shifting and broadening of the characteristic bands at 1200 cm-1 and 
1700 cm-1, which showed stretching vibrations of C-O and C=O, respectively. This can 
indicate hydrogen bonds between OA and both carboxyl groups of loratadine. Similar 
observations were also reported by Nacsa et al. in 2008 in a study of loratadine 
interacting with a cyclodextrin (157). As the oxygen atoms of loratadine are not sterically 
hindered, it could be expected that they were more exposed to an interaction compared to 
a basic nitrogen atom within the rings. Moreover, the point charge of the basic nitrogen in 
the pyridine ring was similar to the oxygen atoms (calculated using chemicalize.org, 
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ChemAxon Ltd., Hungary). Our findings therefore point to the well accessible oxygen 
groups of loratadine that interact with OA. However, broadening/shifts of IR bands in the 
same region (around 1200 cm-1 and 1700 cm-1) could also indicate changes in amine and 
the stretching of the (aromatic) C=N group. Therefore, it could not be excluded that the 
“basic” groups of loratadine were also involved in the interactions with OA, especially 
since OA was in excess in the lor-OA mixture. In case of carvedilol, the relevant N-H 
bonds at 1600 cm-1 and below 3500 cm-1 disappeared in the car-OA spectrum. Moreover, 
we observed the changes in the region between 1200-1000 cm-1, which correspond to C-O 
stretching in ethers and primary alcohols. In a classical sense, this could be interpreted as 
deprotonation of N-H groups and change of environment around C-O groups. Thus, 
spectroscopic results indicate several possible intra- and intermolecular interactions of 
drug and OA. 
The drug-OA interactions were also observed with respect to the increased drug 
solubility. The excipient demonstrated a substantial influence on both loratadine and 
carvedilol solubility (Table 5.1). These results are in line with the observations reported 
by Patel et al. for lumefantrine-OA formulations (158). In summary, our findings indicate 
that the strong drug-OA interactions can be viewed as molecular complex formations on 
the level of the anhydrous formulation. 
2) Level of dispersion, precipitation inhibition and drug release 
To better understand the drug-OA interactions following aqueous dispersion, we studied 
zeta potential of dispersed drug-free and drug-loaded formulations in acidic environment 
(pH = 1.6) and at an intestinal pH of 6.5 (Table 5.2). At the low pH, both drug bases were 
protonated, which resulted in a positive zeta potential of their dispersions and indicated 
that both drugs were associated with the surface of micelles. In the same acidic medium 
dispersion of drug-free formulation exhibited an almost neutral zeta potential probably 
because any fatty acids on the surface would be in neutral form. In phosphate buffer, zeta 
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potential of the dispersed drug-free formulation was slightly negative, which is a common 
observation for dispersed glyceride oils or other systems with low dielectric constant. 
Zeta potential of the dispersed loratadine-containing formulation was also slightly 
negative, reflecting the neutral form of the weak base (pKa = 4.33). For the dispersed 
carvedilol-loaded formulation (carvedilol pKa=8.74), the net charge was almost neutral. 
Here, the negative charge observed with the drug-free formulation was probably 
suppressed by the presence of protonated carvedilol at the surface of the micelles. Thus, a 
fraction of protonated drug was evidently interacting with the colloidal surfaces, while 
some other drug may have also partitioned as charged molecules into the bulk solution.  
Subsequently, it was important to evaluate the effect of OA on drug precipitation. As 
evident from Tables 5.3 and 5.4, the dispersions of both model drugs loaded either in 
PEG-32 S or OA-containing systems resulted mostly in supersaturated solutions. While 
the dispersed PEG-32 S precipitated already as unsaturated formulations (S<1 in the 
anhydrous formulation), OA-containing systems precipitated only at formulation drug 
saturation of 1.1 and beyond. The addition of OA increased the equilibrium drug 
solubility in the dispersion medium. Therefore, the degree of supersaturation was 
decreased, which in turn inhibited drug precipitation. This mechanism of precipitation 
inhibition is well known for using surface active excipients. 
Interesting findings were also inferred from a comparison of the maximum 
supersaturation ratios (SRM) between the different formulations for a given drug. As 
mentioned earlier, the addition of OA almost doubled the solubilizing capacity of the 
dispersion medium (see section 5.3.4.1.). As a consequence, although the drug loading 
was much higher for OA-containing formulations (at the same S), the corresponding SRM 
values upon dispersion were lower compared to SRM of systems without OA. Moreover, 
both systems started to precipitate at analogous SRM values (Tables 5.3 and 5.4). 
Interesting is the report of Rodriguez-Hornedo et al. (159) who studied a critical 
supersaturation regarding spontaneous drug precipitation. Such critical supersaturation for 
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spontaneous nucleation was compared between systems containing different solvents. 
When the drug solubility was in a two or threefold regimen (as in our case), such critical 
supersaturation was similar. However, when the drug solubility was fivefold or higher, 
clearly reduced values of critical supersaturation were observed. Recently, Anby et al. 
(86) showed danazol (practically spontaneous) precipitation upon dispersion of various 
formulations, when SRM values were higher than 2. The authors differentiated this 
situation from lipolysis-induced drug precipitation, where another critical value of SRM 
was proposed. Our results of the supersaturation upon dispersion demonstrated that for 
values lower than 2, the Precipitation number became critical (i.e. > 1). Certainly, a 
different time span was considered here as opposed to nearly spontaneous precipitation. 
Interesting was the finding of a different critical SRM value for the two bases. This implies 
that critical SRM values for precipitation might be useful to compare formulations, but 
may be rather drug specific. In addition, our systems contained considerably higher drug 
amounts (especially all supersaturated formulations), which could have been relevant for 
precipitation kinetics. 
As evident from Figures 5.11 and 5.12, OA influenced the extent of precipitation and its 
kinetics. It can be compared to findings of Gao et al. (80), who reported that the amount 
of surfactant (Tween® 80) in the formulation dictated the initial degree of drug (AMG 
517) supersaturation, and therefore, its precipitation kinetics. In the present study, there 
was a substantially lower extent of precipitation when OA was added to the formulation. 
The precipitation kinetics of these OA-containing formulations was, however, 
characterized by a high initial rate. The portion of drug that precipitated almost 
spontaneously might have been primarily solubilized base in the bulk. Some drug-OA 
interactions might have occurred also in the bulk but it was mainly on the colloidal level, 
where the molecular interactions were assumed. This direct drug-OA interaction on the 
level of micelles was probably one mechanism of nucleation inhibition. OA could have 
further reduced the interfacial energy of forming drug nucleates and it may have 
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interfered with the particle growth process. The latter effect may, however, be more 
pronounced in case of polymeric precipitation inhibitors as reported elsewhere (97, 98).  
Besides the extent of precipitation and its kinetics, the solid state of the evolving material 
can be of crucial biopharmaceutical importance. If drug precipitates in a crystalline form 
in the intestinal environment, it is often problematic, since re-dissolution of drug crystals 
is typically rather slow. In the present study, the precipitates of both drugs in PEG-32 S 
were crystalline (Figure 5.12). Interestingly, the presence of OA affected the solid state of 
precipitates, resulting in an amorphous material. Drug could have formed a solid 
dispersion or co-precipitate with the fatty acid. Such differentiation was not further 
attempted as it was deemed as less crucial from a biopharmaceutical perspective. Another 
recent study by Stillhart et al (160) found also an amorphous precipitate of carvedilol in a 
digested formulation medium, whereas pure formulation dispersion (no lipolysis) 
produced crystalline material. It might have been due to generation of fatty acids during 
lipolysis that an interaction with carvedilol enabled an amorphous precipitate. In our 
study the presence of a fatty acid in the anhydrous formulation could be a beneficial 
formulation strategy to target amorphous drug precipitates. The advantage of such 
amorphous precipitates from lipid-based formulations has for example been shown 
recently for halofantrine in vivo by Thomas et al. (102).  
There is a high interest from biopharmaceutical perspective in intraluminal generated 
amorphous drug and supersaturation. Only few studies correlate in vitro supersaturation 
with in vivo absorption characteristics. For example, it was shown that for some drugs the 
initial production of a highly supersaturated system appeared to be more important for 
absorption enhancement as compared to long-term stabilization of supersaturation (93, 
94). The reason for this might be that the model drugs used in these studies (celecoxib and 
tacrolimus) are fast permeating drugs, and the trans epithelial flux generated sink 
conditions, limiting the importance of long-term stabilization. Therefore, such drugs 
should be evaluated optimally with an absorption step as part of an in vitro test. In the 
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present study the precipitation kinetics was studied using FBRM, in a closed system. 
Although, both loratadine and carvedilol are fast permeating drugs, the focus was more 
on the effects of OA on drug precipitation kinetics rather than attempting to make 
absolute predictions for in vivo drug absorption. 
We introduced a biopharmaceutically relevant dimensionless parameter: the Precipitation 
number (Pnc). It is the ratio of the drug residence time in GIT (tres) to the induction time of 
crystalline precipitation (τind). The induction time is a parameter characteristic to chemical 
engineering and the comparison with a physiologically relevant time was meaningful. All 
dispersed drug-loaded PEG-32 S formulations resulted in supersaturated solutions 
(SRM>1). However, not all of them precipitated within a relevant intestinal transit time, 
which was reflected by different Pnc values. Therefore, the Precipitation number (Pnc) 
provides a simple tool for fast screening of different formulations and/or drug loadings in 
formulations with respect to a relevant physiological time frame. It is important to 
compare crystalline precipitates, whereas the amorphous precipitates obtained from the 
OA-containing formulations were not directly comparable using Pnc. 
The importance of applied hydrodynamics in the precipitation evaluation should be 
mentioned. As presented earlier, already unsaturated drug-loaded systems (anhydrous 
formulations without OA) were precipitating upon aqueous dispersion, when rigorous 
mixing of 500 rpm during FBRM testing was employed. In case of the drug release 
testing (USP 3 apparatus, 20 dpm), the precipitation occurred only for supersaturated 
systems (S = 1.5). The release rate of loratadine was strongly influenced by the presence 
of OA and marked precipitation was noted in absence of the excipient. This excipient 
effect was also observed in case of carvedilol, but it was less pronounced. Such drug 
comparison on the same supersaturation level is meaningful to standardize the driving 
force of nucleation, but it is accompanied by different drug loads. Moreover, drug 
solubilities were different, i.e. carvedilol exhibited much higher solubility as compared to 
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loratadine. This certainly affected drug release under non-sink conditions, so the extent of 
the excipient effect for different drugs should be interpreted carefully. 
Tables 5.3 and 5.4 allow comparing formulations at similar doses in view of the resulting 
maximal supersaturation. OA had always a clear effect and this would be also expected in 
a release experiment with comparing formulations at constant dose level. For absolute 
values, some care is needed when different in vitro tests are compared. Recently, Carlert 
et al. (161) also explored two different hydrodynamics for the in vitro precipitation 
studies of a basic BCS class II drug (AZD0865). They observed that precipitation rates 
were remarkably slower in the shaking model (85 cycles/min, amplitude 2 cm) compared 
to the stirring model (USP 2 mini-vessel set up, paddle speed of 150 rpm). The various 
shears were likely to be the main difference also in our FBRM experiments compared to 
the release analysis in the USP 3 apparatus. The effects of the capsule shell may have 
been less critical given the rather fast immediate drug release profiles.  
5.5. Conclusions 
The aim of the current study was to better understand the effects of basic drug-OA 
interactions in a solid lipid-based system on different biopharmaceutical levels, i.e. in the 
anhydrous formulation and upon aqueous dispersion. A particular interest was the 
influence on drug precipitation kinetics and on the solid-state properties of obtained 
precipitates following dispersion. 
On the level of the anhydrous formulation, it was likely that the drug-OA molecular 
complexes were formed, which led to a substantial increase of solubilized drugs in the 
formulations. Once the formulations were dispersed, a clear complex formation was no 
longer apparent. This may have been due to the analytical sensitivity of the methods, but 
most likely the interactions were indeed partially lost. However, some interactions were 
still present upon dispersion on the level of evolving micelles, and probably also within 
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the bulk solution. OA clearly influenced supersaturation and the extent of drug 
precipitation as well as its kinetics. Most importantly, OA acted as a precipitation 
modifier, since it induced an amorphous precipitate that was otherwise crystalline without 
this excipient. Such an in situ forming amorphous system can be viewed as a novel 
formulation strategy to deliver poorly soluble basic drugs. 
It was further concluded that relevant drug-excipient interactions must be studied 
separately on the different levels of biopharmaceutical testing. This appears to be critical 
for an improved biopharmaceutical understanding and also with respect to a more rational 
selection of systems in pharmaceutical formulation development. For such a development 
purpose, the introduced Precipitation number appears to be highly attractive to screen 
lipid-based candidate formulations. Future studies should address other drug-excipient 
systems on different biopharmaceutical levels that may also include an absorption step. 
An improved understanding of drug-excipient interactions would also advance the field of 
biopharmaceutical drug absorption modeling. 
  
Chapter 6 
 
Final remarks and outlook 
 
For decades, gelatin has been used worldwide for the production of soft capsules due to 
its unique physicochemical properties. However, soft gelatin capsules (SGCs) are very 
dynamic systems and they present a challenge with respect to commonly observed drug-
excipient-shell interactions. This motivates the need for novel inert shell-forming 
materials. This thesis presents an innovation in soft capsule technology using the novel 
starch-based thermoplastic shell material. In particular, the mechanistic understanding of 
drug-excipient-shell interactions using SGCs and various starch-based thermoplastic 
capsules (VegaGels® and S-PVA-Cs) were explored. 
In the present work we successful introduced the novel starch-based thermoplastic 
capsules (S-PVA-Cs). The water migration pattern of these capsules was markedly 
superior to that of SGCs. The novel shell material was found to be suitable for 
encapsulation of a hydrophilic lipid-based formulation without exhibiting any drug 
crystallization. Moreover, the high resistance to mechanical deformation of the novel 
shell material may shorten manufacturing times (e.g. allow shorter drying process) and 
enable storage of capsules in bulk containers. Other characteristics of the new material, 
such as surface roughness and thermal stability can be advantageous for a subsequent 
coating step. Although the hydrophilic lipid-based system in this study profited from the 
new capsule technology, encapsulation of other formulations might be less critical. In the 
future work more formulations containing different drugs at varying dose strengths 
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should be examined. Moreover, to completely evaluate the inertness of the novel shell 
material, studies on co-solvent migration from the fill into the shell are needed. In 
addition, the investigation of possible drug migration into the shell is of major interest, as 
it could cause variations in drug release profiles. In summary, S-PVA-C could be a 
promising capsule technology for encapsulation of hydrophilic lipid-based formulations, 
but more studies are needed to finally assess the potential of these capsules in 
pharmaceutics. 
The study on biorelevant drug release from the novel thermoplastic capsules 
demonstrated that capsule shell material is freely selectable for a given formulation. 
Commonly, optimizing the biopharmaceutical formulation performance is the main 
objective during formulation development. However, our results suggested that some care 
is needed while choosing adequate capsule technology. Disintegration testing of various 
capsule types revealed different opening mechanisms. This influenced the drug release 
profile of a given formulation, but only in case of S-PVA-Cs. The interaction of the 
opening mechanism of capsules with formulation hydration should be considered during 
early formulation development. It would also be worthwhile to elucidate the structures of 
hydrated colloids formed during dilution, as it would help to better understand the 
biopharmaceutical formulation behaviour. 
The quality of drug-excipient interactions may be different at the level of the anhydrous 
formulation and upon aqueous dispersion. Since such interactions are likely to impact on 
drug formulation loading in the anhydrous formulation and the drug behaviour upon 
formulation dispersion, it is of major importance to study them on these different levels. 
In our study, the addition of oleic acid to basic drugs resulted in different qualities of 
molecular interactions. On the level of the anhydrous formulation, molecular complexes 
were observed that caused marked drug solubility increase. Later upon formulation 
dispersion, drug-excipient interactions influenced the extent of drug precipitation and its 
kinetics. The most remarkable finding was the role of OA as a precipitation modifier, 
since the precipitated model drugs were amorphous. This in situ formation of amorphous 
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precipitates could be a novel formulation strategy for weak bases. In the future work, 
studies of other drug-excipient systems on different biopharmaceutical levels could also 
include an absorption step. In addition, advances in the field of biopharmaceutical drug 
absorption modeling may be expected with an improved understanding of drug-excipient 
interactions. 
The present thesis introduced the novel starch-based thermoplastic capsules (S-PVA-Cs) 
and showed their advantage over SGCs with respect to hydrophilic lipid-based 
formulations. Drug-excipient-shell interactions observed in various capsule types (SGCs, 
S-PVA-Cs, and VegaGels®) were explored on different biopharmaceutical levels. In 
general, this thesis offers a better mechanistic understanding of such interactions, which 
should help in the future development of soft capsule products. 
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